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Medication errors and discrepancies occur frequently at transitions of care in inpatient 
settings and can lead to adverse drug events. This retrospective cohort study involving older 
adults has a pre-post design and is set in London, Ontario. This study evaluates the impact of a 
healthcare technology program called HUGO on the proportion of patient hospitalizations in 
which an antipsychotic, benzodiazepine or gastric acid suppressant medication was potentially 
continued inappropriately (i.e. continued after discharge with no medical indication for 
continued use). After HUGO’s implementation, the proportion of hospitalizations where a 
potentially inappropriate antipsychotic, benzodiazepine, or gastric acid suppressant medication 
was filled post-discharge decreased abruptly by 7.0% (p<0.0001), and there was a significant 
(p=0.0001) decrease in the potentially inappropriate continuation of these medications over time. 
Had HUGO not been implemented, the pre-HUGO trend suggests that potentially inappropriate 
continuation of these medications may have continued to increase. 
 














Summary for Lay Audience 
During a patients’ hospital stay medication errors can occur such as the wrong dose of a 
medication being recorded for a patient, or a medication being mistakenly discontinued or 
continued after hospital discharge. This can cause harm to patients, and sometimes such adverse 
drug events cause a patient to present to an emergency room and possibly be admitted again to 
hospital. One way to prevent medication errors from occurring is healthcare providers practicing 
medication reconciliation, where a patients’ medications are carefully reviewed by a healthcare 
provider for errors at the time of hospital discharge. Some hospitals have now adopted technology 
into their healthcare practices to improve patient safety, including moving to an electronic format 
of medication reconciliation. Hospitals in London, Ontario adopted such a healthcare technology 
program referred to as HUGO. We used health administrative databases to assess whether adopting 
HUGO was associated with fewer patients being continued on antipsychotics, benzodiazepines, 
and gastric acid suppressant medications after hospital discharge. We found that after HUGO was 
implemented there was a significant decrease in the number of patients being continued on these 
medications after hospital discharge. We suggest that implementation of HUGO in London’s 
hospitals has had a positive impact, and that other hospitals could look at implementing a program 














I would first like tot hank my supervisors Dr. Blayne Welk and Dr. Amit Garg for their 
mentorship and support throughout my Master’s degree. Their guidance and constant 
encouragement were critical to the completion of this thesis and towards my career aspirations. I 
would also like to thank my supervisory committee member, Dr. Kelly Anderson, for helpful 
feedback and expertise when completing my thesis and systematic review. 
I would like to extend my appreciation the staff at ICES Western-namely Ms. Jennifer Reid, Dr. 
Salimah Shariff, and Mr. Eric McArthur.  Ms. Reid provided support on the analytics side of this 
thesis, and was an invaluable resource throughout my thesis. Dr. Shariff and Mr. McArthur 
provided much appreciated methodological and analytic expertise respectively. I would also like 
to thank Dr. Andrew Appleton, a general internal medicine physician at LHSC, for his clinical 
expertise and input.  
Finally, I would like to extend my appreciation to my friends and family for all their 















Chapter 3: I’d like to acknowledge the work of Ms. Areej Hazam, Dr. Kelly Anderson, and Dr. 
Blayne Welk on the systematic review portion of the thesis. Ms. Areej Hazam acted as a 
secondary reviewer for data extraction and risk of bias assessment of the studies included in the 
review. Dr. Kelly Anderson provided valuable insights and edits of the systematic review and 
Dr. Blayne Welk acted as a secondary reviewer for primary screening as well as offered valuable 
insights and edits of the review. 
Chapter 4: I’d like to acknowledge the work of Ms. Jennifer Reid in ensuring the accuracy of the 
methods section of my thesis and for her description of the CERNER database which is included 


















Table of Contents 
Abstract…………………………………………………………………………………………….i 
Summary for lay audience………………………………………………………………………...ii 
Acknowledgements………………………………………………………………………………iii 
Co-authorship statement………………………………………………………………………….iv 
Table of contents……………………………………………………………………………….….v 
List of tables………………………………………………………………………………..…..vii 
List of figures……………………………………………………………………………..……..viii 
List of appendices……………………………………………………………………………..….ix 
List of abbreviations…………………………………………………………………………........x 
Chapter 1 
1.1 The problem-an overview………………………………………………………….….1 
1.2 Thesis objectives…………………………………………………………………...….1 
1.3 Thesis overview…………………………………………………………………….....2 
Chapter 2 
2.1 Chapter overview……………………………………………………………………...3 
2.2 Medications errors, discrepancies and ADE, and the scope of the problem…………..3 
2.3 Priority Medications……………………………………………………………...18 
2.4 Medication Reconciliation……………………………………………………..…….19 
2.5 Medication reconciliation at London Health Sciences Centre and St. Joseph’s                    
Healthcare………...….22 
Chapter 3 
3.1 Chapter overview…………………………………..……………………………….24 
vi 
 
3.2 Advanced medication reconciliation: a systematic review of the impact on medication 
errors and ADEs associated with transitions of care…………………………….....24 
Chapter 4 
4.1 Chapter overview…………………………………………………………………….48 
4.2 Study design…………………………………………………………………….…....48 
4.3 Cohort Build…………………………………………………………………….…...55 
4.4 Baseline conditions……………………………………………………………….….58 
4.5 Data analysis…………………………………………………………………..……..60 
Chapter 5 
5.1 Chapter overview…………………………………………………………………….66 
5.2 Results…………………………………………………………………………..........66 
Chapter 6 
6.1 Chapter overview…………………………………………………………………….78 
6.2 Discussion………………………………………………………………….………...78 












List of Tables 
Table 1: Description of study interventions…………………………………………………….20 
Table 2: Summary of study outcome definitions ………………………………………………22 
Table 3: : Summary of ROB assessment for randomised studies according to A Cochrane ROB 
Assessment Tool for Randomized Controlled Trials (RoB-2)………………………………….24 
Table 4: Summary of ROB assessment for non-randomised studies according to A Cochrane 
ROB Assessment Tool for Non-randomized Studies of Interventions (ROBINS-
1)…………………………………………………………………………………………………25 
Table 5: Primary outcomes across studies with electronic medication reconciliation interventions 
organized low to high ROB for each outcome ……………………………….............................26 
Table 6: Primary outcomes across studies with enhanced medication reconciliation interventions 
organized low to high ROB for each outcome………………………………………………….28 
Table 7: Cohort inclusion/exclusion steps in CERNER ……………………………………..…44 
Table 8: Interpretation of the regression coefficients for the segmented linear regression model of 
our data…………………………………………………………………………………………...62 
Table 9: Absolute difference between the counterfactual and actual outcome post-HUGO at 
various time points……………………………………………………………………………….64 









List of Figures 
Fig.1: PRISMA flow diagram……………………………………………………………………17 
Fig.2: Cohort build results-CERNER and ICES combined……………………………………...55 
Fig.3a: Bar graph of binary/categorical baseline characteristics over 4 equal time segments…..57 
Fig.3b: Bar graph of mean los over 4 equal time segments……………………………...………57 
Fig.3c: Bar graph of primary and specialist care visits over 4 equal time segments…….………57 
Fig.3d: Bar graph of mean Charlson comorbidity score over 4 equal time segments…………...58 
Fig.3e: Bar graph of mean age over time over 4 equal time segments…………………………..58 
Fig.3f: Bar graph of mean no. medications in year prior over 4 equal time segments…………..58 
Fig.3g: Top  main diagnoses over 4 equal time segments………………………………………59 
Fig.3h: Main diagnoses Pre- and Post-HUGO…………………………………………………..60 
Fig.4: The proportion of hospitalizations where a medication of interest was filled……………61 
Fig.5: Trendline of the observed vs. counterfactual proportion of hospitalizations where a 












List of Appendices 
Appendix A-Search strategies for Ovid MEDLINE, EMBASE, and Scopus…………………...79 
Appendix B-Summary of the characteristics of included studies in systematic review………....81 
Appendix C-Medications of interest for exclusion and outcome ascertainment………………...91 
Appendix D- Exclusion diagnoses for cohort build…………………………………………….220 
Appendix E-Cohort inclusion/exclusion steps with ICES databases…………………….……..229 
Appendix F-Seasonal makeup of the four time segments used for measuring baseline 
conditions……………………………………………………………………………………….230 
Appendix G-Coding for patient characteristics…………………………………………….......231 
Appendix H-Linear regression model assessment……………………………………………...253 
Appendix I-CERNER and ICES cohort build……………………………………………….…258 
Appendix J- Standardized differences for baseline conditions pre- vs. post-
HUGO…………………………………………………………………… …………..………...259 
Appendix K-Assessment of segmented regression model…………………………………......262 
Appendix L-sensitivity analyses………………………………………………………………..265 
Appendix M-Interpretation of the regression coefficients of the segmented linear regression 













List of Abbreviations 
ADE= adverse drug event 
ARR= absolute risk reduction 
BPMH= best possible medication history  
CHIP= clinical health informatics program 
CI=confidence interval 
CIHI= Canadian Institute for Health Information 
COPD= Ontario chronic obstructive pulmonary disease dataset also COPD= chronic obstructive 
pulmonary disease 
CPDB= corporate provider database 
CPOE= computerized physician order entry 
DAD= discharge abstract database 
DIN= druglist file also DIN=drug identification number 
ED= emergency department 
e-MAR= electronic medical administration record 
GI= gastrointestinal 
HPharm= high level pharmacist record 
HPR=high level physician record 
HUGO= healthcare undergoing optimization 
HYPER= Ontario hypertension dataset 
ICD-10= international classification of disease, tenth revision 
ICES= Institute of Clinical and Evaluative Sciences 
ICU= intensive care unit 
xi 
 
IKN= ICES key number 
INST=institution information system 
INSTNUM= institution number 
IPDB= ICES physician database 
IQR= interquartile range 
IT= information technology 
LHSC= London health sciences centre 
LOS= length of stay 
LPharm= low level pharmacist record 
LPR= low level physician record 
MH= mental health 
MoHLTC= Ministry of Health and Long Term Care 
MPharm= mid level pharmacist record 
MPR= mid level physician record 
NACRS= national ambulatory care reporting system 
NNT= number needed to treat 
NPV= negative predictive value 
ODD= Ontario diabetes dataset 
OHIP= Ontario health insurance plan 
OHIP-dx= OHIP diagnoses code 
OPHRDC= Ontario Physician Human Resource Data Centre 
OR= odds ratio 
ORAD= Ontario rheumatoid arthritis dataset 
xii 
 
PADE= potential adverse drug event 
PPV= positive predictive value 
PRISMA= preferred reporting items for systematic review and meta-analyses 
Q-Q plot= quantile-quantile plot 
RCT= randomised controlled trial 
ROB= risk of bias 
ROP= required operational practice 
RPDB= registered persons database 
RR= risk ratio 
SD= standard deviation 
SDS= same day surgery 






1.1 The problem-an overview 
 Medication errors and discrepancies occur frequently at transitions of care in inpatient 
settings and can lead to adverse drug events (ADE). A systematic review by Alquenae et al. 
found that for adult patients the median rate of medication errors and discrepancies following 
hospital discharge was 53% (IQR: 33-60.5) and 50% (IQR: 39-76) respectively.1 Medication 
errors come in many forms and can include the inappropriate continuation of medications after 
hospital discharge. The impact of medication errors and discrepancies can be significant, 
contributing to hospital readmissions, Emergency department (ED) visits, undue harm to 
patients, and increased healthcare costs.2–8 One solution to prevent medication errors, 
discrepancies  and ADEs is medication reconciliation, which involves maintaining an accurate 
list of all medications taken by a patient in a systematic and comprehensive manner and 
communicating this information consistently across transitions of care. 9–12 Traditionally 
medication reconciliation programs have been delivered in a paper-based format, however, 
recently there has been a movement towards electronic-based medication reconciliation 
programs and enhanced medication reconciliation programs that incorporate additional 
components that support medication reconciliation (e.g. having a secondary reviewer for 
medication lists, faxing discharge medication lists directly to outpatient pharmacies). London 
health sciences centre (LHSC) and St. Joseph’s Health Care (SJHC) in London, Ontario 
implemented an electronic medication reconciliation program as part of HUGO (Healthcare 
Under Going Optimization); while media reports suggest that HUGO has resulted in a decrease 
in medication errors no formal evaluation of the program has been conducted. 13 
1.2 Thesis objectives 
We first conducted a systematic review of the existing literature on the impact of 
electronic and enhanced medication reconciliation at hospital discharge on medication errors, 
discrepancies, and ADEs. We specifically sought studies that compared the efficacy of basic 
medication reconciliation programs to computer-based approaches or enhanced medication 
reconciliation programs. We then conducted a retrospective cohort study with a pre-post design 
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of older adults hospitalized at LHSC and SJHC between 2011 and 2019, who were prescribed an 
antipsychotic, benzodiazepine, or gastric acid suppressant medication during their hospital stay. 
We conducted this study to evaluate the impact of HUGO-a healthcare technology program 
implemented at LHSC and SJHC in 2014-to improve patient safety. Specifically, we compared 
the frequency of potentially inappropriate continuation of antipsychotics, benzodiazepines and 
gastric acid suppressant medications pre- versus post implementation of HUGO. 
1.3 Thesis overview 
 Chapter 2 of this thesis provides a background on medication errors, discrepancies, and 
ADE, medication reconciliation programs,  and on the medication classes mentioned above. 
Chapter 3 presents the findings of our systematic review on the effectiveness of electronic and 
enhanced medication reconciliation. Chapter 4 details the methods used in our study of the 
impact of HUGO and the results of this study are described in chapter 5. An overall discussion of 
the findings of this thesis, their implications, strengths and limitations of our work and directions 




















2.1 Chapter Overview 
 In this chapter medication errors, medication discrepancies and adverse drug events 
(ADE) will be defined, and the threat these pose to patient safety will be explored. Medications 
which are of particular interest for assessing and reducing medication errors will be described, 
including how these medications have been used in previous studies for this purpose. Medication 
reconciliation will be explored as a method for reducing medication errors, medication 
discrepancies, and ADEs. This exploration will include describing the history of and current state 
of medication reconciliation in Canada, and methods of medication reconciliation. Our current 
knowledge on the impact of basic medication reconciliation on medication errors, discrepancies, 
and ADEs as well as on clinical outcomes will be summarized. Finally, the medication 
reconciliation program implemented at London Health Sciences Centre (LHSC) and St. Joseph’s 
Health Care (SJHC) in London, Ontario will be described. 
2.2 Medications errors, discrepancies and ADE, and the scope of the problem 
In the broadest definition, medication errors are ‘a failure in the treatment process 
that leads to, or has the potential to lead to, harm to the patient’.14 Medication errors can occur 
at any point along the process of a medication being prescribed to it being dispensed, although 
errors commonly occur at the ordering or prescribing stage.14 At this stage common errors 
include the wrong medication, route, dose or frequency of a medication being written by a 
clinician; these account for 50% of all medication errors.14 Medication errors frequently arise at 
transitions of care, which occurs when patients move across or out of sites of care within the 
health system. These sites are hot spots for medication errors and discrepancies as they provide 
opportunities for miscommunication and simple transcription errors which can lead to 
unintentional changes in a patients’ medication regimen.6,15–21 Because of this, the common 
method for detecting medication errors is a deviation between two medication lists for a 
patient, such as a deviation between the list of medications reported for a patient at hospital 
admission and that reported at hospital discharge. Although some changes are intentional, 
deviations can include inappropriate continuation or discontinuation of medications after hospital 
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discharge, errors of duplication, and incorrect dosing.6 This study definition for medication 
errors allows for the term medication discrepancy to sometimes be used interchangeably with 
the term medication error to describe a similar phenomenon. A common difference between a 
medication discrepancy and a medication error in the literature is that a medication 
discrepancy refers to a difference between two medications lists (typically before and after 
transitions of care) whereas the definition for medication error additionally requires the absence 
of a documented reason for the change in medication.22,23 Exceptions to these classifications 
exist, which makes comparing studies examining medication errors and discrepancies 
challenging. Additionally, the terms discharge summary or medication order discrepancies 
are commonly used interchangeably with the term medication discrepancy and describe a 
similar phenomenon. An ADE describes when exposure to a medication results in patient 
harm.24 Of interest here are preventable and potential ADEs. Preventable ADEs occur when a 
patient has a medication error which causes harm, whereas potential ADEs occur when a 
medication error exists but does not result in harm to the patient either due to the medication 
error being caught and corrected or by luck.24 
Estimating the frequency of medication errors and discrepancies across hospital settings 
is challenging due to the large variation in observation methods, study definitions and standards 
used in studies investigating medication errors and discrepancies.  However, a systematic review 
by Alquenae et al. found that for adult patients the median proportion of medication errors and 
discrepancies following hospital discharge was 53% (IQR: 33.0-60.5) and 50% (IQR: 39.0-76.0) 
respectively.1 In the case of ADEs, it has been found that about 19% of patients discharged from 
an acute care facility experience an adverse event (not limited to but includes adverse drug 
events) within three weeks of hospital discharge.19 Of these adverse events approximately 66% 
are ADEs and 62% are preventable.19  
The impact of medication errors, discrepancies and ADEs can be significant for patients, 
their families, the healthcare system and society. For patients and their families these events may 
be associated with loss of life, prolonged disability, temporary harm, complicated recovery, loss 
of income, and confusion about a treatment plan.25 In the United States medication errors and 
their consequences are anonymously reported through the MEDMARX reporting system.26 
Hospitals pay to participate in MEDMARX, and this system allows hospitals to report, track and 
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share medication error data in a standardized format and to receive regular updates on 
medication error reports.26 A study by Pham et al. abstracted and analyzed records for emergency 
departments from the MEDMARX system over a four year period (2000-2004).26 Among other 
objectives, this study examined consequences of the reported medication errors, finding that  
2.6% of errors resulted in harm to the patient.26 In 2% of the reported medication errors the error 
contributed to or resulted in temporary harm to patients which required intervention, while 0.4% 
of medication errors contributed or resulted in temporary harm which required initial or 
prolonged patient hospitalization.26 In 0.06% of  the reported medication errors the error 
contributed to, or resulted in, permanent patient harm, and 0.06% of medication errors required 
intervention necessary to sustain life which includes cardiovascular and respiratory support such 
as CPR, defibrillation, and intubation.26 In 0.02% of reported medication errors the error 
contributed to, or resulted in, the death of a patient.26  
The healthcare system experiences a financial expense associated with  avoidable 
readmissions and emergency department visits, decreased efficiency due to longer recovery 
times, and decreased access to healthcare services for patients on account of the resources 
occupied by ADE s. 25 Various studies have investigated the frequency of ADEs leading to 
emergency department visits and hospital admissions: ADEs account for 8.3% to 16.2% of 
emergency department visits and up to 7% of hospital admissions.2–6 It should be noted that these 
were all-cause ADEs, not purely potential and preventable ADEs.  
As a result of ADEs society faces loss of productivity, absenteeism in the workplace, 
increased healthcare costs (and hence increased taxes), and a loss of confidence in the healthcare 
system.25 Absenteeism in the workplace can result in a loss of taxable revenue and may incur 
disability expenses for the government. Studies have found that the attributable cost per ADE 
(converted to 2008 Canadian dollars; includes but is not limited to ADEs that are a consequence 
of medication errors) to be estimated at $3034 to $4352.7 Extrapolating these costs, the national 
burden associated with in hospital ADEs has been estimated to be $2.2 to $5.6 billion (2008 
Canadian dollars) annually.7 For these reasons finding a method for reducing medication errors, 





2.3 Priority Medications 
 As previously mentioned, one type of medication error is the inappropriate continuation 
of medications after hospital discharge. Medications that are at risk for inappropriate 
continuation are those that are primarily intended for acute use while in hospital, which are 
intended to treat symptoms and conditions during a hospital stay but should be discontinued at 
discharge. When chronic use of these medications is associated with negative side effects and 
health outcomes, the inappropriate continuation of medications is a great threat to patient safety. 
We selected three medication classes that fall into this category of medications generally 
intended for acute use in hospital: antipsychotics, benzodiazepines, and gastric acid suppressant 
medications. Antipsychotics such as aripiprazole (Abilify), clozapine (Clozaril), olanzapine 
(Zyprexa), quetiapine (Seroqual) and risperidone (Risperdal) are used to treat a broad range of 
symptoms and conditions. In the elderly population antipsychotics are often used to manage 
agitation and hospital-induced delirium.27 However, chronic use of this class is associated with 
anticholinergic effects, tardive dyskinesia, falls, arrythmias, and cognitive decline making 
medications within this class generally restricted to acute use.27 Benzodiazepines such as 
alprazolam (Xanax), clonazepam (Klonopin), diazepam (Valium), and lorazepam (Ativan), are 
sedatives commonly used to treat temporary sleep disturbances.28 However, the long-term use of 
these medications may cause cognitive impairment, sedation, falls and addiction making them 
not generally intended for chronic use.28 Gastric acid suppression medications are commonly 
used to treat gastrointestinal symptoms observed during hospitalization, however, the long-term 
use of this class of medication is associated with increased risk of community-acquired 
pneumonia and enteric infection such as C. difficile.29  This includes H2 antagonists (such as 
famotidine, cimetidine) and proton pump inhibitors (such as omeprazole, pantoprazole, and 
esomeprazole). 
 These three medication classes have been used previously to study the frequency of 
inappropriate prescriptions in a pre-post study by Scales et al.30 In this paper the researchers 
recognized that patients discharged from acute care hospitals might be at an increased risk of 
unintentionally continuing medications prescribed to prevent or treat complications associated 
with acute illness, but which were no longer indicated after hospital discharge (i.e. inappropriate 
prescriptions).30 The aim of the study by Scales et al. was to evaluate the frequency of and risk 
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factors for  unintentional medication continuation after hospitalization.30 The study by Scales et 
al. was conducted as a population-based cohort study, and the hospitalized cohort included all 
individuals aged  ≥66 years who were discharged alive from an acute care hospital during the 
study period.30 The researchers subdivided the hospitalized cohort into four medication 
subgroups: antipsychotic medications, benzodiazepines, gastric acid suppressants, and inhaled 
bronchodilators and inhaled steroids.30 The researchers also  excluded patients where the use of 
these medications after discharge appeared warranted, including those who received these 
medications in the year prior to hospitalization and those whose admission was associated with a 
clear indication for receiving the medication or for continuing the medication post-discharge.30 
Within each cohort the dispensing of the associated medication in an outpatient pharmacy within 
7 (primary analysis) and 30 days (secondary analysis) after discharge was assessed.30 The 
following subgroups were restricted to in order to identify risk factors for continuing a 
medication prescribed during hospitalization after hospital discharge: patients with emergency 
admission, patients with ICU admission during hospitalization, and patients with length of stay 
(los) ≥7 days.30  
The study found that 1.4% of patients  continued antipsychotics, 3.3% of patients 
continued benzodiazepines, 6.1% of patients continued gastric acid suppressants, and 2.2% of 
patients   continued respiratory inhalers as identified by filling discharge prescription within 7 
days of discharge.30 The 7 day period was chosen to primarily report on as the authors felt this 
strengthened the association with exposure to hospitalization.30 Risk factors for continuation of 
meds within 7 days of discharge varied across medication groups, but rates were consistently 
higher for hospitalizations admitted through the emergency department, older patients, and those 
with multiple comorbidities.30 The  greatest risk factor for inappropriate medication continuation 
across all medication groups was a hospital los greater than 7 days.30 
 
2.4 Medication Reconciliation 
2.4.1 History of medication reconciliation in Canada 
Medication reconciliation is one solution to improve communication during transitions of 
care. It involves  maintaining an accurate list of all medications taken by a patient in a systematic 
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and comprehensive manner and communicating this information consistently across transitions 
of care.9–12 In Canada medication reconciliation is recognized as a patient safety priority and 
became a required operational practice (ROP) by Accreditation Canada in 2008. Accreditation 
Canada is a non-for-profit organization which accredits most hospitals in Canada based on their 
ability to meet a set of ROPs on an annual basis.25,31 ROPs are designed to mitigate risk and 
improve the quality and safety of health services, with mandatory compliance to receive 
accreditation.25 Since its implementation, the national compliance rate with the Accreditation 
Canada medication reconciliation ROPs has increased by nearly 15.0%, yet in Canada remains 
an ROP with some of the lowest compliance amongst all ROPs.25  
2.4.2 Methods of medication reconciliation 
 
 Medication reconciliation involves three main steps starting at hospital admission with 
creating and completing a best possible medication history for the patient.32 This history includes 
all details on the patient’s medications, dose, route and frequency and is obtained through patient 
and family interviews, phoning a patients’ outpatient pharmacy and by reviewing other reliable 
sources of information.32 A patient’s best possible medication history serves as a standard to 
reconcile medications in admission, transfer and discharge orders and to identify/ resolve 
discrepancies.32 Next changes in medication orders should be communicated to the patient, their 
family, and to the next provider of care.32 However, these steps can be carried out using different 
tools or techniques, resulting in medication reconciliation programs that are quite heterogenous 
across hospitals and healthcare networks. Some hospitals adopt a more simplistic intervention, to 
be considered basic medication reconciliation, while others incorporate many components to 
create an enhanced medication reconciliation process. This heterogeneity makes medication 
reconciliation programs difficult to compare, however, two  defining features of medication 
reconciliation programs are their format and their method of delivery.  
  
Traditionally medication reconciliation programs have been delivered in a paper-based 
format, including printed medication lists for patients and medication reconciliation checklists.32 
However, in alignment with advancements in electronic medical records, there has been a 
movement towards electronic-based medication reconciliation programs. Electronic medication 
reconciliation uses information technology to access and integrate patient medication data which 
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has been stored electronically.32 Electronic medication reconciliation has the advantage of being 
able to integrate with internal hospital systems (e.g. computerized physician order entry) and 
external systems (e.g. drug information systems) in a way paper-based medication reconciliation 
cannot.32 Additionally, electronic medication reconciliation can increase the efficiency of 
medication reconciliation through its provision of electronic tools to support clinical activities 
and patient safety.32 
  
The delivery of medication reconciliation programs also varies widely, and can include 
pharmacy lead programs, pharmacist-clinician collaborations, and clinician/nurse-based 
programs. Pharmacy lead programs are quite common and make up a large portion of the body 
of literature on medication reconciliation programs. In these programs the duties and roles of the 
pharmacist can vary but may include: medication history taking, confirming a patients’ 
medication history with community healthcare professionals, patient counselling, communication 
with outpatient provider, medication review and counselling, and reconciling medications at 
admission and discharge.33 Clinician/ nurse-based programs are typically more simplistic, for 
example consisting of reconciling medications and creating a discharge medication list for 
patients, and sending discharge summaries to primary care providers.11,22,23,34 Pharmacist-
physician collaborations can be seen to have an added layer of complexity compared to clinician-
only programs, additionally including components such as completion of a medication review to 
identify drug-related problems and inappropriate drug use, creation of systematic medication 
care plan, medication counselling and discharge medication teaching sessions, follow up patient 
phone calls, and structured home medication interviews.11,35–37  
  
2.4.3 Impact of medication reconciliation-current knowledge 
A comprehensive Cochrane systematic review and meta-analysis on the topic of 
medication reconciliation was conducted by Redmond et al. with the objective of assessing the 
effect of medication reconciliation on medication discrepancies, patient-related outcomes and 
healthcare utilisation in patients receiving medication reconciliation during transitions of care 
versus those who did not.38 The researchers identified 25 eligible randomised trials, all in 
hospital settings, with 23 studies provider-oriented (pharmacist mediated), and two focused on 
electronic reconciliation tools and medical record changes.38  
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Pooled results from 20 of the included studies comparing medication reconciliation to 
standard care found that those who received medication reconciliation had an almost 50.0% 
lower risk of experiencing at least one medication discrepancy compared to  standard care [RR= 
0.53, 95% CI 0.42 to 0.67].38 However, the certainty of the evidence for this outcome was very 
low due to poor quality of the primary studies, making knowledge regarding the ability of 
medication reconciliation to reduce discrepancies uncertain.38 The researchers pooled the results 
of 4 studies to examine the effect of medication reconciliation on the number of reported 
discrepancies per patient, yielding uncertain findings due to very low certainty of the available 
evidence [mean difference=-1.18, 95% CI -2.58 to 0.23].38 Additionally, the impact of 
medication reconciliation on the percentage of medications with a discrepancy or prescription 
error (yes/no) as compared to standard care was found to be uncertain as the certainty of the 
evidence was low  [RR=0.13, 95% CI 0.01 to 1.29; pooled 2 studies].38 Medication 
reconciliation was found to have little or no effect on experiencing a  preventable ADEs as 
compared to standard care [RR=0.37, 95% CI 0.09 to 1.57; pooled 3 studies] due to very low 
certainty of evidence, and an uncertain effect on ADEs [RR=1.09, 95% CI 0.91 to 1.30; pooled 4 
studies] due to low certainty of evidence.38 Researchers found conflicting evidence on the effect 
of medication reconciliation programs on healthcare utilisation. When unplanned 
rehospitalisation was reported alone there was no significant overall effect detected (Z=1.31, 
p=0.19) with the pooled results of 5 studies with moderate-certainty evidence, [RR=0.72, 95% 
CI 0.44 to 1.18; pooled 5 studies].38 It should be noted that there was substantial imprecision in 
the estimates of the pooled studies, which could contribute to a lack of detected significant 
overall effect. 38Med rec had an uncertain effect on a composite measure of hospital utilisation 
(emergency department, rehospitalisation) due to very low-certainty evidence [RR=0.78, 95% 
0.50 to 1.22; pooled 4 studies].38  
 
Overall, this points to an uncertain impact of medication reconciliation on decreasing 
medication errors and ADEs and on clinical outcomes. It should be noted that at least some of 
this uncertainty stems from the heterogeneity of the interventions and outcome definitions of the 




2.5 Medication reconciliation at London Health Sciences Centre and St. Joseph’s 
Healthcare 
 London Health Sciences Centre (LHSC), situated in London Ontario, is one of Canada’s 
largest acute care teaching hospitals.  LHSC is composed of multiple sites including but not 
limited to: Victoria Hospital, University Hospital, and Children’s Hospital. St Joseph’s Health 
Care (SJHC) is also situated in London, and provides specialised ambulatory, psychiatric and 
rehabilitation care across 3 sites. Among other reasons, LHSC and SJHC adopted the HUGO ( 
Hospital Under Going Optimization) system to address the issue of medication errors and 
adverse drug events. HUGO is a system which has been implemented in 14 hospital sites across 
southwestern Ontario, and includes electronic medication reconciliation. With this electronic 
medication reconciliation physicians are prompted to indicate whether a patient should continue 
or discontinue a medication every time they interact with a patient. By prompting this 
reconciliation of medication at every point of interaction, then  medication errors and associated 
adverse drug event should theoretically be reduced. Media reports suggest that there has been a 
42.0% reduction in adverse medication errors and events at St. Joseph’s and a 34.0% reduction in  
adverse medication errors at LHSC since HUGO’s implementation.13 However, no formal 
evaluation of HUGO has been performed in London since it’s implementation in 2014. This 
proposed study will evaluate the effectiveness of the program at reducing discharge medication 
errors. Given HUGO’s software is customizable, evaluating the current effectiveness of the 
program is important for system optimization. In addition, if it were to be found that the program 














3.1 Chapter Overview 
 This chapter is a systematic review of studies assessing the impact of electronic and 
enhanced medication reconciliation (medication reconciliation) programs on medication errors, 
discrepancies and adverse drug events (ADE). In the primary studies the outcomes of a group of 
patients who received electronic or enhanced medication reconciliation at the time of hospital 
discharge were compared to a group of patients who received paper-based/basic medication 
reconciliation.   
 
3.2 Advanced medication reconciliation: a systematic review of the impact on medication 
errors and ADEs associated with transitions of care 
3.2.1 Background 
Transitions of care occur when patients move across or out of sites of care within the 
health system. These transitions may pose a threat to patient safety, as miscommunication or 
simple transcription errors can lead to unintentional changes in a patients’ medication 
regimen.6,15–21 Although some changes in a patient’s medication regimen between hospital 
admission and discharge are deliberate, other discrepancies are unintentional and can occur due 
to incomplete or inaccurate information about a patient’s current medications or doses.6 These 
medication errors can include inappropriate continuation or discontinuation of medications after 
hospital discharge, errors of duplication, and incorrect dosing.6 
Both unintentional continuation and discontinuation of medications after discharge are of 
death, ER visits, and unplanned hospitalizations.30,39 It has been estimated that 19% of patients 
discharged from the hospital experience an adverse event within three weeks, with 66% of these 
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being adverse drug events (ADE) and 62% being preventable.40 ADE describes harm caused to a 
patient as a result of a medication, which includes medication errors. 40 System errors contributed 
to all of the preventable adverse events, with poor communication between hospital staff and 
patients or primary care physicians being the most common deficit in the provision of discharge 
care.40  
Medication reconciliation is one solution to improve communication during transitions of 
care. It involves obtaining and maintaining an accurate list of all medications taken by a 
patient.9–12 Multiple methods of medication reconciliation exist, including standardized forms, 
collaborative programs, and pharmacy-led programs.41–46 Recently there has been a movement 
away from standard paper-based medication reconciliation to electronic medication 
reconciliation, where electronic tools are used to deliver and support medication reconciliation. 
These tools may allow health care providers to better reconcile medications and doses.32,47 
Additionally medication reconciliation programs have evolved to enhanced medication 
reconciliation, which incorporate multiple components (e.g. multidisciplinary checklists and 
discharge summaries in addition to basic medication reconciliation processes). Previous 
systematic reviews have focused on describing the electronic tools and evaluating their usability, 
user adherence, and satisfaction48 or they have focused primarily on medication reconciliation at 
the time of admission.49 Discharge medication reconciliation appears to be the most important 
intervention to reduce errors at home after a hospital admission.21,50 Additionally, previous 
reviews have not focused on the impact of enhanced medication reconciliation.  
Our objective was to conduct a systematic review of the existing literature on the impact 
of electronic and enhanced medication reconciliation at hospital discharge on medication 
errors, discrepancies, and ADE. We specifically sought studies that compared the efficacy of 
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basic medication reconciliation programs to electronic or enhanced medication 
reconciliation programs.  
3.2.2 Methods 
3.2.2.1 Search strategy 
This review follows PRIMSA reporting guidelines for systematic reviews. We conducted 
an electronic search of the EMBASE and MEDLINE databases using the Ovid platform and 
Scopus database with the date range of 1946 (EMBASE, Ovid MEDLINE)/ 1966 (Scopus) to 
Oct. 9, 2019. We conducted the initial search up to Sept.18, 2018 and then conducted a 
secondary search up to Oct. 9, 2019 to ensure we had identified any relevant recently published 
studies. We used a combination of controlled vocabulary and keywords reflecting the following 
concepts: “Patient transfer”, “Continuity of care”, “Medication errors”, “Inappropriate 
prescribing”, “Adverse drug events”, and “Medication reconciliation”.  Details on the exact 
search terms and combinations are presented in appendix A. Only peer-reviewed studies in the 
English language were included, and no restrictions were placed in the year of publication.  
3.2.2.2 Study selection 
Two independent reviewers (LK, BW) performed title and abstract screening, and one 
reviewer (LK) performed full-text screening. We included studies that met the following 
inclusion criteria: (i) the study was conducted in hospital setting; (ii) electronic medication 
reconciliation or enhanced medication reconciliation was implemented at hospital discharge; 
(iii) the study assessed ADEs or medication errors or discrepancies; and (iv) the study design 
was a randomized controlled trial or quasi-randomized controlled trial or controlled pre-post 
study or an interrupted time series design with a comparison group (basic medication 
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reconciliation). We defined basic medication reconciliation as comparing a patient’s 
medication lists (e.g. home medication history taken at admission compared to a discharge 
summary) in a paper-based format. Electronic medication reconciliation processes were not 
limited to but must involve reconciling a patient’s medication lists that are in an electronic 
format (e.g. electronic medical record). Enhanced medication reconciliation processes must 
include the components of basic medication reconciliation and another intervention designed to 
enhance patient safety concerning medications (e.g. involving a second practitioner to further 
verify medication reconciliation accuracy). Studies were excluded from this review if 
participants were in a long-term care setting, the study was conducted in an intensive care, 
ambulatory or pediatric setting as the medication reconciliation procedure in these departments 
may vary greatly from medication reconciliation practices in other departments. Conference 
proceedings, editorials, review articles, and commentaries were not included as they do not 
contain all information necessary for data extraction. Where there were discrepancies between 
the two reviewers, the final decision was made based a consensus process.  
3.2.2.3 Data extraction and Risk of Bias (ROB) assessment 
Two reviewers (LK, AH) performed data extraction using a standardized form. This 
included an assessment of the ROB for all included studies using the Cochrane ROB assessment 
tool RoB-2 for randomized trials51 and the Cochrane ROB tool ROBINS-1 for nonrandomized 
intervention studies.52 Two independent reviewers (LK, AH) performed ROB assessments. Data 
extracted included: author, year of study, study setting and design, number of study participants, 
study inclusion/exclusion criteria, participant characteristics, description of the intervention, 
description of outcome definition, and length of the study. The outcomes of interest were the 
proportion of patients with medication discrepancies or ADEs, the mean number of discrepancies 
16 
 
per patient, the proportion of medications or medication orders/discharge summaries with 
discrepancies, or the total number of medication errors. Study results were grouped by 
intervention time (electronic or enhanced medication reconciliation) and further subdivided by 
outcome type (i.e. proportion of patients with medication discrepancies or ADEs, mean number 
of discrepancies per patient etc.). Results were qualitatively compared within outcome type for 
each intervention type. 
3.2.3 Results 
3.2.3.1 Search results 
The electronic database search yielded 1009 (919 from the initial search and 90 from the 
updated search) studies from EMBASE, 1074 (982+92) from Ovid MEDLINE, and 536 
(447+89) from Scopus. After duplicates were removed 1725 (1490+235) studies remained for 
title and abstract screening. Of those, 52 (48 +4) studies were selected for full-text screening and 
14 of which met the inclusion criteria for this review (Fig.1). Reasons for study exclusion after 
full-text screening are presented in Fig.1. After full-text screening, we added two additional post-
hoc inclusion criteria, specifically that the study compared electronic and paper-based 
medication reconciliation processes or the study compared basic versus enhanced medication 
reconciliation processes. After applying post-hoc inclusion criteria, a total of 10 studies were 






3.2.3.2 Study characteristics 
Characteristics of the included studies are summarized in appendix B. The included 
studies were published between 2009 and 2018. Of the included studies three were randomized 
trials22,23,53 and the remainder were nonrandomized studies, with a pre/post study design being 
the most common. The study settings were quite heterogenous in terms of level of care and units 
involved, however six of the ten included studies took place at academic hospitals.22,34,35,50,53,54 
The country of origin of the studies also varied, with half of the study interventions occurring in 
hospitals in the USA.22,34,35,50,54 Some studies involved patients from single units whereas other 
18 
 
studies involved multiple units. The mean/median number of medications per patient was not 
reported in all studies but varied between studies where it was reported with a low of 2(range:2-
4)34 and a high of 12.8(IQR:11.7, 13.9).54 It should be noted that the mean/median number of 
medications per patient did not appear to vary based on the hospital units involved in the study. 
The number of participants included in each study ranged from 85 to 3577. With the exception of 
one study in which the study duration was length of hospital stay plus 90-day post discharge 
follow-up22, all studies had a length of participation equalling the duration of a patient’s hospital 
stay. The mean/median age of participants was not reported in all studies but varied between 
studies where it was reported, with the youngest mean age of 5754and an oldest mean age of 84.37 
The inclusion and exclusion criteria for the studies were also heterogeneous, with one study not 
reporting any inclusion/exclusion criteria.22 The intervention (medication reconciliation) was 
delivered at discharge for six of the included studies23,34,50,53–55 and at both admission and 
discharge for four of the included studies.22,35–37 The personnel delivering the intervention 
included a physician (n=1)54, a pharmacist (n=1)22, a physician and a pharmacist team 
(n=4)36,37,50,55, a physician versus a pharmacist in each of the intervention arms (n=1)23, a nurse 
and a pharmacist team (n=1)35, and by unspecified hospital personnel.34 Six of the included 
studies compared electronic medication reconciliation programs to another intervention (e.g. 
paper-based medication reconciliation programs).34,36,50,53–55 The remaining studies compared 
different medication reconciliation procedures (e.g. basic medication reconciliation programs to 
enhanced versions).22,23,35,37 
3.2.3.3 Summary of study interventions 
A summary of the study interventions is presented in table 1 and study outcome in table 2 
Six of the included studies 34,36,50,53–55 compared electronic medication reconciliation 
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procedures to basic medication reconciliation. The electronic medication reconciliation 
interventions typically consisted of the generation of medication lists for patients within their 
electronic medical record, which was then reconciled during hospital discharge.34,36,50,54,55 One 
study’s electronic medication reconciliation consisted of an automated medication 
reconciliation app through which discharge prescriptions were generated.53 Four of the included 
studies compared  basic medication reconciliation to an enhanced version of medication 
reconciliation. 22,23,35,37 Components of enhanced medication reconciliation varied 
significantly by study, but all included the components of basic medication reconciliation. A 
component common between three of the included studies was the collaboration between 
physicians and pharmacists to complete discharge medication reconciliation.23,35,37Additionally, 
two of the studies with enhanced medication reconciliation had admission medication 
reconciliation performed by a pharmacist who checked for potential drug-related symptoms, 
drug-related problems, and inappropriate drug use.22,37 Outcome definitions also varied between 
studies as described in table 2. In general, in the included studies a discrepancy (medication, 
discharge summary, medication order) referred to a difference between two medications lists 
(typically before and after transitions of care). 22,23,37Comparatively, a medication error generally 
additionally required an absence of a documented reason for the change in 
medication.23,34,36,37,55Two exceptions exist: one study fails to mention an outcome definition for 
medication error35 and another uses the term medication error but the definition is more similar 
to a medication discrepancy.50 An ADE is unique from a medication error or discrepancy and 






Table 1 Description of study interventions 
Study Type of 
intervention 
Components of the comparison  Components of the intervention 






Discharge: paper-based discharge medication 
reconciliation with discharge medications 
transcribed by hand from the inpatient electronic 
medication list. 
Admission/during hospital stay: Physicians input home 
medications electronically allowing them to easily select 
which home medications are appropriate for inpatient 
orders. The electronic list has mandatory fill-in boxes for 
strength, form, dose, route and time for every medication. 
The current inpatient list shows which medications were 
home medications and which are medications added 
during the inpatient stay.  
 
Discharge: At time of hospital discharge, the prescribing 
physician creates an electronic list of medications from 
the current inpatient list. Inpatient and home medications 
that stay on the discharge list can be easily selected, and 







Admission/during hospital stay: Medication 
reconciliation performed by a pharmacist. The 
patient’s potential drug-related 
symptoms were checked. A medication review 
was performed to identify drug-related problems 
and inappropriate drug use. Based on identified 
problems, a systematic medication care plan was 
created 
in which all changes to the medication therapy 
were noted. The care plan was updated 
continuously and was decided 
on by the team. 
 
Discharge: Physician completed the discharge 
summary which here included a medication 
report and a medication list with no evaluation 
by pharmacist.  
 
Admission/during hospital stay: Medication reconciliation 
performed by a pharmacist. The patient’s potential drug-
related 
symptoms were checked. A medication review was 
performed to identify drug-related problems and 
inappropriate drug use. Based on identified problems, a 
systematic medication care plan was created 
in which all changes to the medication therapy were 
noted. The care plan was updated continuously and was 
decided 
on by the team. 
 
Discharge: Physician completed the discharge summary 
which here included a medication report and a medication 
list at the day of discharge, and the 








Provider updated and nursing theoretically 
reviewed with the patient and connected with the 
providers for any issues they hospitalization. 
Platforms for the medication home list and 
inpatient list did not interface.   
Admission: Nurse/pharmacist collaboration to collect and 
document medication history and conduct medication 
history verification prior to making chronic continuity 
therapy orders. 
  
Discharge: Pharmacist and prescriber work together to 
verify medications with a multidisciplinary checklist, with 
discharge medications issued after the discharge huddle.  





Control- no specific medication reconciliation 
process. 
 
Minimal intervention-  
Admission/during stay: Patients received 
medication counselling from a pharmacist case 
manager (PCM). The PCM took a detailed 
medication 
history, followed by medication reconciliation 
comparing 
the inpatient medications to the patent's home 
medication list.  
 
Discharge: medication reconciliation focused on 
comparing current inpatient medications to 
medications prior to hospital admission.  A 
discharge medication teaching session was 
provided and patients received a discharge 
medication list. 
Admission/during stay: Patients received medication 
counselling from PCM. The PCM took a detailed 
medication 
history, followed by medication reconciliation comparing 
the inpatient medications to the patent's home medication 
list.  
 
Discharge: medication reconciliation focused on 
comparing current inpatient medications to medications 
prior to hospital admission.  A discharge medication 
teaching session was provided and patients received a 
discharge medication list. Discharge care plan prepared 
and faxed to community physician and pharmacy. Plan 
focused on medication issues and changed during 
hospitalization. Follow up phone call from PCM 3-5 days 









Basic medication reconciliation-  
Admission: Home medication history of patients 
obtained via structured interview by clinical 
pharmacist. This was compared to the treatment 
recorded in computerized primary care register. 
Admission: Home medication history of patients obtained 
via structured interview by clinical pharmacist and 
entered into a computerized tool integrated into the 
electronic clinical history 
of the patient. This tool was designed to facilitate 
medication reconciliation by identifying every field 
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Prescription bottle or medical reports supplied 
by patients checked and recorded in form. 
 
Discharge: Medication reconciliation performed 
comparing the treatment prescribed to a patient 
at discharge with the patient’s home medication 
history (taken at admission) accounting for 
treatments initiated during a patient’s hospital 
stay.   
 
necessary to correctly define a medication (route, dose, 
active ingredient, frequency). 
 
Discharge: Medication reconciliation performed 
comparing the treatment prescribed to a patient at 
discharge with the patient’s home medication history 
(taken at admission) accounting for treatments initiated 
during a patient’s hospital stay.   
Other: A training session at the beginning of the 
intervention period 







Phase1-Discharge: paper based medication 
reconciliation in a form containing general 
information, a medication report (contains 
information of changes to medications during 
hospital stay), and a medication list of current 
medications. At discharge this form is discussed 
with and given to the patient and, if applicable, 
sent to the community health care and the 
patient’s general practitioner within the same 
day. 
 
Phase2-Discharge: Medication list in electronic patient 
record gets reconciled by a physician and then reconciled 
by a pharmacist for quality control. Other components of 
the form and discharge process remain the same as pre-
intervention.  
 
Period3-Builds on period1 processes to incorporate 
physicians reconciling medications listed in an electronic 
web-based medication dispensing system called ApoDos. 
A pharmacist checked the correctness 









Paper based discharge medication reconciliation 
program in place but components not described. 
Admission: Clinical pharmacist obtains patient’s home 
medication list and enters into the electronic medical 
record. 
  
Discharge: A discharge medication reconciliation report 
form was created through the electronic medical record. 
This form captures patients’ home and inpatient 
medications and is used to order medications at discharge. 
It contains all active inpatient medications 
at the time the report is printed After the 
physician completes the order form, 
the final discharge orders are updated 
on the patient’s medication list within the electronic 
medical record by pharmacist assistants. The discharge 
orders are then reviewed and verified 
by pharmacists for accuracy. Patients’ 
updated discharge medication lists 
are immediately available for review 
across the continuum of care. 
 





Discharge: A paper-based nonmandatory 
discharge medication reconciliation process 
reconciling a patient’s discharge medication list 
against medication histories obtained by hospital 
personnel. 
 
Discharge: a mandatory electronic medical record-based 
discharge medication reconciliation procedure involving 
reconciling discharge medications against medication 
histories obtained at hospital admission.  Discharge 









Admission through discharge: Used a fillable 
PDF form to complete medication reconciliation. 
 
Admission through discharge: An automated medication 
reconciliation application retrieves community-based 
medications from the provincial insurance agency and 
aligns it with in-hospital medications from the hospital 
drug information system. Discharge prescription 
generated using a one-click action bar where the 
community and hospital drugs to be continued, stopped, 
modified or started are determined.  
 









summaries prepared by physician with medication 





Table 2 Summary of study outcome definitions 
Study Outcome definition Gold standard 
Allison et al. 
(2015) [54]  
Medication discrepancies: Were categorized by dose, frequency and route. 
When a drug was present on the gold standard list and absent on the discharge 
list, this was considered an antibiotic omission. Conversely, when a drug was 
absent on the gold standard list and present on the discharge list, this was 
considered an antibiotic addition. If a drug was prescribed that differed from 
the gold standard this was considered two medication errors: an antibiotic 
omission and antibiotic addition. We summarized antibiotic error by type 




For every patient an inpatient infectious disease 
consulting physician documented recommended 
post-discharge oral antibiotics. This 
recommendation was considered the gold standard 
and compared to the oral antibiotics in a patient’s 




Medication error: The occurrence 
of one of the following discrepancies (identified by the pharmacist when 
comparing the medication list in the discharge summary with the medication 
list in the community health care) together with the lack 
of documentation to indicate that the change in the 
medication therapy was done deliberately: 
1) A medication was missing in the medication list from 
the community health care. 
2) A medication had been added to the medication list 
from the community health care. 
3) The total dosage over 24 h had been changed in the 




Not reported N/A 
Farley et al. 
(2014) [22] 
Medication discrepancy:  
If a) medications that documentation indicated should be active were not on 
the patient’s medication list 
(unintended omission), b) medications were on list without documentation 
(unintended 




Sáez et al.(2016) 
[36] 
Reconciliation error: Any discrepancy between the medication upon 
admission and that prescribed at discharge that could not be justified clinically 
 
N/A 
Midlov et al. 
(2011) [55] 
Medication error: Any discrepancy between medication lists before and after 
transfer to a community care/nursing home. If there was any indication (from 
comments or notes in any record or written documentation for a patient), it 
was not regarded as an error. Change of generic meds or withdrawal of drugs 
with long dosage intervals was not regarded as error. In-hospital medication 
list on day of discharge considered correct if no other information was 
documented and this was compared to community care dispensing list when 
first dose had been given. For ApoDos patients the ApoDos-list when 
packages delivered were checked.  
 
N/A 
Murphy et al. 
(2009) [50] 
Medication error: Errors and omissions in physician discharge 
orders, errors on written prescriptions given to patients, and errors on the 
nursing discharge summary. Includes 
omission of home or inpatient medications, missing routes of administration, 
missing medication dosages, missing directions, missing durations of 
treatment, unacceptable medical abbreviations in discharge orders. 
 
N/A 
Smith et al. 
(2016) [34] 
Medication variances: Any differences between the study-based preadmission 
medication 
case summary (gold standard) and discharge medications.  
Medication errors: Medication variances not considered changes required by 
the patient’s clinical status.  
Clinically important medication errors: Errors in which there was the potential 
to cause death, permanent or temporary disability, prolonged hospital stay, 
readmission, or additional treatment or monitoring to protect the patient from 
harm.  
 
Gold standard: A gold standard preadmission case 
summary was created for each patient 
retrospectively by research personnel examining 
ambulatory electronic medical record data on a 
patient’s medications at the time of their last 
hospitalization with a primary care physician. This 
gold standard for pre-admission medications was 
compared to inpatient medication orders and 
discharge medication orders to identify medication 
variances and errors.  
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Tamblyn et al. 
(2018) [53] 
Potential adverse drug events (PADEs): Errors in omission of community 
medications and therapy duplications of 2 or more medications from the same 
therapeutic class.  
 
N/A 
Tong et al. (2017) 
[23] 
Medication error: An omitted drug, an 
incorrect dose or dose frequency, an incorrect or unnecessary drug, 
or an incorrect route of administration.                                                Types 
and risks of error: Errors were classified on an ordinal severity scale of  5 
(corresponding to insignificant risk, 





ROB was assessed separately for randomized and non-randomized studies. Results for 
the randomized studies are described in table 3. The ROB (ROB) due to random sequence 
generation procedures was unclear in two studies22,53 and high in another.23 Allocation 
concealment bias was low, unclear, and high (see table 3). 22,23,53 The ROB presented in the 
blinding of personnel and participants was unclear in three studies (see table 3). 22,23,53 There was 
a low ROB in the blinding of outcome assessments for one study23 and is unclear in others (see 
table 3). 22,53 Using the ROBINS-1 tool, the overall ROB among non-randomized studies was 













Table 3: Summary of ROB assessment for randomised studies according to A Cochrane ROB 
Assessment Tool for Randomized Controlled Trials (RoB-2)51 





























































 Low ROB 
 Unclear ROB 


















Table 4: Summary of ROB assessment for non-randomised studies according to A Cochrane 










































































































































































 Low ROB 
 Moderate ROB 
 Serious ROB 
 Critical ROB
Summary of study findings 
Study outcomes were grouped and organized into two tables-one for studies with 
electronic medication reconciliation interventions (table 5) and one for studies with enhanced 
medication reconciliation interventions (table 6). Within each outcome category studies were 
organized from lowest to highest ROB; this was done as the results varied by study and we felt 
more weight should be placed on the results of studies of lower ROB.  
Table 5: Primary outcomes across studies with electronic medication reconciliation interventions 
organized low to high ROB for each outcome 
Author 
(reference) 
Study design ROB Outcome 
measure 
Effect measure 













Crude OR 0.41 (95% CI 0.19, 0.90, p=0.027) 
 







Low Not reported Crude OR 0.63, (95% CI 0.51-0.77, p<0.001) 
 
Adjusted** OR 0.54, (95% CI 0.43-0.69, p<0.001) 
 
Adjusted***OR: 0.52, (95% CI 0.41-0.67, p<0.001) 
 










ward: 44.1%  
OR 0.31 (95% CI 0.27‐0.37) 
 




















P<0.001 between pre and intervention and intervention 
and post  
 









Moderate Time period 









































1) 95% CI, 42–53%; p < 0.001 
 
2) 95% CI, 28–38%; p < 0.001) 
* adjusted for day of discharge and total number of discharge medications 
**adjusted for age sex and insurance 
*** adjusted for age sex insurance and comorbidity score 
****adjusted for age sex insurance comorbidity score and number of medications 
Note: moderate and unclear ROB considered equivalent and serious and high ROB considered 
equivalent for the purposes of the above table. 
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Table 6: Primary outcomes across studies with enhanced medication reconciliation interventions 
organized low to high ROB for each outcome 
Author 
(reference) 
Study design ROB Outcome measure Effect measure 






Serious Baseline: 67.0-90.0%  
 
Enhanced:16.0-33.0% 
No statistical test 
reported 
Outcome 2: Mean number of medication discrepancies/medication errors per patient 
Farley et al.(22) Randomized 
controlled trial 
Unclear At 30 days (control, minimal, 
enhanced):HPR-: 0.51, 0.49, 0.26 
MPR-2.89, 2.45, 2.61 LPR-2.31, 
2.14, 2.31 HPharm-0.38, 0.40, 
0.45 MPharm-3.36, 3.68, 3.42, 
0.655 LPharm-3.92, 4.34, 4.56 
 
At 90 days:HPR-0.50, 0.41, 0.44 
MPR-3.03, 2.56, 2.83 LPR-2.78, 
2.50, 2.78 HPharm-0.41, 0.44, 
0.49 MPharm-3.25, 3.44, 3.62 
LPharm-4.12, 4.60, 5.04 




































52.3%). If 100 
discharge 
summaries were 
reconciled 46.5 of 
them would be 
prevented from 
containing a min. of 
1 error.  
 
NNT(95%CI): 

















Low Intervention group: 4.8% of  
medications with medication 
errors 
 
Control group: 12% of  








Serious At baseline: 8-26% of 
medications 
 
With enhanced medication 
reconciliation: 1-6% of 
medications 
Not reported 








15.0% of discharge summaries 
P<0.01 
 
HPR=high level physician record 
MPR= mid level physician record 
LPR= low level physician record 
HPharm= high level pharmacist record 
MPharm= mid level pharmacist record 
LPharm= low level pharmacist record 
Note: moderate and unclear ROB considered equivalent and serious and high ROB considered 
equivalent for the purposes of the above table. 
Electronic medication reconciliation compared to basic medication reconciliation was 
associated with a lower proportion of patients with at least one medication discrepancy or ADE 
in two34,54 out of three studies.34,53,54 Specifically, two studies of a low ROB 34,54 found the crude 
and adjusted odds ratios to be statistically significant (crude OR=0.4,  p=0.027;  crude OR=0.63, 
p<0.001), and a third with unclear ROB found no statistically significant improvement.53 It was 
unclear whether electronic medication reconciliation was associated with a significant reduction 
in the mean number of medication discrepancies or medication errors per patient; in one study 
there was a significant decrease observed in the intervention period compared to the pre-
intervention period (p<0.01)36, however another study did not report any statistical significance. 
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55 It was also found that electronic medication reconciliation was associated with a significant 
reduction in the proportion of medications with errors compared to basic medication 
reconciliation (p<0.001).50 
Enhanced medication reconciliation showed no significant impact on the proportion of 
patients with at least one medication discrepancy.35 The impact of enhanced medication 
reconciliation on the mean number of medication errors/discrepancies per patient is less clear, 
with one study of unclear ROB finding no significant impact22 and another of high ROB finding 
a significant positive impact (p<0.01).23 The impact of enhanced medication reconciliation on the 
proportion of medications/medications orders/discharge summaries with discrepancies is also 
unclear. Two studies of low and high ROB, respectively, found a statistically significant 
reduction (p=0.012, p<0.01).23,37  In the first study clinically relevant errors (those of moderate, 
high, and extremely severe magnitude) were reduced, and the second study observed a decrease 
from 66 total medication errors across all study patients to 25 total across all study patients 
which in a comparable previous study was found to reduce negative clinical outcomes (hospital 
readmission associated with medication errors).23 A third study of serious ROB did not report 
any statistical measures for their results, however did consider the results clinically significant. 35 
3.2.4 Discussion 
Looking first at the studies with electronic medication reconciliation interventions we see 
that both of the studies that showed no significant improvement post-intervention involved 
automated procedures. The study by Tamblyn et al. involved an automated electronic medication 
reconciliation program53 and the study by Midlov et al. involved an automated medication 
dispensing system (ApoDos).55 Although the studies that showed a positive impact of electronic 
medication reconciliation varied in their intervention components, none involved an automated 
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procedure and this represents a perhaps important difference in intervention components between 
studies showing a positive impact versus no impact of electronic medication reconciliation. 
Looking at studies that reported on the proportion of patients with minimum of one medication 
discrepancy or ADE, we see that both of the studies that showed a positive impact of electronic 
medication reconciliation used gold standards as a comparison to identify medication errors34,54 
whereas no gold standard was used in the study that showed no effect. 53 This difference in 
ascertaining the presence of medication errors may contribute to the difference in the observed 
outcome between studies. It should be noted that in the study by Allison et al. only medication 
errors for oral antibiotics were considered; focusing on one medication class may have allowed 
for greater ease of reconciliation which may have contributed to a positive impact of electronic 
medication reconciliation found here and not in other studies. There were no other major 
variables (such as patient age, mean number of medications per patient at discharge, setting) that 
seemed systematically different between studies showing a positive impact versus no impact of 
electronic medication reconciliation.  
In the case of enhanced medication reconciliation all studies involved some form of 
provider-pharmacist collaboration, however, there was no deeper commonality in intervention 
components between studies showing a positive impact of enhanced medication reconciliation 
versus those showing no impact. Studies showing a positive impact of enhanced medication 
reconciliation involved only medical units23,37 versus studies that showed no impact of enhanced 
medication reconciliation involved medical and surgical units35,53; the importance of this 
difference is not known. There were no other major variables (e.g. patient age, mean number of 
medications per patient at discharge, setting) common to all studies showing positive impact of 
enhanced medication reconciliation that was not also common to studies showing no impact.  
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Although not unanimous, it appears that electronic medication reconciliation may have a 
positive impact on medication errors and discrepancies. This message becomes clearer if we 
focus on studies with a low ROB; the two studies of low ROB which focused on electronic 
medication reconciliation both showed a significant positive impact of the intervention.34,54 
Additionally, of the two studies which did not report a statistically significant positive impact of 
electronic medication reconciliation, one study did consider the intervention to have had a 
clinically significant positive impact which should not be dismissed. 53  In the second study there 
was already a small number of medication discrepancies per patient pre-intervention as 
compared to other studies in our review; perhaps this small initial number may explain why a 
statistically significant decrease was not observed with implementation of the intervention.55  
The studies with enhanced medication reconciliation as an intervention varied widely in the 
components of the intervention, the components of the basic medication reconciliation 
comparison group and in their outcome definitions. Due to this it is more accurate to say that we 
observed inconsistent studies versus inconsistent results.  
To the best of our knowledge no previous reviews have explored the impact of enhanced 
medication reconciliation, however, we identified one previous review examining the impact of 
electronic medication reconciliation on unintentional medication discrepancies during transitions 
of hospital care. In contrast to our study which focused on discharge medication reconciliation, 
the systematic review by Mekonnen et al. focused on electronic medication reconciliation at 
admission and the impact on clinical outcomes, namely medication discrepancies between a 
patient’s home medications and admission orders.49 However,  admission medication 
reconciliation doesn’t help improve communication across the transition of patients returning 
home from the hospital, and hence doesn’t directly target the issue of patients being sent home 
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on unnecessary medications or medications with errors (such as incorrect dosing). This was 
shown in a study by Murphy et al. (2009) which evaluated discharge medication errors firstly 
after an admission medication reconciliation system was implemented, and then again after a 
discharge medication reconciliation system was implemented.21 We found that errors remained 
after admission-only medication reconciliation but were significantly reduced after the addition 
of discharge medication reconciliation.50 To build on this review we chose to exclude studies 
with admission-only medication reconciliation to evaluate interventions targeted at the issue of 
patients being sent home with unnecessary medications or medications with errors. Despite our 
change in approach we came to the same conclusion as Mekonnen et al., namely that there was 
inconsistent impact of electronic medication reconciliation on minimizing the occurrence of 
unintentional medication discrepancies, with no statistically significant reduction in patients with 
medication discrepancies or mean number of medication discrepancies per patient.  
One landmark study involving enhanced medication reconciliation is the MARQUIS 
study by Schipper et al. This study is a pragmatic quality improvement study involving five US 
sites-three academic medical centres, two community hospitals and one Veterans Affairs 
Medical Center. Medication reconciliation was implemented at all 5 sites based on a 17 point 
medication reconciliation toolkit. Toolkit components were grouped into 8 domains and 
included: taking the best possible medication history (BPMH); discharge medication 
reconciliation and counseling; clarifying roles and responsibilities of healthcare personnel; risk 
stratification; health information technology improvements to the electronic health record; 
improving access to medication sources; measuring then intervening to correct discrepancies in 
real time; and, stakeholder engagement. Not all domains were addressed by all sites, and what 
intervention components were implemented differed by site. We chose to exclude the 
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MARQUIS study from our review due to this inconsistency; results of studies included in our 
review would likely be difficult to compare due to differences between interventions across 
studies and we did not want to include a study where interventions varied within one study. The 
study authors concluded that implementation of a multifaceted medication reconciliation 
program was associated with a reduction in total, but not potentially harmful, medication 
discrepancies.  
3.2.4.1 Study limitations 
Our study is not without its limitations. We did not have access to unpublished research 
and restricted our search to studies published in the English language, which may have 
introduced publication bias. Additionally, there was a lack of consistency across the included 
studies for the term medication error/medication discrepancy and ADEs as well as how the 
outcome was measured. Consequently, what qualifies as a medication error or discrepancy may 
differ between studies and may reduce the comparability of the outcomes of different studies. 
This is one of the reasons we chose not perform a meta-analysis. The interventions evaluated 
also displayed heterogeneity, in particular among studies evaluating enhanced medication 
reconciliation which made comparing the effects of studies challenging. Variability in setting 
(e.g. different healthcare systems, single unit versus multi-unit interventions, some involved 
outpatient programs) posed additional limitations to being able to accurately compare study 
results. There were also some limitations in terms of study design: only three studies were RCTs, 
with the remaining being predominantly controlled before/after studies. However, very few 
controlled before/after studies adjusted for post-intervention covariates which could explain the 
lack of changes in pre/post measures such as medication errors. Additionally, the majority of 
studies lacked information on whether blinding of participants/assessors was present, on protocol 
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for randomization (as applicable), or allocation concealment (as applicable), which contributed 
to a large number of studies being of unclear, moderate, or serious ROB. Additionally, 
medication reconciliation was only mandatory in one study intervention, and the majority of 
studies did not report on the completeness of medication reconciliation delivery. 35 Hence, a lack 
of significant observed effect in some studies may be due to a failure to consistently deliver 
medication reconciliation to patients. As enhanced medication reconciliation programs contain 
multiple components it is not possible to decipher the impact that each intervention component 
had alone, which is a limitation inherent to the nature of these interventions.  
3.2.5 Conclusion 
There may be a positive impact of electronic medication reconciliation on medication 
errors and discrepancies, however there is a lack of agreement across studies which in addition to 
some inconsistencies in the interventions and outcome definitions between our studies we were 
unable to come to a definitive conclusion. The lack of comparability of studies is more 
pronounced in studies with enhanced medication reconciliation, making a clear direction of the 
effect of enhanced medication reconciliation not possible.  Additional studies with lower ROB, 
evaluating a consistently implemented intervention(s) with a uniform definition for medication 
discrepancies, medication errors and ADEs and which are more similar in terms of intervention 
and comparison group components are required to fully form a conclusion on the true impact of 
electronic and enhanced medication reconciliation. Development of a universal definition for 
medication discrepancies, medication errors and ADEs would be beneficial as it would allow for 







4.1 Chapter overview 
This chapter describes our study design-including study type, timeline, exposure and 
outcome definitions- as well as the databases used. Methods used to create our study cohort, 
including inclusion and exclusion criteria will also be detailed. Patient characteristics measured 
and methods of measuring these conditions will be described and the data analysis methods 
employed will be discussed.  
4.2 Study design 
4.2.1 Setting and timeline 
This is a retrospective cohort study set at Victoria Hospital and University Hospital- two 
of the sites of the larger London Health Sciences Centre (LHSC) system – as well as at St. 
Joseph’s Health Care (SJHC) in London Ontario. Both LHSC and SJHC are large teaching 
hospitals and are associated with Lawson Health Research Institute and Western University’s 
Schulich School of Medicine and Dentistry. This study used a  pre/post design, with the date of 
HUGO’s implementation serving as the cut-off between the pre-HUGO and post-HUGO cohorts. 
Both entry into and exit out of the cohort was dynamic, with patients entering and exiting the 
cohort as they gained or lost eligibility. It should be noted that a patient could be included in the 
cohort multiple times, for example if they had a hospital visit in June 2012 and another visit in 
September 2015. Hence, each record and data point represents a patient hospitalization not a 
unique patient. The accrual window for this study was February1st, 2011 to March 26th, 2019. 
This start date was chosen to provide sufficient data points from the pre-HUGO cohort, and the 
end date was chosen to include the most up-to-date information that can be provided by the 
databases used in this study. The lookback window was up to 6 months prior to hospitalization in 
order to examine patient characteristics, with a maximum follow-up of March 31st, 2019 (end of 
accrual window plus 5 days to measure primary outcome). Follow up was terminated when one 
of the three following events was reached: discharge date plus 5 days, outcome (medication of 




4.2.2 Data sources 
This study made use of linked data from ICES (previously known as the Institute for 
Clinical and Evaluative Sciences) databases for cohort creation, measurement of patient 
characteristics, and exposure and outcome ascertainment. ICES is a non-for-profit research 
institute where scientists and clinicians collaborate to improve health and healthcare through 
research using administrative health data. At ICES records are linked across datasets using 
unique person-level identifiers called ICES key numbers (IKN). IKNs are themselves generated 
using a secure ICES algorithm based on Ontario health card numbers. Descriptions of each 
database used in the study are detailed below.  
4.2.2.1 Discharge Abstract Database (DAD) 
After a patient is discharged from hospital (or is transferred, signed-out or dies), a 
discharge abstract is created by a trained member of the health records department.57 They use 
standardised codes to represent important aspects of the patient’s hospital stay.57 This record is 
forwarded to CIHI (Canadian Institute for Health Information) who maintains national records in 
the Discharge Abstract Database (DAD).57 CIHI receives data from all participating hospitals, 
accounting for about 75% of all hospital inpatient discharges in Canada, and all of the hospitals 
in Ontario.57 There’s typically a 3 to 4-month lag time between the end of the month and when 
the data are received by CIHI.57  We used DAD to identify eligible patient hospitalizations for 
inclusion into our study, to determine exposure status of patient hospitalizations based on 
discharge date, and to measure a variety of patient characteristics.  
 
4.2.2.2 Same Day Surgery (SDS) 
SDS contains patient-level data for day surgery institutions in Ontario, with each entry 
corresponding to one same-day surgery or procedure stay.58 From April 2003 onwards SDS is 
derived from NACRS and beginning in 2009 data from SDS is available to ICES quarterly.58 
Main data elements from this database include patient demographics (e.g. sex, date of birth), 
clinical data (diagnoses, procedures, physician), administrative data (e.g. institution/hospital 
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number), financial data, and service-specific data elements.58 We used SDS to identify eligible 
patient hospitalizations for inclusion into our study. 
 
4.2.2.3 Ontario Health Insurance Plan (OHIP) 
The majority of claims paid out by OHIP are contained in the OHIP database.59 Claims 
are made either by healthcare providers who are paid in a fee-for-service model, or by non fee-
for-service physicians who submit shadow billings to OHIP.59 A shadow billing claim is 
identical to a fee-for-service claim except the billing amount is $0.59 The service provider 
prepares and submits OHIP claims to the MOHLTC (Ministry of Health and Long Term Care), 
who in turn provides the data to ICES. Information collected in the claims include patient and 
physician identifiers (e.g. physician number and speciality), fee codes for services provided, 
associated diagnoses and the date service was provided.59 We used OHIP to exclude ineligible 
patient hospitalizations from our study and to measure patient characteristics such as prior 
medical conditions. 
4.2.2.4 National Ambulatory Care Reporting System (NACRS) 
NACRS captures information on patient visits to hospital and community-based 
ambulatory care services.58 These services include visits to the ED (Emergency Department), day 
surgeries, and outpatient clinics, with information being collected from ED starting July 2000 
and information from the remaining services collected from 2003 onwards.58 For each patient 
visit to one of these services, a NACRS abstract is completed using information from 
admission/discharge/transfer systems, ED information systems, patient records, physician notes, 
and laboratory and diagnostic imaging results.58 Participating facilities, regional health 
authorities and the ministry of health directly submit data to CIHI who maintain the database.58 
Demographic information as well as clinical, administrative, financial, and service-specific data 
are collected into the database. From 2009 onwards these data have been available to ICES on a 
quarterly basis.58 We used NACRS to exclude ineligible patient hospitalizations, and to measure 
inpatient admissions from the ED as a patient characteristic.  
4.2.2.6 Corporate Provider Database (CPDB) 
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 The CPDB contains files maintained by the MOHLTC Provider Services branch with 
information on all physicians and some non-physician providers, such as chiropractors and 
physiotherapists, who are funded by the Ministry.60 ICES receives information on demographics, 
speciality and practice location of physicians.60 
 
4.2.2.5 ICES Physician database (IPDB) 
Data on all Ontario physicians by fiscal-year is contained within IPDB.61 IPDB is created 
at ICES from files received from the OPHRDC (Ontario Physician Human Resource Data 
Centre) on a yearly basis containing their ‘best guess’ speciality for all physicians in Ontario.61 
ICES combines this information with in-house information from OHIP and CPDB (corporate 
provider database) to create the IPDB.61 Data contained in the IPDB includes physician 
demographics (gender, sex), speciality (functional and certified), location, and measures of 
physician activity (billings, workload, types or services provided).61 This data can be used for 
tasks including physician profiling, predicting physician behaviour, and measuring physician 
supply.61  
 
4.2.2.7 Registered Persons Database (RPDB) 
Demographic information of everyone who holds or has held an Ontario health card from 
1990 onwards is contained in the RPDB.62 This information includes date of birth, gender, and 
postal code. ICES receives this data directly from the MoHLTC.62 We used RPDB to apply 
inclusion and exclusion criteria such as restricting the age of patient hospitalizations, and to 
measure patient characteristics such as age, neighbourhood income quintile and sex. 
4.2.2.8 The Druglist file (DIN) 
DIN is a file housed at ICES which contains a near exhaustive list of DINs (Drug 
Identification Number) used in Canada from 1990 onwards.63 Drug and product names, subclass 
information, PCG  codes, drug strength, route of administration and first and last dispensing 
dates from ODB are all contained in this file.63 This file can be used to obtain a list of all DINs 
which fall under generic drug names, drug subclasses or PCG codes, and to look up properties of 
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a drug to gather information on the dose of a drug dispensed in an ODB claim. 63 We used DIN 
to create a druglist to apply as exclusion criteria and to use in exposure and outcome 
ascertainment. We also used DIN to measure medication-related patient characteristics such as 
presence of polypharmacy. 
4.2.2.9 Institution Information System (INST) 
INST is a series of  datasets that contain information about Ontario health care 
institutions funded by the MOHLTC.64 These datasets are linkable to administrative data by the 
unique institution number assigned by the MOHLTC.64 For example, one dataset called acute 
beds contains information on the number and type of beds available in acute care hospitals, while 
INSTNUM tracks changes to institution numbers over time.64 We used INST to exclude patient 
hospitalizations that were not discharged from LHSC or SJHC.  
 
4.2.2.10 CERNER 
CERNER is a hospital-based electronic medical record system that is shared across 
LHSC and SJHC sites. It contains information about all patient hospitalizations (visits) and is 
continually updated with events like registration, admission, laboratory results, physician orders, 
medication administration, and electronic medication reconciliation completion. The CHIP 
(Clinical Health Informatics Program) at ICES Western, in collaboration with the Decision 
Support team at LHSC/SJHC has reviewed and created data dictionaries for the relevant 
variables for this study. We used CERNER to identify eligible patient hospitalizations, including 
to flag inpatients who were prescribed a medication of interest during their hospital stay, and to 
identify the type of service (medical, surgical, geriatric, other) a patient received during 
hospitalization. 
4.2.2.11 Ontario Drug Benefit (ODB) 
Claims for prescription drugs received under the Ontario Drug Benefit program are 
contained in the ODB database. The Ontario Drug Benefit program covers prescription 
medications of those over the age of 65, those living in a long-term care home or home for 
special care, receiving professional home and community care services, those enrolled in the 
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Trillium Drug program, who are eligible for OHIP+, and those covered by the Ontario Disability 
Support Program or who are on social assistance. OHIP+ is a program introduced in 2018 which 
provides basic drug coverage for individuals under 25 who do not coverage under private health 
insurance. Each record represents a drug claim (i.e. a dispensed prescription) paid for by the 
Ontario Ministry of Health and Long Term Care.65 Main data elements include: DIN (drug 
identifier), quantity, cost, patient, pharmacy and physician identifiers, date prescription was 
dispensed and a long-term care indicator.65 We used ODB to exclude ineligible patient 
hospitalizations, for outcome ascertainment, and to measure patient characteristics such as 
polypharmacy. 
4.2.2.12 Ontario Hypertension dataset (HYPER) 
HYPER is an ICES-derived cohort which captures prevalent and incident cases of 
patients with hypertension in Ontario from 1991 onwards.66 ICES-derived cohorts are datasets, 
not disease registries, which have been developed in-house to identify individuals with specific 
diseases.66 The algorithms used to create these datasets usually use a combination of hospital, 
emergency department, and outpatient data, and specify a combination of a certain number of 
records coupled with diagnostic codes, that have occurred within a specific time period.66 
Validation studies for these cohorts usually involve medical chart reviews, producing sensitivity, 
specificity, positive (PPV) and negative predictive values (NPV).66 For the HYPER database 
cases of hypertension are identified with 72% sensitivity, 95% specificity, an 87% PPV and an 
88% NPV.66 We used HYPER to measure hypertension as a patient characteristic. 
4.2.2.13 Ontario Chronic Obstructive Pulmonary Disease dataset (COPD) 
COPD is another ICES-derived cohort and captures prevalent and incident cases of 
patients in Ontario with Chronic Obstructive Pulmonary Disease (COPD) from 1991 onwards.67 
Specifically, this dataset is made up of two cohorts-a COPD specific cohort and a COPD 
sensitive cohort, both identifying cases of patients >35 years of age but with slightly different 
case definitions.67 The COPD sensitive cohort has an 85% sensitivity and 78.4% specificity67, 
and the COPD specific cohort has as sensitivity of 57.5% and a specificity of 95.4%.67 We used 
the COPD dataset to measure COPD as a patient characteristic. 
4.2.2.14 Ontario Rheumatoid Arthritis dataset (ORAD) 
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Prevalent and incident cases of patients >15 years old in Ontario with rheumatoid arthritis 
are identified in the ICES-derived dataset ORAD.68 Cases from 1991 onwards are captured in the 
dataset, and the dataset has a sensitivity of 78%, a specificity of 100%, a PPV of 78% and an 
NPV of 100%.68 We used ORAD to measure arthritis as a patient characteristic. 
4.2.2.15 Ontario Diabetes dataset (ODD) 
ODD is another ICES-derived dataset, and it captures prevalent and incident cases of 
patients in Ontario with diabetes from 1991 onwards.69 Specifically, the dataset is made up of 
three cohorts-children/youth (<=18 years old), a sensitive cohort (19+) and a specific cohort 
(19+) with the case definitions being slightly different for each.69 The validation values for the 
children/youth cohort are as follows: 82.8% sensitivity, 98.9% specificity.69 The sensitive cohort 
(19+) has a sensitivity of 90.0%, a specificity of 97.7% and a PPV of 82.6% while the specific 
cohort (19+) has a sensitivity of 79.9%, a specificity of 99.1% and a PPV of 91.4%.69 We used 
ODD to measure diabetes as a patient characteristic. 
 
4.2.3 Measurements 
4.2.3.1 Exposure definition 
Our exposure was defined as discharge from an inpatient admission after implementation 
of HUGO. HUGO was implemented on April 13, 2014 at University Hospital, April 27, 2014 at 
Victoria Hospital, and on May 21, 2014 at SJHC. Hence our exposed group were patients 
discharged after HUGO’s implementation and our unexposed group were patients discharged 
during our study period prior to HUGO’s implementation. We used CERNER, with verification 
from INST, to identify patients discharged from our hospitals under study, and both CERNER 
and DAD to identify the discharge date of patients and group patients into pre- and post-HUGO 
groups accordingly. 
4.2.3.2 Outcome definition 
Our outcome of interest was the filling of at least one of the prescriptions of interest 
(antipsychotics, benzodiazepines or gastric acid suppressant medications, details in Appendix C) 
within 5 days of discharge. We chose a 5 day window to measure our outcome as in this 
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population the  majority of discharge prescriptions are filled within 5 days of hospital discharge; 
upon exploration we found that >99% of medications were filled within 5 days of discharge. We 
used DIN to identify our medications of interest and the ODB to identify if and when patients 
filled a prescription of interest.  
4.3 Cohort Build 
4.3.1 CERNER inclusion/exclusion criteria 
Table 7 shows the exclusion steps taken in CERNER to create the study cohort. We first 
used CERNER to identify eligible patient records. We initially restricted to patient records 
whose discharge date was between Jan.1, 2011 and Mar. 26, 2019; this time frame was changed 
in the ICES database environment for our final cohort build for ease of analysis (later discussed). 
Patients must have been >55 years old at time of registration, stayed in hospital for a minimum 
of one day, and been an inpatient or have a “one day stay” (applicable to SJHC) hospitalization 
type. Records with poor data quality (such as a missing discharge date or  health card number) 
were not included. As patients may have experienced multiple different hospital stays during the 
study period, they could contribute more than one hospital hospitalization. Accordingly, total 
number of patients in the cohort and total number of hospitalizations in the cohort will not be 
equal.  
In 2017, after several years of development, a data sharing agreement with ICES and 
CERNER was signed. This agreement allows CERNER data to be pulled on a project by project 
basis. Prior to data collection, each project requires approval from a local subcommittee made up 
of both LHSC and SJHC employees (such as privacy/risk officers and physicians). Once 
approved, a designated ICES analyst (CHIP analyst), who has access to real-time CERNER data, 
prepares the cohort build for the specific project. Decision Support teams at LHSC and SJHC 
then review the data pull and when approved transfer it to ICES using Axway Secure Transport 
web portal (a secure transfer system). This data is received by an ICES Data Covenantor, who 
removes direct personal identifiers and replaces them with a confidential ICES identifier (IKN) 
to enable data linkage across data holdings at ICES. The final encrypted dataset is then posted on 
the ICES network, where only ICES analytical staff working on the approved project are 





Table 7: Cohort inclusion/exclusion steps in CERNER 
Step Description Database 
1 
Include all Patients discharged from LHSC 
or St. Joseph’s Health Care London between 
January 1 2011 and March 31 2018  CERNER 
2 Exclude length of stay(LOS)<1  CERNER 
3 Exclude age <55 at registration CERNER 
4 
Exclude encounter type not equal to 
'Inpatient' or 'One Day Stay' (SJHC only) CERNER 
 
4.3.2 ICES inclusion/exclusion criteria 
 Our goal was to identify patients who had no recent (6 month lookback period from time 
of hospital admission) use of antipsychotics, benzodiazepines, or gastric acid suppressant 
medications, who were exposed to one of these medications during their hospitalisation and who 
did not have evidence of a diagnosis that would justify continued outpatient use of that 
medication. We only included patients who received one of the medications (Appendix C) of 
interest during the hospital admission; we did this by using a medication flag that had been 
created in CERNER specifically for this study. We then aligned CERNER records with DAD 
based on discharge dates, keeping only CERNER records that aligned exactly with DAD, while 
also making sure institutions matched using INST. We then excluded records without a valid 
IKN (a unique identifier assigned to patient records by ICES), those for patients <66 or >105 
years old, and records of patients who were non-Ontario residents (using RPDB). Additionally, 
records where the patient died within 5 days of discharge, were readmitted within 5 days of 
discharge, or returned to the ED within 5 days of discharge were not included as there may be 
insufficient time to experience the outcome of interest, which could introduce survivor bias. We 
used RPDB, DAD and NACRS to apply these exclusion criteria. We also excluded records of 
patients whose site names, according to CERNER, were not University Hospital, Victoria 
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Hospital or St. Joseph’s Campus to ensure we were only capturing patients at the main sites of 
interest (i.e. not Parkwood or London Regional Cancer Program).  
As our study was interested in whether there was a reduction in the proportion of patients 
who filled a potentially inappropriate prescription post-discharge after HUGO was implemented, 
we had to differentiate between appropriate and inappropriate continuation of antipsychotics, 
benzodiazepines, and gastric acid suppressant medications. To minimise the number of people 
who were receiving medically appropriate prescriptions for the medications of interest, we 
excluded hospitalizations where the patient had a mental health or gastrointestinal diagnosis in 
the 6 months prior to admission and during their hospital stay (see appendix D for exclusion 
diagnoses) that would warrant the use of these medications. We used DAD and OHIP for these 
exclusion diagnoses. To make sure we were identifying incident prescriptions, we excluded 
patients who filled a prescription for one of our medications of interest (see appendix C) in the 6 
months prior to admission using ODB. As will be discussed in the analysis section we divided 
our study timeline into 2 month intervals; to achieve a whole number of intervals we decided to 
eliminate patient records from January 2011 by excluding patient records with an index date 















4.4 Patient Characteristics 
Patient characteristics were measured at the aggregate level at 4 equidistant time points 
across the study timeline in order to assess the comparability of patients across time. To address 
the potential impact of seasonality on the patient characteristics we calculated the season makeup 
of each time segment, which is presented in appendix F. Additionally, patient characteristics 
were measured and the standardized difference calculated for pre- and post-HUGO periods in 
order to determine whether there might be clinically significant differences that would affect the 
comparability of these groups. Coding for all patient characteristics can be found in appendix G.  
4.4.1 Demographics 
Basic demographic characteristics included: age sex, neighbourhood-level income 
quintile, and long-term care status (yes/no). We measured the mean and median age of patients at 
discharge using RPDB. The RPDB was also used to measure the proportion of patients of each 
gender and in each income quintile at time of discharge. The ODB was used to measure the 
proportion of patients who were long term care residents as of discharge.  
4.4.2 Comorbidities 
We used the Charlson comorbidity score as an overall measure of comorbidity. The 
Charlson comorbidity index is a validated method that uses ICD-10 diagnosis codes in 
administrative data to assess comorbidities.70 Each comorbidity category has an associated 
weight ranging from 1 to 6, which is based on the adjusted risk of mortality or resource use.70 
The sum of all the weights yields a comorbidity score for a patient.70 The higher the score the 
greater the likelihood that the patient will experience mortality or have higher healthcare 
resource use, with a score of zero indicating no comorbidities were found.70 We used DAD to 
measure mean comorbidity score of patients at time of discharge, with a 3 year lookback period 
in the administrative data. 
We measured the prevalence of a number of different prior conditions including: COPD, 
diabetes, hypertension, ischemic heart disease, liver disease, inflammatory bowel disease, renal 
disease, arthritis, stroke, cerebrovascular disease, dementia, and congestive heart failure. We 
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used a combination of OHIP fee and diagnoses codes, and DAD/SDS diagnoses codes as per the 
coding definitions used in prior studies involving a comparable population.71 For measuring prior 
COPD, diabetes, hypertension and arthritis validated ICES-derived cohorts were additionally 
used to identify prior conditions in our cohort (ODD, HYPER, COPD, ORAD). We used a 5-
year lookback from time of discharge to determine the presence of these conditions. All of the 
prior conditions measured are chronic conditions which, especially when multimorbid, have been 
found to be associated with increased medication use in elderly populations (>65 years old). As 
prior research indicates that a greater number of medications is associated with a higher 
proportion of ADE and medication errors, we wanted to ensure these factors were balanced 
between the pre- and post-HUGO periods.72 Similar comorbidities have been used in prior 
studies assessing ADE.30 
 
4.4.3 Admission characteristics 
 Various characteristics were measured in our study including: hospital los, type of 
inpatient service (medical, surgical, geriatric, other), ED to inpatient transfer, ICU admission, 
whether a patient was discharged to a nursing home, and whether the surgery/procedure that was 
the cause of the patient’s admission was performed. Los has been shown to be associated with 
medication errors and ADEs72 and was assessed using DAD. Prior research evaluating 
medication reconciliation procedures also indicates that the ICU is a particularly vulnerable 
environment for medication errors as patients in this unit receive more drugs that in other units.39 
Medication errors are more common in the ICU versus other inpatient environments, and the 
resulting ADE often have more serious consequences.39 ICU admission status was assessed using 
DAD. The literature also indicates that the prevalence of medication errors varies by hospital 
service, so we measured type of inpatient service at discharge via CERNER, categorizing the 
service codes into medical, surgical, geriatric and other services, and looked for significant 
differences pre- and post-HUGO periods.73 We hypothesized that patients who were transferred 
to inpatient care from the ED would experience more transitions of care, again meaning more 
opportunities for medications to be changed or a mistake to occur when entering information 
about a patient’s medication regime. Additionally, we hypothesized that those who had the 
surgery or procedure they were admitted to hospital for would be more likely to have more 
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medication changes in their regime than patients who did not have the surgery/procedure 
performed. We used NACRS and DAD to assess ED to inpatient transfer and surgery/procedure 
performed respectively. We also used DAD to identify whether patients were discharged to long 
term care facilities, as these patients may have additional medication reconciliation procedures 
performed once they arrive at long-term care. 
4.4.4 Prior healthcare utilization 
Primary care and specialist care visits in the year prior to hospital admission were 
measured separately using OHIP fee codes. We chose to measure this as the literature indicates 
that being exposed to multiple care providers is associated with an increased risk of medication 
errors and ADE. As a referral from a family physician is required in the Canadian healthcare 
system to visit a specialist, measuring the number of specialist care visits was our way of 
measuring patient interaction with multiple care providers. Exposure to primary care physicians 
was also found to be a risk factor for medication errors and ADE. By measuring and comparing  
primary care and specialist care visits in the year prior to hospital admission pre- and post-
HUGO we could assess whether there was an equal distribution of this risk factor.  
4.4.3 Medication utilization 
 We measured the number of medications patients used in the year prior to hospital 
admission as well as the proportion of patients with polypharmacy. We defined polypharmacy as 
a patient filling >=10 unique DINs in the year prior to hospital admission (similar to prior 
studies)74, and measured the total proportion of patients with polypharmacy in each of our four 
time segments and pre- vs. post-HUGO.74 We also used ODB to measure the aggregate mean 
and median number of medications pre- and post-HUGO as prior research indicates that 
polypharmacy and a higher number of medications is associated with a higher proportion of 
ADE and medication errors.72 
 
4.5 Data analysis 
4.5.1 Transformation of timeline and outcome 
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 We grouped our study timeline into 2-month intervals starting Feb.1, 2011 and ending 
Mar. 26, 2019. This yielded intervals 1-19 capturing the pre-HUGO time segment, and intervals 
20-49 capturing the post-HUGO time segment. Although HUGO was implemented on different 
dates across Victoria Hospital, University Hospital and SJHC, one time interval (interval 20) 
captured all three dates. We aggregated our data by 2-month interval to convert our outcome 
from a count of patient hospitalizations with our primary outcome (filled a prescription of 
interest within 5 days of discharge) to a proportion. The number of patient hospitalizations in a 
given 2-month interval with our primary outcome was the numerator, and total number of patient 
hospitalizations in a given 2-month interval was our denominator.  
4.5.2 Preliminary analysis 
 With our transformed timeline and outcome, we derived the primary outcome status and 
calculated the proportion of patients with the primary outcome in the time period pre-HUGO 
(intervals 1-19) and post-HUGO (intervals 20-49). We additionally plotted our outcome over 
time, for the pre- and post-HUGO periods and the time of HUGO implementation.  
4.5.3 Building a simple linear regression model 
 We first attempted to fit our data to a simple regression model. We chose not to include 
additional covariates (converting to a multiple regression model) as we found various covariates 
potentially related to medication errors to be comparable between the pre-HUGO and post-
HUGO. The basic equation for this model is as follows: 
Equation 1: Proportion(t)= Β0 + Β1*interval(t) 
Where proportion is the proportion of hospitalizations in a given 2-month time interval where the 
patient fills a medication of interest. Where t is a continuous variable for time in 2-month time 
intervals since the start of the observation period, and interval(t) indicates the two month time 
interval during the observation period. 
To assess the goodness of fit of the model we examined the F and R2 statistic, looking for 
a statistically significant F statistic to indicate that the independent variable (time interval) is able 
to accurately predict the dependent variable (filled prescription of interest within 5 days of 
hospital discharge), and a large R2 value to indicate that the independent variable can explain a 
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significant percent of the variation in the dependent variable. We also used a residual-fit spread 
plot, a fit plot, and an outcome vs. predicted values plot to assess goodness of fit. If the model 
was a good fit we would expect (i) the spread of the residuals to be similar to the spread of the 
fit-mean in the residual-fit spread plot; (ii) the data points to fall within the 95% confidence 
limits in the fit plot and to hug the fitted line; and (iii) the predicted values to lie on the 45˚line in 
the outcome vs. predicted values plot.  
We used a residual vs. predicted plot to check the assumption of constant variance 
(homoscedasticity), expecting no pattern in the plot. We used a histogram of residual density and 
a Q-Q (quantile-quantile) plot to check the assumption of normality. We would expect the 
residuals to fit a bell-shaped curve in the former and the datapoints to fall on the diagonal in the 
plot of the latter if the assumption of normality were met. To check the assumption of linearity 
we examined a plot of the dependent vs. independent variable (using the loess smooth feature in 
SAS) for evidence of a linear relationship. Results of this assessment are presented in appendix 
H. 
  
4.5.4 Building a segmented regression model 
 We performed segmented regression using a linear model. An interrupted time series 
design is a  quasi-experimental approach for evaluating longitudinal effects of intervention, such 
as HUGO.75 Segmented regression analysis is a method used to statistically model interrupted 
time series data so that formal conclusions about the impact of an intervention or event can be 
made.75A time series is a sequence of values which are measured at regularly spaced intervals 
over time. When a sequence of measures is divided into two or more portions at change points, 
segments are created in a time series.75 These change points reflect a real-world event, policy 
change or experimental intervention where the values of the time series may exhibit a change 
from a previous pattern-̲thus, the time series has been ‘interrupted’.75 
In the case of our study, the data fit the definition of interrupted time series data, with a 
clear change point (HUGO’s implementation). Our two time segments were pre-HUGO 




Equation 2: Proportion(t)= Β0 + Β1*interval(t)+ Β2*intervention(t)+ Β3*time_after(t) 
Where proportion is the proportion of hospitalizations in a given 2-month time interval 
where the patient fills a medication of interest. Where t is a continuous variable for time in 2-
month time intervals since the start of the observation period, interval(t) indicates the two month 
time interval during the observation period, intervention is an indicator for time (t) occurring 
before (intervention=0) or after (intervention=1) HUGO’s implementation. Time_after is a 
continuous variable capturing the number of two-month time intervals that have passed since 
HUGO was implemented, with time_after=0 before HUGO (time intervals 1-19) and (time-19) 
after HUGO’s implementation.  
We interpreted the regression coefficients in terms of trend and level change. Trend 
describes the slope of an outcome over a time segment.75 Here we are interested in how the 
proportion of discharges where a medication of interest is filled (within 5 days of discharge) 
changes from one 2-month interval to another and how the overall slope for pre-HUGO time 
segment compares to that of the post-HUGO time segment. Β1 captures interval to interval 
changes in our proportion outcome in the pre-HUGO period, with a significant p value indicating 
significant interval to interval change. Β3 captures whether there was significant interval to 
interval change in in our proportion outcome in the post-HUGO time segment as compared to the 
pre-HUGO time segment (i.e. if there is a significant difference in slope from the pre- and post-
HUGO time segments). Β1 + Β3 yields the post-HUGO slope. A level change is an immediate 
change in outcome from one time segment to another.75 In this case, we examined if there was a 
significant change in the proportion of hospitalizations where a medication of interest was filled 
(within 5 days of discharge) after HUGO was implemented. This level change is captured by Β2. 
Β0 captures the prevalence of the outcome just before the beginning of the observation period 
(baseline), which here is the proportion of hospitalizations where a medication of interest is 
filled.  
Autocorrelation (where one data point is correlated to another datapoint) can be an issue 
in time series models, so after fitting the model we checked for autocorrelation using the Durbin-
Watson statistic which was checked for statistical significance.75 We then tested for goodness of 
fit and to see if model assumptions were met in a similar fashion to that described in 4.5.3. We 
also assessed our data for unusual or influential points using Cook’s D statistic which measures 
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the change in predicted values that occur when you delete an observation and refit the model and 
can identify outliers, leverage points and influential points. 
4.5.5 Exploring the counterfactual 
 The counterfactual is a theoretical condition in which for the same population, under the 
same conditions, and at the same time, a group which was exposed to a factor is no longer 
exposed and the outcome of interest can be re-assessed. In this study the counterfactual is  the 
proportion of hospitalizations where patients filled a medication of interest (within 5 days of 
discharge) in the post-HUGO time segment under the theoretical condition that HUGO had not  
been implemented. We graphically examined the counterfactual using equation 2, with 
intervention and time_after both equal to zero and applied a linear trendline to the graph. We 
chose time points 6 months, 1 year, 2 years and 5 years after interval 20 (when HUGO was 
implemented in reality) and used equation 2 with intervention and time_after both equal to zero 
to calculate our outcome at these time points. We then compared our counterfactual outcome to 
the observed outcome at the aforementioned time points and calculated the absolute difference in 
outcomes that could potentially be attributed to the implementation of HUGO. 
  
4.5.6 Additional analyses  
4.5.6.1 Sensitivity analyses for leverage/influential data points 
To assess the potential impact of high leverage points on our model we repeated 4.5.4 
excluding these data points.  
4.5.6.2 Sensitivity analysis for washout period 
 We recognized that time intervals immediately before, during and after HUGO’s 
implementation may not give an accurate representation of the impact of HUGO. HUGO was not 
implemented simultaneously across the hospital sites in our study, and this lag time may result in 
an underestimate of the potential impact of HUGO on our primary outcome. There may also 
have been a lag time in terms of the electronic medication reconciliation portion of HUGO being 
adopted fully by all hospital units, and there may have been a learning curve to effectively using 
this medication reconciliation system which could again underestimate the impact of HUGO on 
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our primary outcome. In anticipation of HUGO’s implementation, healthcare workers may have 
become more stringent about completing medication reconciliation which again would 
underestimate the potential impact of HUGO. Consequently, we repeated analyses 4.5.2 and 
4.5.4  with a washout period where the 2-month interval before, during, and after HUGO’s 
implementation (intervals 19-21) were excluded from analysis.  
4.5.6.3 Subgroup descriptive analysis for each medication class 
 We repeated 4.5.2 of the primary analysis for each of the following medication classes 
separately: antipsychotics, benzodiazepines, gastric acid suppressant medications. We did this to 
investigate whether a particular medication class was prone to more errors at discharge (and 
hence would have a higher proportion of hospitalizations where patients filled a medication of 


















5.1 Chapter overview 
In this chapter we will discuss our results including the cohort build and patient characteristics of 
the sample, and the observed relationship between HUGO’s implementation and the frequency 
of potentially inappropriate continuation of medications post discharge. We will also describe the 
results of our secondary analysis. 
5.2 Results 
5.2.1 Cohort build and patient characteristics of the sample 
The total number of hospitalizations and patients, including the number of 
hospitalizations and patients excluded at each stage of exclusions in the final cohort, is shown in 
table 6. Note that these values for the CERNER and ICES derived cohorts individually can be 
found in appendix I. A total of 18,405 hospitalizations corresponding to 15,932 patients were 
included in our analysis. This corresponds to 6063 hospitalizations pre-HUGO and 12,342 
hospitalizations post-HUGO. The number of hospitalizations within each of the four  time 


















Patient characteristics of our cohort over time are shown are shown visually in fig.3a-g. 
We did not observe any irregularities in the four time periods that were felt to be relevant. Note 
that the pre-HUGO era is captured predominantly within time intervals 1 and 2 and the post-
HUGO era is predominantly captured within time intervals 3 and 4, with some overlap in time 
interval 2. We chose not to test for statistically significant differences across the four time 
periods, opting instead to look for potentially clinically relevant differences. Testing for 
statistical significance would have required multiple comparisons for each variable, and we were 
more interested in  clinically relevant differences than small differences that may have been 
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We also assessed the characteristics of the patients with hospitalizations pre and post 
HUGO, and compared these two groups using standardized differences. There were no 
significant difference in any of the above covariates  pre- and post-HUGO (see appendix J for 








Endometrial cancer (malignant neoplasm of the
endometrium)
Heart attack (trasnmural, inferior wall)
Fig.3gTop  main diagnoses over 4 equal time segments
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standardized difference values), with the exception of  a higher prevalence of ischemic heart 
disease pre-HUGO (pre-HUGO: 24.5%, post-HUGO: 19.8%, standardized difference=0.11), a 
longer hospital los pre-HUGO (pre-HUGO: 10.51±14.38 days, post-HUGO: 9.04±11.55 days, 
standardized difference=0.11), and a greater mean number of primary care visits pre-HUGO 
(pre-HUGO: 0.99±1.71 visits/year, post-HUGO: 0.72±1.29 visits/year, standardized 
difference=0.18). Additionally, there was some minor variation in the most frequent diagnoses of 
patients pre- and post-HUGO; coronary artery disease appears to be more prevalent in our cohort 
pre-HUGO whereas heart attacks, knee osteoarthritis and hip joint arthritis appear to be more 
prevalent post-HUGO (see fig.3h).  
 
5.2.2 The relationship between HUGO’s implementation and the rate of potentially inappropriate 
continuation of medications post discharge  
 In order to explore the relationship between HUGO’s implementation and the frequency 
of potentially inappropriate continuation of medications, we calculated the proportion of 
potentially inappropriate medication filled post discharge in each two month period. We then 
graphed this proportion over time (figure 4), which demonstrated a decrease in the proportion of 








Endometrial cancer (malignant neoplasm of the
endometrium)
Heart attack (trasnmural, inferior wall)




hospitalizations where a medication of interest was filled after implementation of HUGO. This is 
corroborated by an observed decrease from 16.26% (971/5,971) of hospitalizations pre-HUGO 
resulting in a potentially inappropriate medication of interest being filled, compared to 13.43% 
(1670/12,434) post-HUGO. 
 
Fig.4: The proportion of hospitalizations where a medication of interest was filled 
 
We found that a segmented linear regression model was a good fit for our data and that 
model assumptions were met (see appendix K), yielding the following equation: 
Equation 3: Proportion(t)= 0.12105 + 0.004212*interval(t) -0.06976*intervention(t) -
0.00403*time_after(t) 
This equation tells us that at the start of the pre-HUGO observation period, the proportion 
of hospitalizations where a medication of interest was filled was 12.1%. There was significant 
(p<0.0001) interval to interval increase in our primary outcome before HUGO’s implementation. 
The proportion of hospitalizations where a medication of interest was filled decreased abruptly 
by 7.0% after HUGO’s implementation, and this was statistically significant (p<0.0001). Finally, 
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there was a significant (p=0.0001) decrease in slope after implementation of HUGO. These 
regression coefficient interpretations are summarized in table 8. In our sensitivity analyses we 
did not find that removing potentially influential points (intervals 18, 19, 21) resulted in a better 
fitting model than in the original primary analysis (see appendix L).  
  
Table 8: Interpretation of the regression coefficients for the segmented linear regression model of 
our data 
Variable Parameter Estimate P-value Interpretation 
Intercept 0.12105 <.0001 Just before the beginning 
of the observation period 
12.1% of hospitalizations 
had a medication of 
interest filled. 
Baseline Trend 0.004212 <.0001 Baseline slope; there was 
significant interval to 
interval increase in the 
proportion of 
hospitalizations with a 
medication of interest 




-0.06976 <.0001 The proportion of 
hospitalizations with a 
medication of interest 
filled decreased abruptly 




-0.00403 0.0001 There was a significant 
change in slope 
(decreasing) after 
implementation of HUGO 
 
By extrapolating our trendline for the counterfactual condition that HUGO had not been 
implemented, we see that there is a large difference between the observed and counterfactual 
outcome indicating that there was a reduction in the proportion of hospitalizations where an 
inappropriate prescription was filled post-discharge that occurred post-HUGO (see fig.5). This is 
further shown by the absolute difference between he counterfactual and observed outcomes at 6 
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months, 1 year, 2 years, and 5 years post interval 19, shown in table 9. For example, at the 6 
months mark we find that if HUGO had not been implemented the proportion of hospitalizations 
where a medication of interest was filled would be 7.8% higher than observed. In accordance 
with our model we see an increasing absolute difference between the observed and 
counterfactual outcome over time.  
Fig.5: Trendline of the observed vs. counterfactual proportion of hospitalizations where a 











Table 9: Absolute difference between the counterfactual and observed outcome post-HUGO at 













post 0.136076 0.213714 -0.077638 
If HUGO had not been 
implemented then the proportion 
of hospitalizations where a 
medication of interest filled 
would be 7.8% higher than the 
current state 
1 year post 0.13241 0.22635 -0.09394 
If HUGO had not been 
implemented then the proportion 
of hospitalizations where a 
medication of interest filled 
would be 9.4% higher than the 
current state 
2 years post 0.133502 0.251622 -0.11812 
If HUGO had not been 
implemented then the proportion 
of hospitalizations where a 
medication of interest filled 
would be 11.8% higher than the 
current state 
5 years post 0.136778 0.327438 -0.19066 
If HUGO had not been 
implemented then the proportion 
of hospitalizations where a 
medication of interest filled 
would be 19.1% higher than the 
current state 
 
5.2.3 Secondary analysis 
 To determine whether there was a short term disruption around the time of HUGO’s 
implementation we used a washout period which excluded the interval before,  during, and after 
HUGO’s implementation. With our washout period we see 16.1% (913/5678) and 13.5% 
(191/11,756) of hospitalizations having a medication of interest filled pre- versus post-HUGO 
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respectively. This is comparable to our findings without the washout period (16.2% pre-HUGO, 
13.4% post-HUGO) (see appendix M).  
We examined the specific medication groups individually to see how the individual 
medication classes changed with the implementation of HUGO. In our subgroup analysis (see 
table 10) we see that the proportion of hospitalizations where an antipsychotic was 
inappropriately filled post-discharge remains unchanged after HUGO, however for the two other 
medication classes the proportion of hospitalizations with our outcome decreases post-HUGO.  













Subgroup Exposure N, Encounters N, Outcomes % with Outcome
Pre-HUGO 438 20 4.57%
Post-HUGO 986 43 4.36%
Pre-HUGO 3047 95 3.12%
Post-HUGO 6190 129 1.40%
Pre-HUGO 4438 855 19.27%










6.1 Chapter overview 
 In this chapter the main results of this study will be summarized and compared to 
previous research on electronic and enhanced medication reconciliation (medication 
reconciliation), and the contribution of this study to the body of knowledge on medication 
reconciliation will be discussed. The implications for policy and clinical practice will also be 
discussed, as well as the study strengths and limitations and future directions for research.  
6.2 Discussion 
This study evaluated the impact that the implementation of HUGO has had on 
medications errors-specifically the potentially inappropriate continuation of antipsychotics, 
benzodiazepines, and gastric acid suppressants. This is the one of the first evaluations of the 
impact of HUGO at LHSC and SJHC, and adds to the limited body of knowledge on the impact 
of electronic medication reconciliation on medication errors.  
6.2.1 Results  
Our study demonstrated that the implementation of HUGO has resulted in a lower proportion 
of hospitalizations where a potentially inappropriate medication (antipsychotics, 
benzodiazepines, gastric acid suppressants) was filled post hospital discharge. There was both a 
significant reduction in the proportion of potentially inappropriate medications overall, and 
significant one time decrease in the filling of potentially inappropriate medications at the time of 
HUGO implementation. This is likely a consequence of the electronic medication reconciliation 
component of HUGO, however,  we are unable to definitively attribute the observed outcome to 
solely the electronic medication reconciliation component of HUGO. HUGO is a multi-faceted 
program, including bar coding, computerized physician order entry (CPOE), electronic 
medication administration (e-Mar), and electronic medication reconciliation (e-medication 
reconciliation) techniques. Although electronic medication reconciliation is the intervention 
which in theory would have the largest impact of reducing medication errors, such as the 
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potentially inappropriate continuation of medications, we cannot definitively discount the role 
other features of HUGO might have had on reducing the proportion of hospitalizations where a 
medication of interest was filled post-discharge.  
 In our exploratory analysis of the individual medication classes, we found there was a 
high relative decrease after HUGO with both gastric acid suppressants (pre-HUGO: 19.27%, 
post-HUGO: 11.31%, relative decrease of 57.69%), and benzodiazepines (pre-HUGO: 3.12%, 
post-HUGO: 1.40%, relative decrease 41.3%). Antipsychotics were not commonly prescribed 
and did not have a large magnitude of relative decrease following the implementation of HUGO 
(pre-HUGO: 4.57%, post-HUGO: 4.36%, relative decrease of 4.57%). This may be due to the 
fact that long-term use of antipsychotics and benzodiazepines are associated with more severe 
side effects (e.g. falls, arrythmias, cognitive decline, sedation, addiction) compared to gastric 
acid suppressants (e.g. increased risk of community-acquired pneumonia and enteric infection), 
resulting in physicians being more vigilant about discontinuing antipsychotics, and 
benzodiazepines when their use is unwarranted. 
This study also assumes that we were able to effectively exclude any hospitalizations 
where continuation of a medication of interest would be appropriate. Although we acknowledge 
that it is possible we were unable to exclude all hospitalizations where continuation of a 
medication  post-discharge would be appropriate, we believe with all of the exclusion in place it 
is unlikely that enough of these appropriate continuations were included in our analyses that the 
results would be affected. This is further supported by similar methodology and assumptions 
being used in a study by Scales et al. to measure potentially inappropriate continuation of the 
same medication classes, with this study being published in a well-respected journal.30 
  
6.2.2 Comparison to previous research  
Our study results are most comparable to prior studies evaluating the impact of electronic 
medication reconciliation. We were unable to isolate the effect of electronic medication 
reconciliation from the other components of HUGO (bar coding, Computerized Physician Order 
Entry, and electronic Medication Administration record), which makes a direct comparison of 
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our study results to those which were able to isolate the effects of electronic medication 
reconciliation challenging.  
Based on our systematic review (chapter 3), we observed inconsistent results in the 
reduction of medication errors and ADEs after implementation of electronic medication 
reconciliation. We found that electronic medication reconciliation compared to paper-based 
medication reconciliation was associated with a lower proportion of patients with at least one 
medication error or ADE in two out of 3 studies.34,35,53 Specifically, two studies with a low risk 
of bias35,53 found the crude and adjusted odds ratios to be statistically significant, and a third with 
unclear risk of bias34 found no statistically significant improvement We found that electronic 
medication reconciliation was not associated with a statistically significant reduction in the mean 
number of medication discrepancies or medication errors per patient.50,55Additionally, we found 
that electronic medication reconciliation was associated with reduction in the proportion of 
medications with errors compared to basic medication reconciliation; one of these studies (with a 
moderate risk of bias) found a significant reduction.54 Our outcome can be classified as the 
proportion of patients with at least one medication error at discharge, represented by the filling of 
at least one medication of interest post discharge. Two studies mentioned above from our 
systematic review match this outcome.34,54 Only one of these studies found a significant 
reduction in the proportion of patients with at least one medication error after implementation of 
electronic medication reconciliation.54 Hence, our results are in alignment with some of the 
literature, and add additional evidence to support the positive impact observed from electronic 
medication reconciliation. Advantages of our study relative to prior literature, include a well-
defined outcome based on clinically relevant medications, the use of health administrative 
databases to ascertain our exposure and outcome, a large sample size, and our analytic 
techniques.  
 
6.2.3 Study strengths and limitations 
This study used the combined power of CERNER and ICES databases to identify our 
cohort, with data linkage allowing us to identify conditions and covariates which would 
otherwise not be possible. For example performing this data linkage allowed us to flag patients 
who received one our medications of interest during their hospital stay, which would otherwise 
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not be possible with standard ICES datasets as inpatient medications are not recorded in ODB. 
To ensure that our exclusion diagnoses were accurate and as complete as possible we enlisted the 
assistance of an internal medicine specialist to identify patients where continuation of 
antipsychotics, benzodiazepines or gastric acid suppressant medications post discharge would be 
appropriate. Furthermore, our outcome measure-filling a medication of interest post-discharge as 
an indication of potentially inappropriate continuation of medications-has been used previously 
in a high-quality study.30 We used validated ICES-derived cohorts to measure prior conditions of 
our cohort where possible, and coding definitions from previous studies where it was not. We 
analyzed our data using segmented regression, which has been documented as a valid, quasi-
experimental approach for evaluating longitudinal effects of interventions such as HUGO.75 
Secondary analyses were used to explore the robustness of our finding, which used a washout 
period to adjust for the time it took for HUGO to be fully implemented, any associated learning 
curves for staff, and potential bias in medication reconciliation performance in anticipation of 
HUGO’s implementation.   
 
As previously mentioned, we are attributing the impact of HUGO to the electronic 
medication reconciliation component of HUGO.  However, HUGO is a multi-faceted program, 
and we cannot definitively discount the role other features included in HUGO may have had on 
our outcome. We attempted to exclude as many hospitalizations as possible where continuation 
of a medication of interest would be appropriate, however this may not have been completely 
successful, so the absolute rates of potentially inappropriate medication continuation may be 
overestimated. In order to avoid introducing survival bias into our study we chose to exclude 
patient encounters where a patient died or returned to the ER within 5 days of discharge, 
however, excluding these patients is not without consequence. Patients who experience death or 
return to the ER may have still experienced our outcome of interest, which would result in an 
underestimate of the effect of HUGO. This study examined the impact of HUGO on medication 
errors but not the clinical impact for patients. Although a reduction in medication errors is 
generally correlated with improved patient outcomes, we cannot conclude that HUGO had a 
significant impact on patient outcomes.  
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Although we used segmented regression, which is recommended for assessing the impact 
of interventions such as HUGO, we did not use a controlled before/after design. In this context a 
controlled before/after design would have required recruiting another hospital to serve as a 
control group which did not implement CERNER but had a comparable medication 
reconciliation design to that implemented at LHSC and SJHC pre-HUGO. Recruiting such a 
hospital was not feasible for the purposes of this study, hence although using a controlled design 
may have strengthened the conclusions of our study this was not possible. 
 We experienced a couple of limitations surrounding the use of ODB. The Ontario Drug 
Benefit database (ODB) which was used to measure our outcome can only capture data on 
patients who are eligible for the ODB program with complete population coverage limited to  
those 65 and older. This resulted in our study cohort only including patients over the age of 66 at 
time of hospital admission, to allow for us to measure our outcome and exclude patients who 
received a medication of interest within 6 months of admission. Excluding patients under 66 
years of age will impact the generalizability of our results, as physician electronic medication 
reconciliation completion habits could differ by age if physicians are more or less likely to 
complete electronic medication reconciliation for older patients. Additionally, using ODB we are 
only able to capture patients who filled prescription. If a large number of prescriptions went 
unfilled, this may have led to an underestimate of the number of potentially inappropriate 
prescriptions being continued post discharge. 
   
 6.2.4 Policy and clinical implications 
6.2.4.1 Implications for LHSC and SJHC 
The positive impact of HUGO on reducing medication errors suggests that investment 
into HUGO has resulted in a clinically relevant improvement in an important metric and 
indicates that continued support for electronic medication reconciliation procedures is worth 
while. This continued support could include more staff awareness campaigns on the impact of 
electronic medication reconciliation at LHSC and SJHC. These results also serve as an  indicator 
that LHSC and SJHC are committed to improving the safety of its patients, and that this has been 
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a successful endeavour which is an important commitment in the eyes of patients who attend this 
hospital system.  
6.2.4.2 Implications for patients 
 The results of this study indicate that electronic medication reconciliation is effective at 
reducing medication errors, specifically the potentially inappropriate continuation of medications 
after hospital discharge. If patients are less likely to be sent home on a medication they do not 
need then they are less likely (in theory) to experience ADEs including emergency department 
visits and re-hospitalizations associated with the medication. Previous research examining the 
impact of medication reconciliation programs on medication errors and ADEs has found that 
both medication errors and ADEs were reduced, supporting the theory that patient outcomes 
were likely improved through HUGO76,77. Future studies could evaluate the impact of HUGO on 
patient outcomes such as 30-day hospital readmissions and return to ER to further explore the 
impact that electronic medication reconciliation has on patients and its value to patient safety.  
 
 
6.2.4.3 Implications for clinicians 
As this study shows an association between electronic medication reconciliation and 
decreased medication errors, physicians may be more diligent when completing electronic 
medication reconciliation, as they may view their efforts as making an impact. This study also 
highlights how frequently medication errors occur, and given the classes of medication under 
study and the known dangers of their long-term use these findings may make physicians more 
vigilant when performing medication reconciliation in the future.  
6.2.4.4 Implications for the healthcare system 
The positive results displayed by HUGO may guide and encourage other hospitals to take 
a similar approach to medication reconciliation. Overall this could lead to fewer medication 
errors, their associated ADEs and negative impacts to the health care system (e.g. increased costs 




6.3 Future research 
Future studies could isolate the effect of the electronic medication reconciliation 
component of HUGO on medication errors by making use of CERNER where medication 
reconciliation completion is documented. Isolating this impact could strengthen the argument for 
a positive effect of electronic medication reconciliation on reducing medication errors. 
Additionally, future studies could evaluate the clinical impact of HUGO for patients, including 
investigating 30-day hospital readmissions and related emergency department visits. This would 
also provide information of the impact of HUGO, and specifically electronic medication 
reconciliation, on ADEs. Establishing a more concrete or uniform definition of medication 
reconciliation, medication discrepancies, and medication errors would allow for a more accurate 
comparison of medication reconciliation programs. Studies of higher quality (lower bias) would 
also allow for more concrete conclusions on the effectiveness of medication reconciliation 




 In this retrospective cohort study of patients >65 years at LHSC and SJHC in London, 
Ontario we evaluated the impact of HUGO on medication errors and provided new evidence of 
the positive impact of electronic medication reconciliation programs on reducing medication 
errors. We were able to demonstrate that implementation of HUGO was associated with a 
significant decrease in the proportion of hospitalizations where there was potentially 
inappropriate continuation of antipsychotics, benzodiazepines and gastric acid suppressants post 
hospital discharge. Additional research is required to evaluate the clinical impact of 
implementing HUGO, and to explore the contribution of electronic medication reconciliation 
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Appendix A-Search strategies for Ovid MEDLINE, EMBASE, and Scopus. 
Ovid MEDLINE <1946 to Oct.9, 2019> 
1 Patient admission/ 
2 Patient discharge/ 
3 Patient transfer/ 
4 continuity of patient care/ 
5 patient admi* or patient discharge* or patient transfer* or care continu* or continu* of care or 
continu* of patient care 
6 1 or 2 or 3 or 4 or 5 
7 Medication errors/ 
8 Patient readmission/ 
9 Inappropriate prescribing/ 
10 “Drug-Related Side Effects and Adverse Reactions”/ 
11 medicat* discrepanc* or inappropriate prescript* or inappropriate Prescrib* or readmi* or 
adverse drug event* or medication error* 
12 7 or 8 or 9 or 10 or 11 
13 medication reconciliation/ 
14 Medicat* reconcil* or reconcil* medicat* or medrec 
15 13 or 14 
16 6 or 12 
17 15 and 16 
18 limit 17 to English 
 
Embase <1946 to Oct.9, 2019> 
1 Hospital admission/ 
2 Hospital discharge/ 
3 Patient transport/ 
80 
 
4 patient admi* or patient discharge* or patient transfer* or care continu* or continu* of care or 
continu* of patient care 
5 1 or 2 or 3 or 4 
6 Medication error/ 
7 Hospital readmission/ 
8 Inappropriate prescribing/ 
9 Medicat* discrepanc* or Medicat* error* or patient readmi* or inappropriate prescript* or 
inappropriate prescrib* or adverse drug event 
10 6 or 7 or 8 or 9 
11 medication therapy management/ 
12 Medicat* reconcil* or reconcil* or medrec 
13 11 or 12 
14 5 and 10 and 13 
15 limit 14 to English 
 
Scopus <1966 to Oct.9, 2019> 
1 ({medication error} OR {medication discrepancy} OR {hospital readmission} OR 
{inappropriate prescribing} OR {adverse drug event}) AND ({medication reconciliation}) AND 
({patient admission} OR {patient discharge} OR {patient transfer}OR {continuity of patient 
care}) 
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Appendix C-Medications of interest for exclusion and outcome ascertainment 
i. Antipsychotics 













02414538 ABBOTT-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 


























02450860 ACH-QUETIAPINE FUMARATE XR 
ANTIPSYCHOTIC 
AGENTS 
02450879 ACH-QUETIAPINE FUMARATE XR 
ANTIPSYCHOTIC 
AGENTS 
02450887 ACH-QUETIAPINE FUMARATE XR 
ANTIPSYCHOTIC 
AGENTS 
02450895 ACH-QUETIAPINE FUMARATE XR 
ANTIPSYCHOTIC 
AGENTS 
02450909 ACH-QUETIAPINE FUMARATE XR 
ANTIPSYCHOTIC 
AGENTS 
02325659 ACT OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02325667 ACT OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02325675 ACT OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02325683 ACT OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02325691 ACT OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02325713 ACT OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02327562 ACT OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02327570 ACT OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02327589 ACT OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02327597 ACT OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02282585 ACT RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02282593 ACT RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02282607 ACT RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02282615 ACT RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 





02282631 ACT RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02487608 AG-OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02487616 AG-OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02487624 AG-OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02487632 AG-OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02487640 AG-OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02487659 AG-OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02487667 AG-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02487675 AG-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02487683 AG-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 



























00312673 APO CHLORPROMAZINE 
ANTIPSYCHOTIC 
AGENTS 
00312681 APO CHLORPROMAZINE 
ANTIPSYCHOTIC 
AGENTS 
00312703 APO CHLORPROMAZINE 
ANTIPSYCHOTIC 
AGENTS 
00587702 APO HALOPERIDOL LIQ 2MG/ML 
ANTIPSYCHOTIC 
AGENTS 
00396796 APO HALOPERIDOL TAB 0.5MG 
ANTIPSYCHOTIC 
AGENTS 























02242361 APO-HALOPERIDOL LA INJECTABLE 
ANTIPSYCHOTIC 
AGENTS 
02242362 APO-HALOPERIDOL LA INJECTABLE 
ANTIPSYCHOTIC 
AGENTS 
00463698 APO-HALOPERIDOL TAB 10MG 
ANTIPSYCHOTIC 
AGENTS 
00396826 APO-HALOPERIDOL TAB 2MG 
ANTIPSYCHOTIC 
AGENTS 

































02360616 APO-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02360624 APO-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02360632 APO-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 


























































































































































































02374803 ASENAPINE (ASENAPINE MALEATE) 
ANTIPSYCHOTIC 
AGENTS 

































02448726 AURO-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02448734 AURO-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02448742 AURO-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 









































00001595 BUPROPION HCL 
ANTIPSYCHOTIC 
AGENTS 
22602390 BUPROPION HCL 
ANTIPSYCHOTIC 
AGENTS 
02385694 BUPROPION HCL SR 
ANTIPSYCHOTIC 
AGENTS 
02383187 BUPROPION HCL XL 
ANTIPSYCHOTIC 
AGENTS 
























01929933 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00232831 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00025496 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00025178 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01929976 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01929909 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00025453 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00232157 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00025518 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01929941 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00580988 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00025461 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 





01929917 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01929992 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01929984 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00163953 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00025488 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00232807 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01929925 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00016993 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00017000 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00017019 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00017027 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00021318 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00021326 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00021334 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00021342 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00131725 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00163988 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00164003 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00209902 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00209910 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00210684 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00249394 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00271101 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00271128 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00295086 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00312673 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 





00312703 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00324299 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00324302 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00386588 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00386596 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00386618 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00430943 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00430951 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00430978 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00478334 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00502456 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00502464 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00523097 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00627615 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00690805 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00743518 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00774383 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00903042 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01933272 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01985434 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01985442 CHLORPROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 











































































































02470020 CLOZAPINE TABLETS 
ANTIPSYCHOTIC 
AGENTS 





02239919 DOM-LOXAPINE TABLETS 10MG 
ANTIPSYCHOTIC 
AGENTS 
02239920 DOM-LOXAPINE TABLETS 25MG 
ANTIPSYCHOTIC 
AGENTS 
02239921 DOM-LOXAPINE TABLETS 50MG 
ANTIPSYCHOTIC 
AGENTS 


















02307375 DOM-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02307383 DOM-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
























02294478 DOM-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 
02294486 DOM-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 


















































00524530 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
00524522 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02156032 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02024950 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02024969 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02091895 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02092816 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02242363 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02242364 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02331713 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
09857337 FLUPENTIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 













00585157 FLUPENTIXOL DIHYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00580619 FLUPENTIXOL DIHYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00580619 FLUPENTIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
00585157 FLUPENTIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 





00544426 FLUPENTIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02024942 FLUPENTIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02025043 FLUPENTIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02091860 FLUPENTIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02092794 FLUPENTIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02129086 FLUPENTIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02156024 FLUPENTIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
00755575 FLUPHENAZINE DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02091275 FLUPHENAZINE DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
00349917 FLUPHENAZINE DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02137402 FLUPHENAZINE DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02189089 FLUPHENAZINE DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02189097 FLUPHENAZINE DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02211157 FLUPHENAZINE DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02211165 FLUPHENAZINE DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02239636 FLUPHENAZINE DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02241928 FLUPHENAZINE DECANOATE 
ANTIPSYCHOTIC 
AGENTS 


















00029173 FLUPHENAZINE ENANTHATE 
ANTIPSYCHOTIC 
AGENTS 
00029378 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00405345 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00245240 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00410632 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 





00504459 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00405361 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00029408 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00029394 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00405353 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00471518 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00504424 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00504432 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00563803 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00563838 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00563846 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00582514 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00632643 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00726338 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00726346 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00726354 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00893420 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
02244166 FLUPHENAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00405353 FLUPHENAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00405345 FLUPHENAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00405361 FLUPHENAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00410632 FLUPHENAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00563846 FLUPHENAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00563838 FLUPHENAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00563803 FLUPHENAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00582514 FLUPHENAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 





00726346 FLUPHENAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00726354 FLUPHENAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 



































































































































































09853758 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
00599093 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02130300 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
00980803 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02130297 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
00599085 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
00559093 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
00897426 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
00980781 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02099616 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02099624 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02194430 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02194449 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02211130 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02211149 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02230707 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02230708 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02236866 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02239639 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02239640 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02242361 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02242362 HALOPERIDOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 



































00808652 HALOPERIDOL INJ 5MG/ML USP 
ANTIPSYCHOTIC 
AGENTS 
02366010 HALOPERIDOL INJECTION 
ANTIPSYCHOTIC 
AGENTS 
02406411 HALOPERIDOL INJECTION, USP 
ANTIPSYCHOTIC 
AGENTS 
02130297 HALOPERIDOL LA 
ANTIPSYCHOTIC 
AGENTS 
02130300 HALOPERIDOL LA 
ANTIPSYCHOTIC 
AGENTS 
00749400 HALOPERIDOL LACTATE 
ANTIPSYCHOTIC 
AGENTS 
00808652 HALOPERIDOL LACTATE 
ANTIPSYCHOTIC 
AGENTS 
02236866 HALOPERIDOL LONG ACTING 
ANTIPSYCHOTIC 
AGENTS 
02242631 HALOPERIDOL LONG ACTING 
ANTIPSYCHOTIC 
AGENTS 
00587796 HALOPERIDOL TAB 0.5MG 
ANTIPSYCHOTIC 
AGENTS 
00587788 HALOPERIDOL TAB 1MG 
ANTIPSYCHOTIC 
AGENTS 
00761745 HALOPERIDOL TAB 2MG 
ANTIPSYCHOTIC 
AGENTS 
00761753 HALOPERIDOL TAB 5MG 
ANTIPSYCHOTIC 
AGENTS 
00761761 HALOPERIDOL-10 TAB 10MG 
ANTIPSYCHOTIC 
AGENTS 
02239639 HALOPERIDOL-LA OMEGA 
ANTIPSYCHOTIC 
AGENTS 





















02387506 IPG-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 





02387522 IPG-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 





















02417243 JAMP OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02417251 JAMP OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02417278 JAMP OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02417286 JAMP OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02417294 JAMP OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02417308 JAMP OLANZAPINE FC 
ANTIPSYCHOTIC 
AGENTS 
02406624 JAMP OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02406632 JAMP OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02406640 JAMP OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02406659 JAMP OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02390140 JAMP QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02390159 JAMP QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02390167 JAMP QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 

































































02239101 LOXAPINE HCL 
ANTIPSYCHOTIC 
AGENTS 
02239921 LOXAPINE HCL 
ANTIPSYCHOTIC 
AGENTS 
02255448 LOXAPINE HCL 
ANTIPSYCHOTIC 
AGENTS 













02237652 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02237535 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02170027 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
00346799 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
00346802 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 





02237653 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02237536 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02237654 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02237537 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02170035 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
00346810 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
00346780 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02170019 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02237651 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02237534 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02236943 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02236944 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02236945 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02236946 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02238196 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02238197 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02238198 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 
02238199 LOXAPINE SUCCINATE 
ANTIPSYCHOTIC 
AGENTS 























































02389088 MAR-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02389096 MAR-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02389118 MAR-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 























BESYLATE)   
00027456 
MESORIDAZINE (MESORIDAZINE 
BESYLATE)   
00027448 
MESORIDAZINE (MESORIDAZINE 
BESYLATE)   
00027448 MESORIDAZINE BESYLATE 
ANTIPSYCHOTIC 
AGENTS 
00259489 MESORIDAZINE BESYLATE 
ANTIPSYCHOTIC 
AGENTS 
00027456 MESORIDAZINE BESYLATE 
ANTIPSYCHOTIC 
AGENTS 



































































































































01927698 METHOTRIMEPRAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00025003 METHOTRIMEPRAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00025194 METHOTRIMEPRAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00025208 METHOTRIMEPRAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01927701 METHOTRIMEPRAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01964925 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
01927663 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
00025593 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
02238405 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
02238403 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
00025577 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
01927647 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
01964933 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
01927671 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
00025607 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
02238406 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
02238404 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
00025585 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
01964909 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
01927655 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
00927647 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
00927655 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
00927663 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
00927671 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 





02239633 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
02239634 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
02239635 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
02241197 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 
02241198 METHOTRIMEPRAZINE MALEATE 
ANTIPSYCHOTIC 
AGENTS 



















































02436965 MINT-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02436973 MINT-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02436981 MINT-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 























02382709 MYLAN-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02382717 MYLAN-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02382725 MYLAN-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 





















02413485 MYLAN-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 
02413493 MYLAN-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 
02413507 MYLAN-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 
02413515 MYLAN-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 
02413523 MYLAN-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 
00021342 NOVO-CHLORPROMAZINE 200MG 
ANTIPSYCHOTIC 
AGENTS 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































02416522 OLANZAPINE FOR INJECTION 
ANTIPSYCHOTIC 
AGENTS 
02338645 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02338653 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02338661 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02343665 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02343673 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02343681 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02343703 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02348160 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02348179 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 





02352974 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02352982 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02352990 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02353008 OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 











































































02354233 PALIPERIDONE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
02354241 PALIPERIDONE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 





02455986 PALIPERIDONE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
02455994 PALIPERIDONE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
02354217 PALIPERIDONE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
02456001 PALIPERIDONE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
02354225 PALIPERIDONE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 


















































































































































































00563722 PERPHENAZINE 16 TAB 
ANTIPSYCHOTIC 
AGENTS 
00563757 PERPHENAZINE 2 TAB 2MG 
ANTIPSYCHOTIC 
AGENTS 
00563730 PERPHENAZINE 8 TAB 8MG 
ANTIPSYCHOTIC 
AGENTS 
00456039 PERPHENAZINE TAB 2MG 
ANTIPSYCHOTIC 
AGENTS 
00456047 PERPHENAZINE TAB 4MG 
ANTIPSYCHOTIC 
AGENTS 









































02307472 PHL-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 





















02294435 PHL-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 
02294443 PHL-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 




































00427918 PIPOTIAZINE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
01926667 PIPOTIAZINE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
00427926 PIPOTIAZINE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
00990507 PIPOTIAZINE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 





00894672 PIPOTIAZINE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
02236468 PIPOTIAZINE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
02236471 PIPOTIAZINE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 
01926667 PIPOTIAZINE PALMITATE 
ANTIPSYCHOTIC 
AGENTS 








00726206 PMS PERPHENAZINE TAB 16MG 
ANTIPSYCHOTIC 
AGENTS 
00726184 PMS PERPHENAZINE TAB 2MG 
ANTIPSYCHOTIC 
AGENTS 
00726192 PMS PERPHENAZINE TAB 4MG 
ANTIPSYCHOTIC 
AGENTS 













00726249 PMS TRIFLUOPERAZINE TAB 10MG 
ANTIPSYCHOTIC 
AGENTS 
00726214 PMS TRIFLUOPERAZINE TAB 1MG 
ANTIPSYCHOTIC 
AGENTS 
00726257 PMS TRIFLUOPERAZINE TAB 20MG 
ANTIPSYCHOTIC 
AGENTS 
00726222 PMS TRIFLUOPERAZINE TAB 2MG 
ANTIPSYCHOTIC 
AGENTS 









































































02303191 PMS-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02303205 PMS-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02303213 PMS-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 

















00753637 PMS-PROCHLORPERAZINE TAB 10MG 
ANTIPSYCHOTIC 
AGENTS 


























02291770 PMS-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 
02291789 PMS-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 
02291797 PMS-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 
02370697 PMS-RISPERIDONE ODT 
ANTIPSYCHOTIC 
AGENTS 






































01927779 PROCHLORPERAZINE MESYLATE 
ANTIPSYCHOTIC 
AGENTS 
00578185 PROCHLORPERAZINE MESYLATE 
ANTIPSYCHOTIC 
AGENTS 
00025216 PROCHLORPERAZINE MESYLATE 
ANTIPSYCHOTIC 
AGENTS 
01927787 PROCHLORPERAZINE MESYLATE 
ANTIPSYCHOTIC 
AGENTS 
00025100 PROCHLORPERAZINE MESYLATE 
ANTIPSYCHOTIC 
AGENTS 
















00017124 PROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00017132 PROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00017140 PROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00030066 PROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00034088 PROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00034177 PROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00034185 PROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00289612 PROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00497509 PROMAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 










































02330423 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02399830 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02397102 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 





02387808 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02438011 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02236952 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02311712 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02317907 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02316099 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02313928 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02314002 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02307812 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02299062 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02296578 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02284243 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02434032 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02439166 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02457237 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02407698 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02240862 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02321513 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02395452 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02457245 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02438046 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02412993 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02407701 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02353199 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02330458 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02399849 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 





02390248 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02387824 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02236953 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02317923 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02316110 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02314010 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02313936 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02311747 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02307839 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02296594 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02284278 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02300192 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02395460 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02434040 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02439182 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02412977 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02353164 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02330415 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02399822 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02397099 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02390205 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02387794 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02438003 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02236951 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02317893 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02316080 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 





02313901 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02311704 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02307804 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02299054 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02296551 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02284235 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02434024 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02439158 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02457253 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02413000 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02407728 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02395479 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02330466 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02399857 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02397129 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02390256 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02387832 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02438054 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02314029 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02317931 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02316129 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02313944 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02311755 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02307847 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02296608 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02284286 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 





02300206 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02434059 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02439190 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02457261 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02407736 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02395487 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02300214 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02457229 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02407671 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02395444 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02300184 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02284251 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02296586 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02298996 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02299003 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02299011 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02299038 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02299046 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02299070 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02299089 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02299097 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02307820 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02316102 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02316692 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02316706 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02316714 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 





02316730 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02317346 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02317354 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02317362 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02317370 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02317915 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02323737 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02323745 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02323753 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02323761 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02323788 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02330431 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02333031 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02333058 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02333066 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02333074 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02339153 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02339161 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02339188 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02339196 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02340127 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02340135 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02340143 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02340151 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02342596 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02342618 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 





02342634 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02342642 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02353172 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02353180 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02361892 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02363925 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02363933 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02363941 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02387816 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02390221 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02395800 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02395819 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02395827 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02400340 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02400359 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02400367 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02400375 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02400383 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02412985 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02417359 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02417367 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02417375 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02417383 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02417391 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02417782 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02417790 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 





02417812 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02417820 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02439174 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02447088 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02447096 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02447126 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02447134 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02447193 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02447207 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02447223 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
02447258 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
22123257 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 
82236951 QUETIAPINE FUMARATE 
ANTIPSYCHOTIC 
AGENTS 


















02429594 RAN-OLANZAPINE IR 
ANTIPSYCHOTIC 
AGENTS 
02429608 RAN-OLANZAPINE IR 
ANTIPSYCHOTIC 
AGENTS 
02429616 RAN-OLANZAPINE IR 
ANTIPSYCHOTIC 
AGENTS 
02429624 RAN-OLANZAPINE IR 
ANTIPSYCHOTIC 
AGENTS 
02429632 RAN-OLANZAPINE IR 
ANTIPSYCHOTIC 
AGENTS 
02429640 RAN-OLANZAPINE IR 
ANTIPSYCHOTIC 
AGENTS 
02414090 RAN-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 





02414112 RAN-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 







































00552429 RATIO-HALOPERIDOL 2MG/ML 
ANTIPSYCHOTIC 
AGENTS 
00552135 RATIO-HALOPERIDOL TAB 0.5MG 
ANTIPSYCHOTIC 
AGENTS 
00728306 RATIO-HALOPERIDOL TAB 10MG 
ANTIPSYCHOTIC 
AGENTS 
00552143 RATIO-HALOPERIDOL TAB 1MG 
ANTIPSYCHOTIC 
AGENTS 
00728292 RATIO-HALOPERIDOL TAB 2MG 
ANTIPSYCHOTIC 
AGENTS 


























02036371 REMOXIPRIDE HCL 
ANTIPSYCHOTIC 
AGENTS 























































































































































































































































































































































































































































































































































































































































































































































































































02296756 RISPERIDONE - 0.25 
ANTIPSYCHOTIC 
AGENTS 
02296764 RISPERIDONE - 0.5 
ANTIPSYCHOTIC 
AGENTS 
02296772 RISPERIDONE - 1 
ANTIPSYCHOTIC 
AGENTS 
02296780 RISPERIDONE - 2 
ANTIPSYCHOTIC 
AGENTS 
02296799 RISPERIDONE - 3 
ANTIPSYCHOTIC 
AGENTS 








02332051 RISPERIDONE TABLETS 
ANTIPSYCHOTIC 
AGENTS 
02332078 RISPERIDONE TABLETS 
ANTIPSYCHOTIC 
AGENTS 
02332086 RISPERIDONE TABLETS 
ANTIPSYCHOTIC 
AGENTS 
02332094 RISPERIDONE TABLETS 
ANTIPSYCHOTIC 
AGENTS 
02332108 RISPERIDONE TABLETS 
ANTIPSYCHOTIC 
AGENTS 
02332116 RISPERIDONE TABLETS 
ANTIPSYCHOTIC 
AGENTS 






































02339811 RIVA-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02339838 RIVA-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02339846 RIVA-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 





















02473658 SANDOZ ARIPIPRAZOLE 
ANTIPSYCHOTIC 
AGENTS 
02473666 SANDOZ ARIPIPRAZOLE 
ANTIPSYCHOTIC 
AGENTS 
02473674 SANDOZ ARIPIPRAZOLE 
ANTIPSYCHOTIC 
AGENTS 
02473682 SANDOZ ARIPIPRAZOLE 
ANTIPSYCHOTIC 
AGENTS 
02473690 SANDOZ ARIPIPRAZOLE 
ANTIPSYCHOTIC 
AGENTS 





02247798 SANDOZ CLOZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02247805 SANDOZ CLOZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02310341 SANDOZ OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02310368 SANDOZ OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02310376 SANDOZ OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02310384 SANDOZ OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02310392 SANDOZ OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02310406 SANDOZ OLANZAPINE 
ANTIPSYCHOTIC 
AGENTS 
02327775 SANDOZ OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02327783 SANDOZ OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02327791 SANDOZ OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02327805 SANDOZ OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
00789720 SANDOZ PROCHLORPERAZINE 
ANTIPSYCHOTIC 
AGENTS 
02279495 SANDOZ RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02279509 SANDOZ RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02279800 SANDOZ RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02279819 SANDOZ RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02279827 SANDOZ RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02279835 SANDOZ RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02292807 SANDOZ RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 
02303655 SANDOZ RISPERIDONE 
ANTIPSYCHOTIC 
AGENTS 







































































02321378 TEVA-OLANZAPINE OD 
ANTIPSYCHOTIC 
AGENTS 
02321386 TEVA-OLANZAPINE OD 
ANTIPSYCHOTIC 
AGENTS 
02321343 TEVA-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 























00028614 THIOPROPAZATE HCL 
ANTIPSYCHOTIC 
AGENTS 
00025763 THIOPROPERAZINE MESYLATE 
ANTIPSYCHOTIC 
AGENTS 
01927639 THIOPROPERAZINE MESYLATE 
ANTIPSYCHOTIC 
AGENTS 
00025747 THIOPROPERAZINE MESYLATE 
ANTIPSYCHOTIC 
AGENTS 
00025755 THIOPROPERAZINE MESYLATE 
ANTIPSYCHOTIC 
AGENTS 
00456101 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00037478 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00360244 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027553 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00575143 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027375 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00456063 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00037508 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00360228 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027529 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00575119 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00456071 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00037494 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00360198 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027537 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00575127 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00238775 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
02229553 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027359 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00775320 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00456098 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 





00360236 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027545 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00575135 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027561 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00238783 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00238791 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00238805 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00238813 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00238821 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00262587 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00268844 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00268852 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00271209 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00271217 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00271225 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00272728 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00324345 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00324353 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00386537 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00386545 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00386553 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00393541 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00431125 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00431133 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00431141 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00445223 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 





00502359 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00502367 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00502375 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00502383 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00776513 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00885592 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00885606 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00885614 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00903700 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00903726 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
66124536 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
66124538 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
66124547 THIORIDAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027359 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00027553 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00027529 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00027561 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00027537 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00027545 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00037478 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00037508 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00037494 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00037486 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00262587 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00575135 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00575143 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 





00775320 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00776513 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00575127 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00431125 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 
00431133 THIORIDAZINE HYDROCHLORIDE 
ANTIPSYCHOTIC 
AGENTS 





















02404702 TORRENT-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02404729 TORRENT-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02404737 TORRENT-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 









































02232692 TRIFLUOPERAZINE 10MG TABLETS 
ANTIPSYCHOTIC 
AGENTS 
02232680 TRIFLUOPERAZINE 1MG TABLETS 
ANTIPSYCHOTIC 
AGENTS 
02232690 TRIFLUOPERAZINE 2MG TABLETS 
ANTIPSYCHOTIC 
AGENTS 
02232691 TRIFLUOPERAZINE 5MG TABLETS 
ANTIPSYCHOTIC 
AGENTS 
00298212 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027022 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01918249 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01918230 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00021881 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00326836 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00280399 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027170 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00249092 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00021857 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00345539 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027146 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00249068 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01918206 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
01918257 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00026999 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00021865 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00312754 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00013900 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027154 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00249076 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 





01918222 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00021873 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00312746 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00013919 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027162 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00271527 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00249084 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00013897 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00013927 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00017183 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00017191 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00017205 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00018473 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00018481 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00018503 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00018511 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00024279 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00024287 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00024295 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027006 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00027030 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00116734 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00210749 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00210757 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00210838 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00210862 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 





00294861 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00303453 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00345881 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00345903 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00345911 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00346381 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00386502 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00386510 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00386529 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00389943 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00431176 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00431184 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00431192 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00431206 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00451630 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00460028 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00460044 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00460052 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00460060 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00503452 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00503460 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00503479 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00503487 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00595942 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00751871 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00886718 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 





02232690 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
02232691 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
02232692 TRIFLUOPERAZINE HCL 
ANTIPSYCHOTIC 
AGENTS 
00389943 TRIFLUOPERAZINE TAB 10MG 
ANTIPSYCHOTIC 
AGENTS 
00431206 TRIFLUOPERAZINE TAB 10MG 
ANTIPSYCHOTIC 
AGENTS 
00386529 TRIFLUOPERAZINE TAB 1MG 
ANTIPSYCHOTIC 
AGENTS 
00431176 TRIFLUOPERAZINE TAB 1MG 
ANTIPSYCHOTIC 
AGENTS 
00386510 TRIFLUOPERAZINE TAB 2MG 
ANTIPSYCHOTIC 
AGENTS 
00431184 TRIFLUOPERAZINE TAB 2MG 
ANTIPSYCHOTIC 
AGENTS 
00386502 TRIFLUOPERAZINE TAB 5MG 
ANTIPSYCHOTIC 
AGENTS 


















02438828 VAN-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02438836 VAN-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 
02438844 VAN-OLANZAPINE ODT 
ANTIPSYCHOTIC 
AGENTS 









































































































02449544 ZIPRASIDONE HCL 
ANTIPSYCHOTIC 
AGENTS 
02298597 ZIPRASIDONE HCL 
ANTIPSYCHOTIC 
AGENTS 
02298600 ZIPRASIDONE HCL 
ANTIPSYCHOTIC 
AGENTS 
02449552 ZIPRASIDONE HCL 
ANTIPSYCHOTIC 
AGENTS 
02449560 ZIPRASIDONE HCL 
ANTIPSYCHOTIC 
AGENTS 
02298619 ZIPRASIDONE HCL 
ANTIPSYCHOTIC 
AGENTS 
02298627 ZIPRASIDONE HCL 
ANTIPSYCHOTIC 
AGENTS 









































02230405 ZUCLOPENTHIXOL ACETATE 
ANTIPSYCHOTIC 
AGENTS 
02162946 ZUCLOPENTHIXOL ACETATE 
ANTIPSYCHOTIC 
AGENTS 
02162946 ZUCLOPENTHIXOL ACETATE 
ANTIPSYCHOTIC 
AGENTS 
02230405 ZUCLOPENTHIXOL ACETATE 
ANTIPSYCHOTIC 
AGENTS 
02230406 ZUCLOPENTHIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02162954 ZUCLOPENTHIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02162962 ZUCLOPENTHIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02230407 ZUCLOPENTHIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02162954 ZUCLOPENTHIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02162962 ZUCLOPENTHIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02230406 ZUCLOPENTHIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02230407 ZUCLOPENTHIXOL DECANOATE 
ANTIPSYCHOTIC 
AGENTS 
02162903 ZUCLOPENTHIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02230402 ZUCLOPENTHIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02230403 ZUCLOPENTHIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02162911 ZUCLOPENTHIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02162938 ZUCLOPENTHIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 
02230404 ZUCLOPENTHIXOL HCL 
ANTIPSYCHOTIC 
AGENTS 









DIN Drug Name DCLASS 
02400111 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02230074 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
01913239 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02137534 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00865397 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
01913484 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00548359 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00677485 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02417634 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02400138 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02349205 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02230075 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00677477 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00548367 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
01913492 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02137542 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
01913247 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00865400 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02417642 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00813958 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00723770 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00913484 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00913492 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
01908170 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
01908189 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02018179 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02018187 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02083418 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02083426 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02147572 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02147580 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02228858 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02228866 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02229813 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02229814 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02230744 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02230745 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02237264 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
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02237265 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02237266 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02237267 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02242107 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02242108 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02243611 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02243612 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02248706 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02248707 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02287277 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02287315 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02287323 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02287331 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02346990 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02347008 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02349191 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02400146 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02400154 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02404877 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02404885 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02404893 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02404907 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02417650 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02417669 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02248706 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02349191 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02349205 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02434601 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02434628 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02434636 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02434644 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02230074 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02230075 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02248707 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
01908189 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
01908170 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02397021 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02397048 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02397056 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02397064 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02400111 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
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02400138 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02400146 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02400154 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02137534 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02137542 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02229813 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02229814 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02417634 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02417642 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02417650 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02417669 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02346990 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02347008 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00677477 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00677485 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02404877 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02404885 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02404893 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02404907 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02242107 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
02242108 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
01913484 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
01913492 ALPRAZOLAM BENZODIAZEPINE DERIVATIVES 
00682314 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02177153 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02171856 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02192705 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02167808 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02167816 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02171864 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02177161 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02192713 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
00518123 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230584 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230585 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
00518131 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02177188 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02167824 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02171872 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02192721 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02220512 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
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02220520 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02220539 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02228874 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02228882 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02228890 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230039 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230040 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230041 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230666 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230667 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230668 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02232556 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02232558 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02242152 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02242153 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
99101489 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
99101490 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02167808 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02167816 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02167824 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02177153 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02177161 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02177188 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02220512 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02220520 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02220539 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02192713 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02192721 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02192705 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02171856 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02171864 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02171872 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02232556 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02232558 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02242152 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02242153 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230584 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230585 BROMAZEPAM BENZODIAZEPINE DERIVATIVES 
00522988 CHLORDIAZEPOXIDE BENZODIAZEPINE DERIVATIVES 
00522996 CHLORDIAZEPOXIDE BENZODIAZEPINE DERIVATIVES 
00522724 CHLORDIAZEPOXIDE BENZODIAZEPINE DERIVATIVES 
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00016764 CHLORDIAZEPOXIDE BENZODIAZEPINE DERIVATIVES 
00430927 CHLORDIAZEPOXIDE BENZODIAZEPINE DERIVATIVES 
00430935 CHLORDIAZEPOXIDE BENZODIAZEPINE DERIVATIVES 
00448737 CHLORDIAZEPOXIDE BENZODIAZEPINE DERIVATIVES 
00903688 CHLORDIAZEPOXIDE BENZODIAZEPINE DERIVATIVES 
00013471 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00020923 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00012637 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00398411 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00012645 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00020931 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00398438 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00013498 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00295051 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00398403 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00013463 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00020915 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00012629 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00012815 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00016756 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00022020 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00134325 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00134333 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00156590 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00210064 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00235873 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00251259 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00251267 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00267090 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00301558 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00314471 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00314498 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00314528 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00324418 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00363596 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00379913 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00434426 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00440183 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00451479 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00451487 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00451495 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
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00502626 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
99101299 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
99101354 CHLORDIAZEPOXIDE HCL BENZODIAZEPINE DERIVATIVES 
00618454 
CHLORDIAZEPOXIDE HCL & CLIDINIUM 
BROMIDE BENZODIAZEPINE DERIVATIVES 
00115630 CHLORDIAZEPOXIDE HCL & CLIDINIUM HCL BENZODIAZEPINE DERIVATIVES 
00391077 CHLORDIAZEPOXIDE HCL & CLIDINIUM HCL BENZODIAZEPINE DERIVATIVES 
00636223 CHLORDIAZEPOXIDE HCL & CLIDINIUM HCL BENZODIAZEPINE DERIVATIVES 
00807516 CHLORDIAZEPOXIDE HCL & CLIDINIUM HCL BENZODIAZEPINE DERIVATIVES 
00522724 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00522988 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00522996 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00156590 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00363596 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00618454 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00448737 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00430935 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00434426 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00235873 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00267090 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00295051 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00391077 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00115630 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00134333 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00134325 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00020923 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00020931 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00020915 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02239110 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00636223 CHLORDIAZEPOXIDE HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00846392 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
01989634 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02221799 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02244474 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02238334 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02238797 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02244638 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
00903405 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02247230 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02248454 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02347598 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
09851844 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
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09851968 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
22123230 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
99101484 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02244638 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02248454 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02247230 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02347598 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02244474 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02238797 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
02238334 CLOBAZAM BENZODIAZEPINE DERIVATIVES 
09852395 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02345676 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02230950 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02233960 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02239024 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02230366 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02236948 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02270641 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
00382825 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02048701 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02173344 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02103656 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02145227 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02207818 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02177889 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02048736 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02177897 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02103737 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02173352 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02145243 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
00382841 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02270676 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02230951 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02230369 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02233985 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02303337 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02239025 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
00903559 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
00907197 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
00907200 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
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02010365 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02048728 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02078736 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02130998 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02131005 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02131013 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02145235 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02179660 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02220598 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02220601 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02224100 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02230368 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02233982 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02235370 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02235379 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02236947 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02237277 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02237278 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02242077 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02242078 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02270668 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02280639 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02303302 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02303310 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02303329 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02311593 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02311607 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02311615 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02340968 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02340976 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02344602 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02344610 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02344629 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02365243 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02365251 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02365278 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02442027 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02442035 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02442043 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02442051 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
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22123231 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
82048736 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
82207818 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02365243 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02365251 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02365278 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02177889 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02177897 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02344602 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02344610 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02442027 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02442035 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02442043 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02442051 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02220598 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02220601 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02344629 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02270641 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02270668 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02270676 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02130998 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02131013 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02224100 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02230950 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02230951 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02173344 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02173352 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02236947 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02145227 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02145235 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02145243 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02236948 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02048701 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02048728 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02048736 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02179660 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02207818 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02311593 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
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02311607 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02311615 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02103656 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02103737 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02242077 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02242078 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02233960 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02233982 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02233985 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02239024 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02239025 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02303310 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02303329 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02303337 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
02345676 CLONAZEPAM BENZODIAZEPINE DERIVATIVES 
00628212 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00264911 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00860697 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00860689 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00628190 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00264938 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00628204 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00264946 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00860700 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
49264946 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00264946 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00264938 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00264911 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00628204 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00628190 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00628212 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00860689 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00860697 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00860700 CLORAZEPATE DIPOTASSIUM BENZODIAZEPINE DERIVATIVES 
00012874 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00466891 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00405337 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00272450 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00013773 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00272639 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00013293 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
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00891797 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00272647 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00405329 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00466905 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00013757 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00272434 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00013277 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00602825 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02065614 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00013285 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00280429 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00396230 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00362158 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00272442 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00013765 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02386143 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00399728 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
09857240 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
09853340 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
09853430 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02238162 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00012661 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00012688 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00013110 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00037265 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00260320 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00260339 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00260347 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00276642 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00276650 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00285439 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00299545 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00303461 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00311596 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00313580 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00313890 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00315052 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00315060 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00315079 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00324264 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00324272 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
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00324957 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00325422 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00326933 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00337307 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00345601 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00345628 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00392847 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00392855 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00392863 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00404632 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00409632 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00432377 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00432385 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00432393 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00434388 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00434396 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00446750 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00446769 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00448850 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00448869 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00448877 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00507962 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00507970 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00519324 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00882380 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00882968 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00964999 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02005492 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02070944 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02070952 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02070960 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02137399 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02232737 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02232749 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02232751 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02243240 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247173 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247174 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247176 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247490 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
181 
 
02247491 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247492 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02385392 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
09991151 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
22123237 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
99101249 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247173 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247174 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247176 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00362158 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00405329 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00405337 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02232751 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00434388 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02232737 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00434396 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00313580 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02232749 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02243240 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02386143 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00399728 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02385392 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247490 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247491 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
02247492 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
00891797 DIAZEPAM BENZODIAZEPINE DERIVATIVES 
66990914 DIAZEPAM & METHYLCELLULOSE BENZODIAZEPINE DERIVATIVES 
02015102 ESTAZOLAM BENZODIAZEPINE DERIVATIVES 
02016060 ESTAZOLAM BENZODIAZEPINE DERIVATIVES 
02016060 ESTAZOLAM BENZODIAZEPINE DERIVATIVES 
02015102 ESTAZOLAM BENZODIAZEPINE DERIVATIVES 
99503020 EXTEMPORANEOUS MIXTURE BENZODIAZEPINE DERIVATIVES 
00496545 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00012696 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00521698 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00483826 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00012718 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00496553 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00521701 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00483818 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00414220 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
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00414239 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00578479 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00578487 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00667099 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00667102 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00844698 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
00844701 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
02232656 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
02232657 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
02241281 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
02241282 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
02248126 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
02248127 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
49012696 FLURAZEPAM HCL BENZODIAZEPINE DERIVATIVES 
02070901 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02070928 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02128934 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02128942 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02248126 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02248127 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00012696 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00012718 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00521698 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00521701 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00578479 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02232656 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00578487 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02232657 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00496545 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00496553 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00667102 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00667099 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02241281 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02241282 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00414220 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00414239 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00483826 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
00483818 FLURAZEPAM HYDROCHLORIDE BENZODIAZEPINE DERIVATIVES 
02459973 IVABRADINE (IVABRADINE HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02459981 IVABRADINE (IVABRADINE HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
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02459973 IVABRADINE HCL 
BENZODIAZEPINE RELATED 
DRUGS 
02459981 IVABRADINE HCL 
BENZODIAZEPINE RELATED 
DRUGS 
00514519 KETAZOLAM BENZODIAZEPINE DERIVATIVES 
00514527 KETAZOLAM BENZODIAZEPINE DERIVATIVES 
00559245 KETAZOLAM BENZODIAZEPINE DERIVATIVES 
01919512 KETAZOLAM BENZODIAZEPINE DERIVATIVES 
01919520 KETAZOLAM BENZODIAZEPINE DERIVATIVES 
00865672 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02041413 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00728187 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00399124 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00711101 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655740 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02041456 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00722138 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02410753 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00865680 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02041421 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00728195 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00348325 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00637742 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655759 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00557757 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02041464 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02410761 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00865699 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02041448 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00728209 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00348333 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655767 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00637750 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00557765 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02041472 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02041405 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00557773 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
09857216 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02243278 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655643 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
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00655651 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655678 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02240725 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02240726 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02240727 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02245784 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02245785 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02245786 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02280477 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02280485 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02298201 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02298228 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02298236 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02347733 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02347741 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02347768 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02351072 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02351080 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02351099 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02388669 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02410745 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02429810 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02429829 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02438704 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
05022457 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
22123248 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
49348325 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
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80637742 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
80711101 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655740 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655759 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655767 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02245784 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02245785 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02245786 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02351072 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02351080 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02351099 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02429802 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02429810 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02429829 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02243278 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02388669 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02438704 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02410745 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02410753 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02410761 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02347733 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02347741 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02347768 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02298201 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02298228 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02298236 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00728187 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00728195 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00728209 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655643 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655651 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00655678 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02240725 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02240726 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02240727 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00637742 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00637750 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
00711101 LORAZEPAM BENZODIAZEPINE DERIVATIVES 
02243254 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02382342 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02382350 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
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02382377 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02382385 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02240285 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02240286 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02242904 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02242905 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02423758 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02423766 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02382873 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02382903 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02382342 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02382350 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02382377 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02382385 MIDAZOLAM BENZODIAZEPINE DERIVATIVES 
02243253 MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02243254 MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02243934 MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02243935 MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02383586 MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02383594 MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02241753 MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02241754 MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02242653 MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02242654 MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) BENZODIAZEPINE DERIVATIVES 
02240285 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
00784516 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
00766011 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
09857438 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
09857437 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
09857436 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
09857225 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02242905 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02240286 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02241753 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02241754 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02242653 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02242654 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02242904 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02243253 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02243934 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02243935 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
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02244788 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02244789 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02382873 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02382903 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02423758 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02423766 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
99100865 MIDAZOLAM HCL BENZODIAZEPINE DERIVATIVES 
02234007 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02245231 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02229655 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
00511536 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
00511528 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02234003 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02245230 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02229654 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
00903215 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02200961 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02200988 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02255561 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02255588 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
22296655 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
99101127 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02245230 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02245231 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02255588 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02255561 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02234003 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02234007 NITRAZEPAM BENZODIAZEPINE DERIVATIVES 
02043653 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00500852 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00483893 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00402680 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00295701 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00496529 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00483915 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00402745 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00295698 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02043661 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02043688 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00496537 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00483907 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
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00402737 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00231363 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00414247 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00414255 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00414263 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00497754 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00497762 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00497770 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00568392 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00568406 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00568414 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00702745 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00726362 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00726370 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00726389 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00903599 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02232721 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02232727 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02232732 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02247177 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02247178 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02247179 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02253968 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02253976 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02253984 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02294079 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02294087 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02294095 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
80402680 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
80402745 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00402680 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00402745 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00402737 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02247177 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02247178 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02247179 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00497754 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02232721 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00497762 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02232727 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00497770 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
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02232732 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00483915 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00483907 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00726362 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00726370 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00726389 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00568392 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00568406 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
00568414 OXAZEPAM BENZODIAZEPINE DERIVATIVES 
02273039 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02243023 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230095 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02231615 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02244814 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229455 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
00604453 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02225964 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02223570 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02225972 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02223589 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
00604461 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02273047 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02243024 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230102 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02231616 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02244815 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229456 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
00513881 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
00518166 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229756 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229758 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229760 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229761 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229854 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230101 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02237294 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02237295 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02239071 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02239072 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02243624 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02247526 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
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02247527 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02253070 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02253089 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02297957 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02297965 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02347865 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02347873 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
06022235 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
22123262 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
99101293 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02244814 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02244815 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229756 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229758 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02231615 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02231616 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02347865 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02347873 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02223570 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02223589 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02239071 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02239072 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02297957 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02297965 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02273039 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02273047 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229455 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229456 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02243023 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02243024 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02225964 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02225972 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229760 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02229761 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230095 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
02230102 TEMAZEPAM BENZODIAZEPINE DERIVATIVES 
00512559 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00614351 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
01995227 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00808563 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00886084 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
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02230024 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
02230025 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00808571 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00886092 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00872431 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
01913506 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00443158 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00614378 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00443123 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00443131 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00860816 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00860824 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00872423 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
02084406 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
02084414 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
02232553 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
02232554 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
05019135 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
99100774 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
99100775 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00614351 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00614378 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
01913506 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
01995227 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
02232553 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
02232554 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00808563 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00808571 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00860816 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
00860824 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 
02230024 TRIAZOLAM BENZODIAZEPINE DERIVATIVES 































iii. Gastric acid suppressants 
DIN Drug Name DCLASS 
02238525 
AMOXICILLIN TRIHYDRATE & CLARITHROMYCIN 
& LANSOPRAZOLE PROTON PUMP INHIBITORS 
02231831 BISMUTH CITRATE & RANITIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02227436 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916793 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00865796 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00563560 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00546232 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00584215 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00582409 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229717 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229718 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00487872 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00397474 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00582417 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00546240 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02227444 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916815 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00865818 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02227452 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916785 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00865826 CIMETIDINE 





HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00603678 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00600059 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00563579 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229719 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229720 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00563587 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00603686 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00600067 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00584282 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916777 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02227460 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00865834 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00749494 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916769 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00663727 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00618616 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00653411 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229721 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00486876 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00596469 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00596477 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00616230 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00618691 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00618705 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00639893 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00639907 CIMETIDINE 





HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00644277 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00644285 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00749454 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00811610 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00811629 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00811637 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00901390 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00916815 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02227479 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231285 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231287 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231288 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231290 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231291 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02237010 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02237412 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02237619 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238161 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238257 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
99101253 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
99101285 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
99101291 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
99101301 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00487872 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00584215 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00600059 CIMETIDINE 





HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00749494 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00596469 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00596477 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00618691 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00618705 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231285 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231287 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231288 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231290 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231291 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02227436 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02227444 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02227452 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02227460 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02227479 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229717 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229718 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229719 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229720 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229721 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02237619 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02237010 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238161 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00582409 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00582417 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00603678 CIMETIDINE 





HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00663727 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00865796 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00865818 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00865826 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00865834 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00546232 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00546240 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00568449 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00584282 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00618616 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916815 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916785 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916777 CIMETIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243085 CIMETIDINE (CIMETIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02209063 CIMETIDINE (CIMETIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916807 CIMETIDINE (CIMETIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00397482 CIMETIDINE (CIMETIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916750 CIMETIDINE (CIMETIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243085 CIMETIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00397482 CIMETIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916750 CIMETIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00397490 CIMETIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00527076 CIMETIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01916807 CIMETIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02209063 CIMETIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02240385 CIMETIDINE HCL 




01927280 CIMETIDINE HYDROCHLORIDE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02354696 DEXLANSOPRAZOLE PROTON PUMP INHIBITORS 
02354950 DEXLANSOPRAZOLE PROTON PUMP INHIBITORS 
02354969 DEXLANSOPRAZOLE PROTON PUMP INHIBITORS 
02423855 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02423863 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02417480 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02417499 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02384329 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02384337 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02379163 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02379171 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02386216 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02386224 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02460920 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02460939 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
DIHYDRATE) PROTON PUMP INHIBITORS 
02449587 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE) PROTON PUMP INHIBITORS 
02449595 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE) PROTON PUMP INHIBITORS 
02479419 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE) PROTON PUMP INHIBITORS 
02479427 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE) PROTON PUMP INHIBITORS 
02383039 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE) PROTON PUMP INHIBITORS 
02383047 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE) PROTON PUMP INHIBITORS 
02300524 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE) PROTON PUMP INHIBITORS 
02244521 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE) PROTON PUMP INHIBITORS 
02244522 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE) PROTON PUMP INHIBITORS 
02444712 
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE) PROTON PUMP INHIBITORS 
02339099 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02339102 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02394839 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
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02394847 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02431173 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02438461 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02438488 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02442493 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02442507 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02414392 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02414406 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02423979 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02423987 ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02300524 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02244522 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02244521 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02339099 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02339102 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02379171 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02383039 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02383047 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02394839 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02394847 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02423855 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02423863 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02423979 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02423987 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02431173 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02442493 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02442507 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02444712 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02460920 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02460939 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
82244522 ESOMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
99503002 EXTEMPORANEOUS MIXTURE PROTON PUMP INHIBITORS 
00728128 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01953842 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02024195 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02022133 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02196018 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00710121 FAMOTIDINE 





HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02240622 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242327 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02351102 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02351110 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02237149 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242328 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02240623 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00710113 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02022141 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02024209 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01953834 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02196026 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00728101 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01953824 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02100541 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02100568 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02185911 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02185938 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229995 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229996 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231104 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231119 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231400 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231567 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02232293 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02235133 FAMOTIDINE 





HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02237150 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02237223 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238212 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238342 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238343 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02240414 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241322 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241372 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241373 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242154 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242155 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242326 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242357 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243053 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02244133 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02244795 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02244796 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02244888 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02244998 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02246364 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247735 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247745 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247799 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247800 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02248222 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02248223 FAMOTIDINE 





HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02252910 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02257645 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02257653 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02259443 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02259451 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02273357 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02296098 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02347636 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02347644 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02373920 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02373939 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
99304725 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231119 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02244888 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02244998 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01953842 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01953834 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02257645 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02257653 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238212 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02244133 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02246364 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02383071 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02383098 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247799 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247800 FAMOTIDINE 





HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247735 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02248222 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02248223 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02351102 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02351110 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241372 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241373 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02196018 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02196026 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02347636 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02347644 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02024195 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02024209 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238342 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238343 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242327 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242328 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02240622 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02240623 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242154 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242155 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02022133 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02022141 FAMOTIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02433001 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02402610 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02357682 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02353830 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02385643 LANSOPRAZOLE PROTON PUMP INHIBITORS 
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02293811 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02280515 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02165503 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02395258 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02353849 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02402629 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02357690 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02385651 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02293838 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02280523 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02165511 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02433028 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02395266 LANSOPRAZOLE PROTON PUMP INHIBITORS 
00000100 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02249472 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02249464 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02258609 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02258617 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02354756 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02354764 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02366274 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02366282 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02367815 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02367823 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02369001 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02369028 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02385767 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02385775 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02410370 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02410389 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02414775 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02422808 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02422816 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02433672 LANSOPRAZOLE PROTON PUMP INHIBITORS 
09991289 LANSOPRAZOLE PROTON PUMP INHIBITORS 
99503010 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02470780 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02293811 LANSOPRAZOLE PROTON PUMP INHIBITORS 
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02293838 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02414767 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02414775 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02357682 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02357690 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02366282 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02385767 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02410389 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02433001 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02433028 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02433672 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02410370 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02385775 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02489805 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02489813 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02353830 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02353849 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02392402 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02392410 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02354756 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02354764 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02395258 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02395266 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02369001 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02369028 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02402610 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02402629 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02422808 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02422816 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02385643 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02385651 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02280515 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02280523 LANSOPRAZOLE PROTON PUMP INHIBITORS 
02258080 LANSOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02443449 NAPROXEN   
02458608 NAPROXEN   
02361701 NAPROXEN   
02361728 NAPROXEN   
00778338 NIZATIDINE 





HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02220156 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02240457 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02246046 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02240458 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02246047 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00778346 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02220164 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02177722 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00220156 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02128888 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02128896 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02155737 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02155745 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02185814 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02185822 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02230976 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238194 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238195 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02239558 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02239559 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247051 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247052 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02220156 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02220164 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02185814 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02246046 NIZATIDINE 





HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02239558 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02239559 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02240457 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02240458 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247051 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247052 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238194 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238195 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02177722 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02177714 NIZATIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02119579 OMEPRAZOLE PROTON PUMP INHIBITORS 
02230737 OMEPRAZOLE PROTON PUMP INHIBITORS 
02245058 OMEPRAZOLE PROTON PUMP INHIBITORS 
00846503 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857285 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857343 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857342 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857341 OMEPRAZOLE PROTON PUMP INHIBITORS 
02348691 OMEPRAZOLE PROTON PUMP INHIBITORS 
02403617 OMEPRAZOLE PROTON PUMP INHIBITORS 
02329433 OMEPRAZOLE PROTON PUMP INHIBITORS 
02320851 OMEPRAZOLE PROTON PUMP INHIBITORS 
02296446 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857314 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857530 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857464 OMEPRAZOLE PROTON PUMP INHIBITORS 
02416549 OMEPRAZOLE PROTON PUMP INHIBITORS 
02374870 OMEPRAZOLE PROTON PUMP INHIBITORS 
02295415 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857500 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857267 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857195 OMEPRAZOLE PROTON PUMP INHIBITORS 
02190915 OMEPRAZOLE PROTON PUMP INHIBITORS 
02260867 OMEPRAZOLE PROTON PUMP INHIBITORS 
02242462 OMEPRAZOLE PROTON PUMP INHIBITORS 
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02245059 OMEPRAZOLE PROTON PUMP INHIBITORS 
02260859 OMEPRAZOLE PROTON PUMP INHIBITORS 
02295407 OMEPRAZOLE PROTON PUMP INHIBITORS 
02296438 OMEPRAZOLE PROTON PUMP INHIBITORS 
02310252 OMEPRAZOLE PROTON PUMP INHIBITORS 
02320843 OMEPRAZOLE PROTON PUMP INHIBITORS 
02329425 OMEPRAZOLE PROTON PUMP INHIBITORS 
02331764 OMEPRAZOLE PROTON PUMP INHIBITORS 
02331772 OMEPRAZOLE PROTON PUMP INHIBITORS 
02333430 OMEPRAZOLE PROTON PUMP INHIBITORS 
02335220 OMEPRAZOLE PROTON PUMP INHIBITORS 
02339927 OMEPRAZOLE PROTON PUMP INHIBITORS 
02340100 OMEPRAZOLE PROTON PUMP INHIBITORS 
02340119 OMEPRAZOLE PROTON PUMP INHIBITORS 
02358050 OMEPRAZOLE PROTON PUMP INHIBITORS 
02358069 OMEPRAZOLE PROTON PUMP INHIBITORS 
02364352 OMEPRAZOLE PROTON PUMP INHIBITORS 
02372258 OMEPRAZOLE PROTON PUMP INHIBITORS 
02372274 OMEPRAZOLE PROTON PUMP INHIBITORS 
02385384 OMEPRAZOLE PROTON PUMP INHIBITORS 
02402416 OMEPRAZOLE PROTON PUMP INHIBITORS 
02411857 OMEPRAZOLE PROTON PUMP INHIBITORS 
02422212 OMEPRAZOLE PROTON PUMP INHIBITORS 
02422220 OMEPRAZOLE PROTON PUMP INHIBITORS 
02435683 OMEPRAZOLE PROTON PUMP INHIBITORS 
02438968 OMEPRAZOLE PROTON PUMP INHIBITORS 
02439018 OMEPRAZOLE PROTON PUMP INHIBITORS 
09093299 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857350 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857391 OMEPRAZOLE PROTON PUMP INHIBITORS 
09857467 OMEPRAZOLE PROTON PUMP INHIBITORS 
09991011 OMEPRAZOLE PROTON PUMP INHIBITORS 
22123268 OMEPRAZOLE PROTON PUMP INHIBITORS 
66123550 OMEPRAZOLE PROTON PUMP INHIBITORS 
02245058 OMEPRAZOLE PROTON PUMP INHIBITORS 
02245059 OMEPRAZOLE PROTON PUMP INHIBITORS 
02422212 OMEPRAZOLE PROTON PUMP INHIBITORS 
02422220 OMEPRAZOLE PROTON PUMP INHIBITORS 
02364352 OMEPRAZOLE PROTON PUMP INHIBITORS 
02329425 OMEPRAZOLE PROTON PUMP INHIBITORS 
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02329433 OMEPRAZOLE PROTON PUMP INHIBITORS 
02339927 OMEPRAZOLE PROTON PUMP INHIBITORS 
02348691 OMEPRAZOLE PROTON PUMP INHIBITORS 
02385376 OMEPRAZOLE PROTON PUMP INHIBITORS 
02385384 OMEPRAZOLE PROTON PUMP INHIBITORS 
02411857 OMEPRAZOLE PROTON PUMP INHIBITORS 
02320843 OMEPRAZOLE PROTON PUMP INHIBITORS 
02320851 OMEPRAZOLE PROTON PUMP INHIBITORS 
02372258 OMEPRAZOLE PROTON PUMP INHIBITORS 
02372274 OMEPRAZOLE PROTON PUMP INHIBITORS 
02403617 OMEPRAZOLE PROTON PUMP INHIBITORS 
02296438 OMEPRAZOLE PROTON PUMP INHIBITORS 
02296446 OMEPRAZOLE PROTON PUMP INHIBITORS 
02432765 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02484617 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02436728 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02449927 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02333422 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02333430 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02420198 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02439549 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02435748 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02432765 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02439018 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02490692 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02436213 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02416549 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02433281 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02310252 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02310260 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02449919 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02374870 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02260859 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02260867 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02402416 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02331764 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02331772 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02295407 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02295415 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02432404 OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
09857536 OMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
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02432404 OMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02420198 OMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02439549 OMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02310260 OMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02365677 OMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02449919 OMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02449927 OMEPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02441853 PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02440628 PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM) PROTON PUMP INHIBITORS 
02386747 
PANTOPRAZOLE (PANTOPRAZOLE SODIUM 
SESQUIHYDRATE) PROTON PUMP INHIBITORS 
02453401 
PANTOPRAZOLE (PANTOPRAZOLE SODIUM 
SESQUIHYDRATE) PROTON PUMP INHIBITORS 
02392615 
PANTOPRAZOLE (PANTOPRAZOLE SODIUM 
SESQUIHYDRATE) PROTON PUMP INHIBITORS 
02392623 
PANTOPRAZOLE (PANTOPRAZOLE SODIUM 
SESQUIHYDRATE) PROTON PUMP INHIBITORS 
02481561 
PANTOPRAZOLE (PANTOPRAZOLE SODIUM 
SESQUIHYDRATE) PROTON PUMP INHIBITORS 
02481588 
PANTOPRAZOLE (PANTOPRAZOLE SODIUM 
SESQUIHYDRATE) PROTON PUMP INHIBITORS 
02306727 PANTOPRAZOLE (PANTOPRAZOLE SODIUM) PROTON PUMP INHIBITORS 
02441527 PANTOPRAZOLE (PANTOPRAZOLE SODIUM) PROTON PUMP INHIBITORS 
02408570 PANTOPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02440628 PANTOPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02441853 PANTOPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02267233 PANTOPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02466147 PANTOPRAZOLE MAGNESIUM PROTON PUMP INHIBITORS 
02428164 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02417448 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02416565 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02415208 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02412969 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02357054 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02437945 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02239616 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
00239616 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02308703 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02307871 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02309866 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02301083 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02300486 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02299585 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02292920 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
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02285487 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02229453 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02305046 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02244730 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02285479 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02291665 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02292912 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02294656 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02294672 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02301075 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02305038 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02306727 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02307863 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02308681 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02309858 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02309998 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02310007 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02310198 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02310201 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02316455 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02316463 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02318687 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02318695 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02328704 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02330709 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02334658 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02334666 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02336308 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02339072 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02340097 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02343789 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02352214 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02354179 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02358867 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02358875 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02363410 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02363429 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02370808 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02385740 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
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02385759 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02408414 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02416557 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02425378 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02428172 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02428180 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02431327 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02439107 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02441527 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02445867 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02458969 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02467372 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02469138 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02471825 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02478781 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
82229453 PANTOPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02422638 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02320614 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02298074 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02296632 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02408392 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02345579 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02356511 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02381737 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02314177 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02310805 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02243796 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
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02422646 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02320622 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02298082 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02296640 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02408406 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02345587 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02356538 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02381745 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02314185 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02310813 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02243797 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02315181 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02315203 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02320452 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02320460 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02320592 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02320606 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02330083 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02330091 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02335166 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02335174 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02345994 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02346001 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02370719 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02370727 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02385449 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02385457 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
03205920 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
24084060 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02422638 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02422646 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02484161 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02484188 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02345579 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02345587 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02320452 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02320460 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02415283 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02415291 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02408392 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02408406 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
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02345994 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02346001 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02243796 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02243797 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02381737 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02381745 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02310805 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02310813 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02315181 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02315203 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02385449 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02385457 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02320614 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02320622 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02356511 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02356538 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02298074 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02298082 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02419785 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02419793 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02330083 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02330091 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02314177 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02314185 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02296632 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
02296640 RABEPRAZOLE SODIUM PROTON PUMP INHIBITORS 
00740756 RANITIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02385961 RANITIDINE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02407523 RANITIDINE (RANITIDINE HCL) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02452464 RANITIDINE (RANITIDINE HCL) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02248570 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02248571 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02484501 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02484528 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02280833 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00733059 RANITIDINE (RANITIDINE HYDROCHLORIDE) 




00733067 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02265591 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02265605 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243038 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243039 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02463717 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02463725 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02473534 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02473542 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02443708 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02443716 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02367378 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02367386 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02207761 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02207788 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02245782 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02245783 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242453 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242454 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02336480 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02336502 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02245615 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02286106 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02286114 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02303353 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02303388 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02343436 RANITIDINE (RANITIDINE HYDROCHLORIDE) 




02343444 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02353016 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02353024 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02385953 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02385961 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00740748 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00740756 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02256711 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02368005 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02350203 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02350211 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02230003 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02230004 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00828688 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00828823 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247814 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247815 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238579 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243229 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243230 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241598 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241599 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00828556 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00828564 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231487 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242940 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229562 RANITIDINE (RANITIDINE HYDROCHLORIDE) 




02229563 RANITIDINE (RANITIDINE HYDROCHLORIDE) 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02367378 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02336480 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243229 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242453 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241598 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02248570 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02230003 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00865737 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00828823 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00828564 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00733059 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02212331 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02207761 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00553379 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00905992 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02212374 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00782386 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242940 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02280833 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02212366 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00603791 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02256711 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243230 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242454 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241599 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02248571 RANITIDINE HCL 




02230004 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02367386 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02336502 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00641790 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00865745 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00828688 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00828556 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00733067 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02212358 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02207788 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00191213 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00740748 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00849421 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00849448 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
00990230 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01951823 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
01951831 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02076284 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02076292 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02212382 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02213397 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02213494 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02213508 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02213516 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02213524 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02219077 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02219085 RANITIDINE HCL 




02229562 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02229563 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02230287 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02230507 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02231487 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02237829 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238579 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02238893 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241208 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241422 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02241597 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242056 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242057 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02242058 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243038 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02243039 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02245615 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02245782 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02245783 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02246167 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02246168 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247551 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247814 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02247815 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02265591 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02265605 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02266806 RANITIDINE HCL 




02277301 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02284022 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02286106 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02286114 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02291282 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02293471 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02296160 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02298740 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02298902 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02303221 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02303353 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02303388 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02323699 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02323702 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02327244 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02327252 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02342871 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02342898 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02343436 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02343444 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02350203 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02350211 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02353016 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02353024 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02363526 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02368005 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02385953 RANITIDINE HCL 




02400103 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02443708 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02443716 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02463717 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02463725 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
09991036 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
22123159 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
49828564 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
80000219 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
99100771 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
99100772 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
99101171 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
99101172 RANITIDINE HCL 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
02219077 RANITIDINE HYDROCHLORIDE 
HISTAMINE H2 RECEPTOR 
ANTAGONIST 
66123562 UNCLASSED THERAPEUTIC PROTON PUMP INHIBITORS 
66123574 UNCLASSED THERAPEUTIC PROTON PUMP INHIBITORS 
66123586 UNCLASSED THERAPEUTIC PROTON PUMP INHIBITORS 
66123598 UNCLASSED THERAPEUTIC PROTON PUMP INHIBITORS 
 
Appendix D- Exclusion diagnoses for cohort build 
  





F062, F200, F201, F202, F203, F205, F206, F208, 
F209, F230, F231, F232, ICD-10 MH 
  295, spec19 OHIP dx   
Major Depressive 
Disorder 
F063, F321, F322, F323, F328, F329, F330, F331, 
F332, F333, F334, F338, F339 ICD-10 MH 
  296, 300, 311, spec19 OHIP dx   
Bipolar Disorder 
F313, F314, F315, F310, F311, F312, F316, F317, 
F318, F319 ICD-10 MH 




F064, F410, F411, F412, F413, F418, F419, F400, 
F401, F402, F408, F409 ICD-10 MH 
  300, spec 19 OHIP dx   
Gastrointestinal 
Bleeding K922 ICD-10 GI 
Gastroduodenal 
Ulcer 
K260, K261, K262, K263, K264, K265, K266, K267, 
K269 ICD-10 GI 
  532 OHIP dx   
Gastroesophageal 
Reflux K210, K219 ICD-10 GI 
Dementia 
F000, F001, F002, F009, F010, F011, F012, F013, 
F018, F019, F020, F021, F022, F023, F024, F028, F03, 
F04 ICD-10 MH 
  290, spec19 OHIP dx   
Esophagitis K20 ICD-10 GI 
  530 OHIP dx   
Gastrinoma 81531, 81533 ICD-10 GI 
Mental and 
behavioural 
disorders due to 
substance 
use/withdrawal 
F100, F101, F102, F103, F104, F105, F106, F107, 
F108, F109, F130, F131, F132, F133, F134, F135, 
F136, F137, F138, F139, F190, F191, F192, F193, 
F194, F195, F196, F197, F198, F199 ICD-10 MH 
Psychotic 
disorders F230, F231, F232, F233, F238, F239, F28, F29,  ICD-10 MH 
  298 OHIP dx   
Induced delusional 
disorders F24 ICD-10 MH 
Schizoaffective 
disorders F250, F251, F252, F258, F259,  ICD-10 MH 
Obsessive-
Compulsive 
disorders F420, F421, F422, F428, F429 ICD-10 MH 
  300 OHIP dx   
Reaction to severe 
stress and 
adjustment 
disorders F430, F431, F432, F438, F439 ICD-10 MH 
  309 OHIP dx   
Dissociative 
disorders 
F440, F441, F442, f443, F444,F445, F446, F447, F448, 
F449 ICD-10 MH 
Somatoform 
disorders F450, F451, F452, F453, F454, F458, F459 ICD-10 MH 
Other neurotic 
disorders F480, F481, F488, F489 ICD-10 MH 




disorders F060 ICD-10 MH 
 
Note: MH=mental health diagnoses, GI=gastrointestinal diagnoses 
Explanation of codes  
Code Source Full-Digit ICD10 Code Description 
Sub Category/Description 
(for OHIP dx) 
F062 ICD-10 
Organic delusional [schizophrenia-like] 
disorder   
F200 ICD-10 Paranoid schizophrenia   
F201 ICD-10 Hebephrenic schizophrenia   
F202 ICD-10 Catatonic schizophrenia   
F203 ICD-10 Undifferentiated schizophrenia   
F205 ICD-10 Residual schizophrenia   
F206 ICD-10 Simple schizophrenia   
F208 ICD-10 Other schizophrenia   
F231 ICD-10 
Acute polymorphic psychotic disorder 
with symptoms of schizophrenia   
F232 ICD-10 
Acute schizophrenia-like psychotic 
disorder   
295 OHIP dx   Schizophrenia 
spec19 OHIP dx   
Variable: identifies 
psychiatrist visit 
F063 ICD-10 Organic mood [affective] disorders   
F321 ICD-10 Moderate depressive episode   
F322 ICD-10 
Severe depressive episode without 
psychotic symptoms   
        
F323 ICD-10 
Severe depressive episode with 
psychotic symptoms   
F329 ICD-10 Depressive episode, unspecified   
F330 ICD-10 
Recurrent depressive disorder, current 




Recurrent depressive disorder, current 
episode moderate   
F332 ICD-10 
Recurrent depressive disorder, current 
episode severe without psychotic 
symptoms   
F333 ICD-10 
Recurrent depressive disorder, current 
episode severe with psychotic 
symptoms   
F338 ICD-10 Other recurrent depressive disorders   
        
F339 ICD-10 
Recurrent depressive disorder, 
unspecified   
296 OHIP dx   
Manic depressive psychosis, 
involutional melancholia 
311 OHIP dx   
Depressive or other non-
psychotic disorders, not 
elsewhere classified 
F310 ICD-10 
Bipolar affective disorder, current 
episode hypomanic   
F311 ICD-10 
Bipolar affective disorder, current 
episode manic without psychotic 
symptoms   
F312 ICD-10 
Bipolar affective disorder, current 
episode manic with psychotic 
symptoms   
F313 ICD-10 
Bipolar affective disorder, current 
episode mild or moderate depression   
F314 ICD-10 
Bipolar affective disorder, current 
episode severe depression without 
psychotic symptoms   
F315 ICD-10 
Bipolar affective disorder, current 
episode severe depression with 
psychotic symptoms   
F316   
Bipolar affective disorder, current 
episode mixed   
F317 ICD-10 
Bipolar affective disorder, currently in 
remission   
F318 ICD-10 Other bipolar affective disorder   
F319 ICD-10 Bipolar affective disorders, unspecified   
F064 ICD-10 Organic anxiety disorder   
F411 ICD-10 Generalized anxiety disorder   
224 
 
F412 ICD-10 Mixed anxiety and depressive disorder   
F413 ICD-10 Other mixed anxiety disorders   
F418 ICD-10 Other specified anxiety disorders   
F419 ICD-10 Anxiety disorder, unspecified   
303 OHIP dx   




unspecified   
K260 ICD-10 
Duodenal ulcer, acute with 
haemorrhage   
K261 ICD-10 Duodenal ulcer, acute with perforation   
K262 ICD-10 
Duodenal ulcer, acute with both 
haemorrhage and perforation   
K263 ICD-10 
Duodenal ulcer, acute without 
haemorrhage or perforation   
K264 ICD-10 
Duodenal ulcer, chronic or unspecified 
with haemorrhage   
K265 ICD-10 
Duodenal ulcer, chronic or unspecified 
with perforation   
K266 ICD-10 
Duodenal ulcer, chronic or unspecified 
with both haemorrhage and perforation   
K267 ICD-10 
Duodenal ulcer, chronic without 
haemorrhage or perforation   
K269 ICD-10 
Duodenal ulcer, unspecified as acute or 
chronic, without haemorrhage or 
perforation   
532 OHIP dx   
Diseases of the digestive 
system/Duodenal ulcer, with 
or without haemorrhage or 
perforation 
K210 ICD-10 
Gastro-oesophageal reflux disease with 
oesophagitis   
K219 ICD-10 
Gastro-oesophageal reflux disease 
without oesophagitis   
F000 ICD-10 
Dementia in Alzheimer's disease with 
early onset   
F001 ICD-10 
Dementia in Alzheimer's disease with 
late onset   
F002 ICD-10 
Dementia in Alzheimer's disease with 
late onset   
F009 ICD-10 
Dementia in Alzheimer's disease, 
unspecified   
F010 ICD-10 Vascular dementia of acute onset   
F011 ICD-10 Vascular dementia   
225 
 
F012 ICD-10 Subcortical vascular dementia   
F013 ICD-10 
Mixed cortical and subcortical vascular 
dementia   
F018 ICD-10 Other vascular dementia   
F019 ICD-10 Vascular dementia, unspecified   
F020 ICD-10 Dementia in Pick's disease   
F021 ICD-10 Dementia in Creutzfeldt-Jakob disease   
F022 ICD-10 Dementia in Huntington's disease   
F023 ICD-10 Dementia in Parkinson's disease   
F024 ICD-10 
Dementia in human immunodeficiency 
virus [HIV] disease   
F028 ICD-10 
Dementia in other specified diseases 
classified elsewhere   
F03 ICD-10 Unspecified dementia   
F04 ICD-10 
Organic amnesic syndrome, not 
induced by alcohol and other 
psychoactive substances   
290 OHIP dx   
Senile dementia, presenile 
dementia 
K20 ICD-10 Oesophagitis   
530 OHIP dx   
Esophagitis, cardiospasm, 
ulcer of esophagus; stricture, 
stenosis, or obstruction of 
esophagus 
81531 ICD-10 Gatsrinoma, NOS   
81533 ICD-10 Gastrinoma, malignant   
F232 ICD-10 
Acute schizophrenia-like psychotic 
disorder   
F233 ICD-10 
Other acute predominantly delusional 
psychotic disorders   
F238 ICD-10 
Other acute and transient psychotic 
disorders   
F239 ICD-10 
Acute and transient psychotic disorder, 
unspecified   
F24 ICD-10 Induced delusional disorder   
        
F250 ICD-10 Schizoaffective disorder, manic type   
F251 ICD-10 
Schizoaffective disorder, depressive 
type   
F252 ICD-10 Schizoaffective disorder, mixed type   
F258 ICD-10 Other schizoaffective disorders   
F259 ICD-10 Schizoaffective disorder, unspecified   
F28 ICD-10 Other nonorganic psychotic disorders   
F29 ICD-10 Unspecified nonorganic psychosis   




Delirium not superimposed on 
dementia, so described   
F051 ICD-10 Delirium superimposed on dementia   
F059 ICD-10 Delirium, unspecified   
F060 ICD-10 Organic hallucinosis   
F100 ICD-10 
Mental and behavioural disorders due 
to use of alcohol, acute intoxication   
F101 ICD-10 
Mental and behavioural disorders due 
to use of alcohol, harmful use   
F102 ICD-10 
Mental and behavioural disorders due 
to use of alcohol, dependence 
syndrome   
F103 ICD-10 
Mental and behavioural disorders due 
to use of alcohol, withdrawal state   
F104 ICD-10 
Mental and behavioural disorders due 
to use of alcohol, withdrawal state with 
delirium   
F105 ICD-10 
Mental and behavioural disorders due 
to use of alcohol, psychotic disorder   
F106 ICD-10 
Mental and behavioural disorders due 
to use of alcohol, amnesic syndrome   
F107 ICD-10 
Mental and behavioural disorders due 
to use of alcohol, residual and late-
onset psychotic disorder   
F108 ICD-10 
Mental and behavioural disorders due 
to use of alcohol, other mental and 
behavioural disorders   
F109 ICD-10 
Mental and behavioural disorders due 
to use of alcohol, unspecified mental 
and behavioural disorder   
F130 ICD-10 
Mental and behavioural disorders due 
to use of sedatives or hypnotics, acute 
intoxication   
F131 ICD-10 
Mental and behavioural disorders due 
to use of sedatives or hypnotics, 
harmful use   
F132 ICD-10 
Mental and behavioural disorders due 
to use of sedatives or hypnotics, 
dependence syndrome   
F133 ICD-10 
Mental and behavioural disorders due 
to use of sedatives or hypnotics, 
withdrawal state   
F134 ICD-10 
Mental and behavioural disorders due 
to use of sedatives or hypnotics, 
withdrawal state with delirium   
F135 ICD-10 
Mental and behavioural disorders due 
to use of sedatives or hypnotics, 




Mental and behavioural disorders due 
to use of sedatives or hypnotics, 
amnesic syndrome   
F137 ICD-10 
Mental and behavioural disorders due 
to use of sedatives or hypnotics, 
residual and late-onset psychotic 
disorder   
F138 ICD-10 
Mental and behavioural disorders due 
to use of sedatives or hypnotics, other 
mental and behavioural disorders   
F139 ICD-10 
Mental and behavioural disorders due 
to use of sedatives or hypnotics, 
unspecified mental and behavioural 
disorder   
F190 ICD-10 
Mental and behavioural disorders due 
to multiple drug use and use of 
psychoactive substances, acute 
intoxication   
F191 ICD-10 
Mental and behavioural disorders due 
to multiple drug use and use of 
psychoactive substances, harmful use   
F192 ICD-10 
Mental and behavioural disorders due 
to multiple drug use and use of 
psychoactive substances, dependence 
syndrome   
F193 ICD-10 
Mental and behavioural disorders due 
to multiple drug use and use of 
psychoactive substances, withdrawal 
state   
F194 ICD-10 
Mental and behavioural disorders due 
to multiple drug use and use of 
psychoactive substances, withdrawal 
state with delirium   
F195 ICD-10 
Mental and behavioural disorders due 
to multiple drug use and use of 
psychoactive substances, psychotic 
disorder   
F196 ICD-10 
Mental and behavioural disorders due 
to multiple drug use and use of 
psychoactive substances, amnesic 
syndrome   
F197 ICD-10 
Mental and behavioural disorders due 
to multiple drug use and use of 
psychoactive substances, residual and 
late-onset psychotic disorder   
F198 ICD-10 
Mental and behavioural disorders due 
to multiple drug use and use of 
psychoactive substances, other mental 




Mental and behavioural disorders due 
to multiple drug use and use of 
psychoactive substances, unspecified 
mental and behavioural disorder   
291 OHIP dx   
Alcoholic psyhcosis, 
delirium tremens, Korsakov’s 
psychosis 
292 OHIP dx   Drug psychosis 
304 OHIP dx   
Drug dependence, drug 
addiction 
F230 ICD-10 
Acute polymorphic psychotic disorder 
without symptoms of schizophrenia   
F231 ICD-10 
Acute polymorphic psychotic disorder 
with symptoms of schizophrenia   
F400 ICD-10 Agoraphobia   
        
F401 ICD-10 Social phobias   
F402 ICD-10 Specific (isolated) phobias   
F408 ICD-10 Other phobic anxiety disorders   
F409 ICD-10 Phobic anxiety disorder, unspecified   
F410 ICD-10 
Panic disorder [episodic paroxysmal 
anxiety]   
F420 ICD-10 
Predominantly obsessional thoughts or 
ruminations   
F421 ICD-10 
Predominantly compulsive acts 
[obsessional rituals]   
F422 ICD-10 Mixed obsessional thoughts and acts   
F428 ICD-10 Other obsessive-compulsive disorders   
F429 ICD-10 
Obsessive-compulsive disorder, 
unspecified   
F430 ICD-10 Acute stress reaction   
F431 ICD-10 Post-traumatic stress disorder   
F432 ICD-10 Adjustment disorders   
F438 ICD-10 Other reactions to severe stress   
F439 ICD-10 Reaction to severe stress, unspecified   
F440 ICD-10 Dissociative amnesia   
F441 ICD-10 Dissociative fugue   
F442 ICD-10 Dissociative stupor   
F443 ICD-10 Trance and possession disorders   
F444 ICD-10 Dissociative motor disorders   
F445 ICD-10 Dissociative convulsions   
F446 ICD-10 
Dissociative anaesthesia and sensory 
loss   
F447 ICD-10 
Mixed dissociative [conversion] 




Other dissociative [conversion] 
disorders   
F449 ICD-10 
Dissociative [conversion] disorder, 
unspecified   
F450 ICD-10 Somatization disorder   
F451 ICD-10 Undifferentiated somatoform disorder   
F452 ICD-10 Hypochondriacal disorder   
F453 ICD-10 Somatoform autonomic dysfunction   
F454 ICD-10 Persistent somatoform pain disorder   
F458 ICD-10 Other somatoform disorders   
F459 ICD-10 Somatoform disorder, unspecified   
F480 ICD-10 Neurasthenia   
F481 ICD-10 
Depersonalization-derealization 
syndrome   
F488 ICD-10 Other specified neurotic disorders   
F489 ICD-10 Neurotic disorder, unspecified   
298 OHIP-dx   Other psychoses 
309 OHIP-dx   Adjustment reaction 
    
 
 
Appendix E- Cohort inclusion/exclusion steps with ICES databases 
Step Description Database 
1 
Include hospitalizations from CERNER 
dataset where patients that were prescribed 
one of the medications of interest. Align 
Cerner records with DAD based on discharge 
dates (CERNER, dischargedate=DAD 




Data cleaning: exclude hospitalizations with 
an invalid IKN,  age <66 yo or >105 yo, non-
Ontario residents, or who were not 
discharged from University hospital, Victoria 




Exclude hospitalizations where death date<= 
discharge date +5 days DAD 
4 
Exclude hospitalizations who were 
discharged from a psychiatric institution 
[insttype institution  not equal to ’AT’ or 




Exclude hospitalizations who were 
readmitted within 5 days of discharge DAD 
6 
Exclude hospitalizations with a mental health 
or gastrointestinal diagnosis in the 6mo prior 
to admission and/or  during hospital stay DAD, OHIP 
7 
Exclude hospitalizations with prior 
medication use (6mo prior to admission) ODB 
8 
Exclude hospitalizations who returned to ED 
within 5 days of discharge NACRS 
9 
Exclude hospitalizations who were 














Appendix G-Coding for patient characteristics 
 
Covariate Codes/variables Source Notes 
Charlson comorbidity 
score %CHARLSON macro DAD   
Hospital los LOS DAD   
Primary care visits in past 
year 
A001, A003-A006, A008, A901, A905, 
A912, C912, K024, K025, Q525, W872, 
W912 OHIP feecodes   
  spec= '00' OHIP   
Specialist care visits in 
past year 
spec= '13', '41', '47', '48', '60', '61', '07', '15', 
'16', '46', '18' OHIP   
Type of inpatient service 
(medical vs. surgical vs. 
geriatric vs. other vs. 
unknown)   CERNER   
Number of medications in 
previous year   ODB   
ED to inpatient transfer TO_TYPE='I' NACRS   
Age   RPDB   
Sex   RPDB   
SES(Income) INCQUINT RPDB 





Long term care resident 
RESIDENT_CODE and absence of 
DISCHARGE_FLAG_IND CCRS 
Long term care 
resident in 3 months 
prior to admission or 
admitted from a long-
term care facility 
  INSTFTYP values=4, 9 DAD Institution from type 
Prior COPD %COPD (ICES derived cohort) OHIP, DAD, SDS   
Prior diabetes %ODD (ICES derived cohort) 
OHIP, DAD, 
ODB   
Prior hypertension %HYPER (ICES derived cohort) OHIP, DAD, SDS   
Prior ischemic heart 
disease ICD-10: I20-I25 DAD 
 Definition for 
ischemic heart disease 
sources from paper by 
Griffith et al. Also 
included patients with 
two physician billings 
within a one-year 
period with one of the 
billings by a specialist 
or a family physician 
in a hospital or 
emergency room 




Look back period of 5 
years 
  CCP:4802, 4803, 4809, 481 DAD   
  CCI: 1IJ50, 1IJ57GQxx, 1IJ76 DAD   
  410, 412, 413, R742, R743, Z434, G298 OHIP   
Prior liver disease     
Definition of liver 
disease sources from 
paper by Griffith et al. 
5 year lookback period  
  
Mild: ICD-10 codes B180,  B181, B182, 
B188, B189, K700-K703, K709, K713- 
K715, K717, K73, K74, K760, K762-K764, 
K768, K769, Z944  DAD/SDS   
  
Moderate/Severe: ICD-10 codes I850, I859, 
I864, I982,K704, K711, K721, K729, K765, 
K766, K767 DAD/SDS   
Prior inflammatory bowel 
disease     
Definition of 
inflammatory bowel 
disease sources from 
paper by Griffith et al. 
5 year lookback 
window 
  
ICD10: K500, K501, K508-K515, K518, 
K519, M074, M075, M091, M092, K52 DAD/NACRS   
  555, 556, 564 OHIP  
Definition of renal 
disease sources from 
paper by Griffith et 
al.Any 2 codes within 
90 days of each other. 
5 year lookback period 
Prior renal disease 
R849, R850, G323, G325, G326, G330, 
G331, G860, G333, G083, G091, G085, 
G295, G082, G090, G092, G093, G094, 
G861, G862, G863, G864, G865, G866, 
G294, G095, G096 OHIP  With chronic dialysis 
  CCP: 51.95, 66.98 DAD With chronic dialysis 
  CCI: 1PZ21HQBR, 1PZ21HPD4 DAD With chronic dialysis 
  
E102, E112, E132,E142,I12, I13, N08, N18, 
N19 DAD 
Without chronic 
dialysis; any of these 
codes 
  403, 585 OHIP  
Without chronic 
dialysis; any of these 
codes 
Prior arthritis %ORAD (ICES derived cohort) DAD, OHIP   
233 
 
Prior stroke     
Definition of stroke 
sources from paper by 
Griffith et al. At least 
one hospitalization 
(DAD) for stroke-in 
ant diagnosis field  
  
G45 (excl. G45.4), H34.0, H34.1, I60 (excl. 
I60.8), I61, I63 (excl. I63.6), I64 DAD   
Prior cerebrovascular 
disease (not stroke)  G45, G46, H340, I60-I69 DAD/SDS 
Definition of 
cebrovascular disease 
sources from paper by 
Grifith et al. 5 year 
look back window.  
Prior congestive heart 
failure      
Definition of 
congestive heart 
failure sources from 
paper by Griffith et al. 
5 year lookback 
window 
  I50 
CIHI-DAD (icd-
10)   
  428 OHIP (dxcode)   
        
Discharged to nursing 
home INSTTYPE DAD   
ICU admission SCU DAD 
Admission to special 
care unit 
Polypharmacy at 




performed PRCODE1-10 CIHI-DAD    
Main diagnoses for 




F000, F001, F002, F009, F010, F011, F012, 
F013, F018, F019, F020, F021, F022, F023, 
F024, F028, F03, F04 DAD    
  290, spec19 OHIP (dxcode)   
 
Description of codes 
Description of baseline 
characteristics codes     
Code Description Source 
spec='13' internal medicine OHIP 
spec= '41' gastroenterology OHIP 
spec='47'  
respiratory disease OHIP 











spec='46' Infectious diseases OHIP 
spec='16' Nephrology OHIP 
spec= '15'  
endocrinology OHIP 
medical service=1 surgery CERNER 
medical service=2 medicine CERNER 
medical service=3 geriatrics CERNER 
medical service=4 other CERNER 
medical service=5 unknown CERNER 
I 
Current NACRS record was transferred to inpatient care 
NACRS 
I200 Unstable angina DAD/ICD-10 
I2080 Atypical angina DAD/ICD-10 
I2088 Other forms of angina pectoris DAD/ICD-10 
I209 Angina pectoris, unspecified DAD/ICD-10 
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I210 Acute transmural myocardial infarction of anterior wall DAD/ICD-10 
I211 Acute transmural myocardial infarction of inferior wall DAD/ICD-10 
I212 Acute transmural myocardial infarction of other sites DAD/ICD-10 
I213 Acute transmural myocardial infarction of unspecified site DAD/ICD-10 
I214 Acute subendocardial myocardial infarction DAD/ICD-10 
I2140 Acute subendocardial myocardial infarction of anterior wall DAD/ICD-10 
I2141 Acute subendocardial myocardial infarction of inferior wall DAD/ICD-10 
I2142 Acute subendocardial myocardial infarction of other sites DAD/ICD-10 
I2149 Acute subendocardial myocardial infarction, unspecified site DAD/ICD-10 
I219 Acute myocardial infarction, unspecified DAD/ICD-10 
I220 Subsequent myocardial infarction of anterior wall DAD/ICD-10 
I221 Subsequent myocardial infarction of inferior wall DAD/ICD-10 
I228 Subsequent myocardial infarction of other sites DAD/ICD-10 




Haemopericardium as current complication following acute 
myocardial infarction DAD/ICD-10 
I231 
Atrial septal defect as current complication following acute 
myocardial infarction DAD/ICD-10 
I232 
Ventricular septal defect as current complication following 
acute myocardial infarction DAD/ICD-10 
I233 
Rupture of cardiac wall without haemopericardium as current 
complication following acute myocardial infarction DAD/ICD-10 
I234 
Rupture of chordae tendineae as current complication following 
acute myocardial infarction DAD/ICD-10 
I235 
Rupture of papillary muscle as current complication following 
acute myocardial infarction DAD/ICD-10 
I236 
Thrombosis of atrium, auricular appendage, and ventricle as 
current complications following acute myocardial infarction DAD/ICD-10 
I2380 
Papillary muscle dysfunction as current complication following 
acute myocardial infarction DAD/ICD-10 
I2381 
Pericarditis as current complication following acute myocardial 
infarction DAD/ICD-10 
I2382 
Postmyocardial infarction angina as current complication 
following acute myocardial infarction DAD/ICD-10 
I2388 
Other current complications following acute myocardial 
infarction DAD/ICD-10 
I2389 
Current complications following acute myocardial infarction, 
unspecified DAD/ICD-10 
I240 Coronary thrombosis not resulting in myocardial infarction DAD/ICD-10 
I241 Dressler's syndrome DAD/ICD-10 
I248 Other forms of acute ischaemic heart disease DAD/ICD-10 
I249 Acute ischaemic heart disease, unspecified DAD/ICD-10 
I250 Atherosclerotic cardiovascular disease, so described DAD/ICD-10 
4802 
MICROSCOPIC EXAMINATION OF SPECIMEN FROM 
LOWER GASTROINTESTINAL TRACT AND OF STOOL DAD/CCP 
4803 
MICROSCOPIC EXAMINATION OF SPECIMEN FROM 
LOWER GASTROINTESTINAL TRACT AND OF STOOL DAD/CCP 
4809 
MICROSCOPIC EXAMINATION OF SPECIMEN FROM 
LOWER GASTROINTESTINAL TRACT AND OF STOOL DAD/CCP 
481 
MICROSCOPIC EXAMINATION OF SPECIMEN FROM 
LOWER GASTROINTESTINAL TRACT AND OF STOOL, 
BACTERIAL SMEAR DAD/CCP 
1IJ50GQBD 
Dilation, coronary arteries, without stent insertion percutaneous 
transluminal approach [e.g. with angioplasty alone] using 




Dilation, coronary arteries, without stent insertion percutaneous 
transluminal approach [e.g. with angioplasty alone] using laser 
(and balloon) dilator DAD/CCI 
1IJ50GQNR 
Dilation, coronary arteries, with (endovascular) stent insertion 
percutaneous transluminal approach [e.g. with angioplasty 
alone] using (endovascular) stent only DAD/CCI 
1IJ50GQOA 
Dilation, coronary arteries, with (endovascular) stent insertion 
percutaneous transluminal approach [e.g. with angioplasty 
alone] using balloon or cutting balloon dilator with 
(endovascular) stent DAD/CCI 
1IJ50GQOB 
Dilation, coronary arteries, with (endovascular) stent insertion 
percutaneous transluminal approach [e.g. with angioplasty 
alone] using laser (and balloon) dilator with (endovascular) 
stent DAD/CCI 
1IJ50GQOD 
Dilation, coronary arteries, without stent insertion percutaneous 
transluminal approach [e.g. with angioplasty alone] using 
ultrasound (and balloon) dilator DAD/CCI 
1IJ50GQOE 
Dilation, coronary arteries, with (endovascular) stent insertion 
percutaneous transluminal approach [e.g. with angioplasty 
alone] using ultrasound (and balloon) dilator with 
(endovascular) stent DAD/CCI 
1IJ50GSBD 
Dilation, coronary arteries using percutaneous transluminal 
approach with placement/implant of stent and mechanical 
balloon dilator DAD/CCI 
1IJ50GTBD 
Dilation, coronary arteries, without stent insertion percutaneous 
transluminal approach with atherectomy [e.g. rotational, 
directional, extraction catheter, laser] using balloon or cutting 
balloon dilator DAD/CCI 
1IJ50GTBF 
Dilation, coronary arteries, without stent insertion percutaneous 
transluminal approach with atherectomy [e.g. rotational, 
directional, extraction catheter, laser] using laser (and balloon) 
dilator DAD/CCI 
1IJ50GTOA 
Dilation, coronary arteries, with (endovascular) stent insertion 
percutaneous transluminal approach with atherectomy [e.g. 
rotational, directional, extraction catheter, laser] using balloon 
or cutting balloon dilator with (endovascular) stent DAD/CCI 
1IJ50GTOB 
Dilation, coronary arteries, with (endovascular) stent insertion 
percutaneous transluminal approach with atherectomy [e.g. 
rotational, directional, extraction catheter, laser] using laser 
(and balloon) dilator with (endovascular) stent DAD/CCI 
1IJ50GTOD 
Dilation, coronary arteries, without stent insertion percutaneous 
transluminal approach with atherectomy [e.g. rotational, 
directional, extraction catheter, laser] using ultrasound (and 
balloon) dilator DAD/CCI 
1IJ50GTOE 
Dilation, coronary arteries, with (endovascular) stent insertion 
percutaneous transluminal approach with atherectomy [e.g. 
rotational, directional, extraction catheter, laser] using 




Dilation, coronary arteries, without stent insertion percutaneous 
transluminal approach with thrombectomy using balloon or 
cutting balloon dilator DAD/CCI 
1IJ50GUBF 
Dilation, coronary arteries, without stent insertion percutaneous 
transluminal approach with thrombectomy using laser (and 
balloon) dilator DAD/CCI 
1IJ50GUOA 
Dilation, coronary arteries, with (endovascular) stent insertion 
percutaneous transluminal approach with thrombectomy using 
balloon or cutting balloon dilator with (endovascular) stent DAD/CCI 
1IJ50GUOB 
Dilation, coronary arteries, with (endovascular) stent insertion 
percutaneous transluminal approach with thrombectomy using 
laser (and balloon) dilator with (endovascular) stent DAD/CCI 
1IJ50GUOD 
Dilation, coronary arteries, without stent insertion percutaneous 
transluminal approach with thrombectomy using ultrasound 
(and balloon) dilator DAD/CCI 
1IJ50GUOE 
Dilation, coronary arteries, with (endovascular) stent insertion 
percutaneous transluminal approach with thrombectomy using 
ultrasound (and balloon) dilator with (endovascular) stent DAD/CCI 
1IJ57GQAG 
Extraction, coronary arteries percutaneous transluminal 
approach no tissue used using laser DAD/CCI 
1IJ57GQAGA 
Extraction, coronary arteries percutaneous transluminal 
approach using autograft using laser DAD/CCI 
1IJ57GQAGK 
Extraction, coronary arteries percutaneous transluminal 
approach using homograft using laser DAD/CCI 
1IJ57GQAGN 
Extraction, coronary arteries percutaneous transluminal 
approach using synthetic material using laser DAD/CCI 
1IJ57GQBD 
Extraction, coronary arteries using percutaneous transluminal 
approach and balloon dilator DAD/CCI 
1IJ57GQFV 
Extraction, coronary arteries percutaneous transluminal 
approach using atherectomy device (e.g. transluminal,  extractor 
catheter, rotoablator, laser) DAD/CCI 
1IJ57GQFVA 
Extraction, coronary arteries percutaneous transluminal 
approach using autograft using atherectomy device (e.g. 
transluminal extractor catheter) DAD/CCI 
1IJ57GQFVK 
Extraction, coronary arteries percutaneous transluminal 
approach using homograft using arthrectomy device (e.g. 
transluminal extractor) DAD/CCI 
1IJ57GQFVN 
Extraction, coronary arteries percutaneous transluminal 
approach using synthetic material using arthrectomy device  
(e.g. transluminal extractor catheter) DAD/CCI 
1IJ57GQGX 
Extraction, coronary arteries percutaneous transluminal 
approach using device NEC [e.g. thrombectomy device] DAD/CCI 
1IJ57GQGXA 
Extraction, coronary arteries percutaneous transluminal 
approach using autograft using device NEC DAD/CCI 
1IJ57GQGXK 
Extraction, coronary arteries percutaneous transluminal 
approach using homograft using device NEC DAD/CCI 
1IJ57GQGXN 
Extraction, coronary arteries percutaneous transluminal 




Extraction, coronary arteries percutaneous transluminal 
approach balloon dilator with (endovascular) stent (insertion) DAD/CCI 
1IJ57GQOB 
Extraction, coronary arteries percutaneous transluminal 
approach and laser with (endovascular) stent (insertion) DAD/CCI 
1IJ57GQOBA 
Extraction, coronary arteries percutaneous transluminal  
approach and laser with (endovascular) stent (insertion) and 
autograft DAD/CCI 
1IJ57GQOBK 
Extraction, coronary arteries percutaneous transluminal 
approach and laser with (endovascular) stent (insertion) and 
homograft DAD/CCI 
1IJ57GQOBN 
Extraction, coronary arteries percutaneous transluminal 
approach and laser with (endovascular) stent (insertion) and 
synthetic material DAD/CCI 
1IJ57GQOC 
Extraction, coronary arteries percutaneous transluminal 
approach and atherectomy device with (endovascular) stent 
(insertion) DAD/CCI 
1IJ57GQOCA 
Extraction, coronary arteries percutaneous transluminal 
approach and atherectomy device with (endovascular) stent 
(insertion) and autograft DAD/CCI 
1IJ57GQOCK 
Extraction, coronary arteries percutaneous transluminal 
approach and atherectomy device with (endovascular) stent 
(insertion) and homograft DAD/CCI 
1IJ57GQOCN 
Extraction, coronary arteries percutaneous transluminal 
approach and atherectomy device with (endovascular) stent 
(insertion) and synthetic material DAD/CCI 
1IJ76BQXXA 
Bypass, coronary arteries endoscopic approach with robotic 
telemanipulation of tools using autograft [e.g. saphenous] DAD/CCI 
1IJ76DAXXA 
Bypass, coronary arteries endoscopic approach using autograft 
[e.g. saphenous] DAD/CCI 
1IJ76DAXXG 
Bypass, coronary arteries endoscopic approach using pedicled 
flap [e.g. internal mammary, thoracic] DAD/CCI 
1IJ76DAXXN 
Bypass, coronary arteries endoscopic approach using synthetic 
tissue (graft) DAD/CCI 
1IJ76DAXXQ 
Bypass, coronary arteries endoscopic approach using combined 
sources of tissue (e.g. graft/pedicled flap) DAD/CCI 
1IJ76LAXXA 
Bypass, coronary arteries open approach [sternotomy] using 
autograft [e.g. saphenous] DAD/CCI 
1IJ76LAXXG 
Bypass, coronary arteries open approach [sternotomy] using 
pedicled flap [e.g. internal mammary, thoracic] DAD/CCI 
1IJ76LAXXN 
Bypass, coronary arteries open approach [sternotomy] using 
synthetic tissue (graft) DAD/CCI 
1IJ76LAXXQ 
Bypass, coronary arteries open approach [sternotomy] using 
combined sources of tissue (e.g. graft/pedicled flap) DAD/CCI 
1IJ76WKXXA 
Bypass, coronary arteries minimal (beating heart keyhole) 





Bypass, coronary arteries minimal (beating heart keyhole) 
incisional technique [e.g. MIDCAB] using pedicled flap [e.g. 
internal mammary, thoracic] DAD/CCI 
1IJ76WKXXN 
Bypass, coronary arteries minimal (beating heart keyhole) 
incisional technique [e.g. MIDCAB] using synthetic tissue 
(graft) DAD/CCI 
1IJ76WKXXQ 
Bypass, coronary arteries minimal (beating heart keyhole) 
incisional technique [e.g. MIDCAB] using combined sources of 
tissue [e.g. graft/pedicled flap] DAD/CCI 
410 Acute myocardial infarction OHIP dx-code 
412 
Old myocardial infarction, chronic coronary 
artery disease of arteriosclerotic heart 
disease, without symptoms OHIP dx-code 
413 
Acute coronary insufficiency, angina 
pectoris, acute ischaemic heart disease OHIP dx-code 
R742 HEART PERI.-CORONARY ARTERY REPAIR-SINGLE OHIP fee code 
R743 HEART PERI.-CORONARY ARTERY REPAIR-DOUBLE OHIP fee code 
R434 JOINT-EXC.-BAKER'S CYST-EXTENSIVE OHIP fee code 
G298 CORONARY ANGIOPLAST STENT OHIP fee code 
B180 Chronic viral hepatitis B with delta-agent DAD/ICD-10 
B181 Chronic viral hepatitis B without delta-agent DAD/ICD-10 
B182 Chronic viral hepatitis C DAD/ICD-10 
B188 Other chronic viral hepatitis DAD/ICD-10 
B189 Chronic viral hepatitis, unspecified DAD/ICD-10 
K700 Alcoholic fatty liver DAD/ICD-10 
K701 Alcoholic hepatitis DAD/ICD-10 
K702 Alcoholic fibrosis and sclerosis of liver DAD/ICD-10 
K703 Alcoholic cirrhosis of liver DAD/ICD-10 
K709 Alcoholic liver disease, unspecified DAD/ICD-10 
K713 Toxic liver disease with chronic persistent hepatitis DAD/ICD-10 
K714 Toxic liver disease with chronic lobular hepatitis DAD/ICD-10 
K715 Toxic liver disease with chronic active hepatitis DAD/ICD-10 
K717 Toxic liver disease with fibrosis and cirrhosis of liver DAD/ICD-10 
K730 Chronic persistent hepatitis, not elsewhere classified DAD/ICD-10 
K731 Chronic lobular hepatitis, not elsewhere classified DAD/ICD-10 
K732 Chronic active hepatitis, not elsewhere classified DAD/ICD-10 
K738 Other chronic hepatitis, not elsewhere classified DAD/ICD-10 
K739 Chronic hepatitis, unspecified DAD/ICD-10 
K740 Hepatic fibrosis DAD/ICD-10 
K741 Hepatic sclerosis DAD/ICD-10 
K742 Hepatic fibrosis with hepatic sclerosis DAD/ICD-10 
K743 Primary biliary cirrhosis DAD/ICD-10 
K744 Secondary biliary cirrhosis DAD/ICD-10 
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K745 Biliary cirrhosis, unspecified DAD/ICD-10 
K746 Other and unspecified cirrhosis of liver DAD/ICD-10 
K760 Fatty (change of) liver, not elsewhere classified DAD/ICD-10 
K762 Central haemorrhagic necrosis of liver DAD/ICD-10 
K763 Infarction of liver DAD/ICD-10 
K764 Peliosis hepatis DAD/ICD-10 
K768 Other specified diseases of liver DAD/ICD-10 
K769 Liver disease, unspecified DAD/ICD-10 
Z944 Liver transplant status DAD/ICD-10 
I850 Oesophageal varices with bleeding DAD/ICD-10 
I859 Oesophageal varices without bleeding DAD/ICD-10 
I864 Gastric varices DAD/ICD-10 
I982 
Oesophageal varices without bleeding in diseases classified 
elsewhere DAD/ICD-10 
K704 Alcoholic hepatic failure DAD/ICD-10 
K711 Toxic liver disease with hepatic necrosis DAD/ICD-10 
K721 Chronic hepatic failure DAD/ICD-10 
K729 Hepatic failure, unspecified DAD/ICD-10 
K765 Hepatic veno-occlusive disease DAD/ICD-10 
K766 Portal hypertension DAD/ICD-10 
K767 Hepatorenal syndrome DAD/ICD-10 
K500 Crohn's disease of small intestine DAD/ICD-10 
K501 Crohn's disease of large intestine DAD/ICD-10 
K508 Other Crohn's disease DAD/ICD-10 
K509 Crohn's disease, unspecified DAD/ICD-10 
K510 Ulcerative (chronic) pancolitis DAD/ICD-10 
K511 Ulcerative (chronic) ileocolitis DAD/ICD-10 
K512 Ulcerative (chronic) proctitis DAD/ICD-10 
K513 Ulcerative (chronic) rectosigmoiditis DAD/ICD-10 
K514 Inflammatory polyps DAD/ICD-10 
K515 Left sided colitis DAD/ICD-10 
K518 Other ulcerative colitis DAD/ICD-10 
K519 Ulcerative colitis, unspecified DAD/ICD-10 
M074 Arthropathy in Crohn's disease [regional enteritis] DAD/ICD-10 
M091 Juvenile arthritis in Crohn's disease [regional enteritis] DAD/ICD-10 
M092 Juvenile arthritis in ulcerative colitis DAD/ICD-10 
K520 Gastroenteritis and colitis due to radiation DAD/ICD-10 
K521 Toxic gastroenteritis and colitis DAD/ICD-10 
K522 Allergic and dietetic gastroenteritis and colitis DAD/ICD-10 
K523 Indeterminate colitis DAD/ICD-10 
K528 Other specified noninfective gastroenteritis and colitis DAD/ICD-10 
K529 Noninfective gastroenteritis and colitis, unspecified DAD/ICD-10 
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555 Regional enteritis, Crohn's disease OHIP dx-code 
556 Ulcerative colitis OHIP dx-code 
564 
Spastic colon, irritable colon, mucous 
colitis, constipation OHIP dx-code 
R849 D./T. PROC.-DIALYSIS-HEMO-INITIAL AND ACUTE OHIP fee code 
R850 
D/T.PROC.DIALYSIS-HAEMODIALYSIS-INSERT 
SCRIBNER SHUNT OHIP fee code 
G323 
D./T. PROC.-DIALYSIS-HAEMODIALYSIS-
ACUTE,REPEAT OHIP fee code 
G325 
D./T. PROC.-DIALYSIS-HAEMODIALYSIS-MEDICAL 
COMPONENT OHIP fee code 
G326 
Dialysis - Chronic, contin. haemodialysis or haemofiltration 
each OHIP fee code 
G330 
D./T. PROC.-DIALYSIS-PERITONEAL-ACUTE (UP TO 48 
HRS) OHIP fee code 
G331 
D./T. PROC.-DIALYSIS-PERITONEAL-REPEAT ACUTE 
(UP TO 48 HRS) OHIP fee code 
G860 HOSPITAL HEMODIALYSIS OHIP fee code 
G333 Home/self-care dialysis - OHIP fee code 
G083 
CONT. VENOVENOUS HAEMODIALYSIS - INIT. & AC. 
(MAX 3) OHIP fee code 
G091 
CONT. ARTERIOVENOUS HAEMODIALYSIS - INIT. & 
AC. (MAX 3) OHIP fee code 
G085 
CONT. VENOVENOUS HAEMOFILTRAT'N - INIT. & AC. 
(MAX 3) OHIP fee code 
G295 
CONT. ARTERIOVENOUS HAEMOFILTRAT'N - INIT. & 
AC. (MAX 3) OHIP fee code 
G082 
CONT. VENOVENOUS HAEMODIAFILTRAT'N - INIT. & 
AC. (MAX 3) OHIP fee code 
G090 
VENOVENOUS SLOW CONT. ULTRAFILTRAT'N-INIT.& 
AC. (MAX 3) OHIP fee code 
G093 Haemodiafiltration - Contin. Init & Acute (repeatx3) OHIP fee code 
G094 HAEMODIALFILTRATION-CONTIN.CHRONIC OHIP fee code 
G861 HOSPITAL PERITONEAL DIALYSIS OHIP fee code 
G862 HOSPITAL SELF CARE OR SATELLITE HEMODIALYSIS OHIP fee code 
G863 
INDEPENDENT HEALTH CARE FACILITY 
HEMODIALYSIS OHIP fee code 
G864 HOME PERITONEAL DIALYSIS OHIP fee code 
G865 HOME HEMODIALYSIS OHIP fee code 
G866 
INTERMITTENT HEMODIAL AUX TREAT CTRE(PER 
TREAT) OHIP fee code 
G294 
ARTERIOVENOUS SLOW CONT. ULTRAFILTRATN-
INIT& ACUTE OHIP fee code 
G095 Slow Continuous Ultra Filtration - Initial & Acute (repeat) OHIP fee code 
G096 SLOW CONTINUOUS ULTRA FILTRATION-CHRONIC OHIP fee code 
51.95 HEMODIALYSIS DAD/CCP 
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66.98 PERITONEAL DIALYSIS DAD/CCP 
 1PZ21HQBR Dialysis, urinary system NEC hemodialysis DAD/CCI 
1PZ21HPD4 Dialysis, urinary system NEC peritoneal dialysis using dialysate DAD/CCI 
E1020 Type 1 diabetes mellitus with incipient diabetic nephropathy DAD/ICD-10 
E10200 
Type 1 diabetes mellitus with incipient diabetic nephropathy, 
adequately controlled with diet or oral agent DAD/ICD-10 
E10201 
Type 1 diabetes mellitus with incipient diabetic nephropathy, 
adequately controlled with insulin DAD/ICD-10 
E10202 
Type 1 diabetes mellitus with incipient diabetic nephropathy, 
inadequately controlled with diet or oral agents (and insulin not 
used to stabilize) DAD/ICD-10 
E10203 
Type 1 diabetes mellitus with incipient diabetic nephropathy, 
inadequately controlled with diet or oral agents but adequately 
controlled with insulin DAD/ICD-10 
E10204 
Type 1 diabetes mellitus with incipient diabetic nephropathy, 
inadequately controlled with insulin DAD/ICD-10 
E10209 
Type 1 diabetes mellitus with incipient diabetic nephropathy, 
level of control unspecified DAD/ICD-10 
E1021 Type 1 diabetes mellitus with established diabetic nephropathy DAD/ICD-10 
E10210 
Type 1 diabetes mellitus with established diabetic nephropathy, 
adequately controlled with diet or oral agent DAD/ICD-10 
E10211 
Type 1 diabetes mellitus with established diabetic nephropathy, 
adequately controlled with insulin DAD/ICD-10 
E10212 
Type 1 diabetes mellitus with established diabetic nephropathy, 
inadequately controlled with diet or oral agents (and insulin not 
used to stabilize) DAD/ICD-10 
E10213 
Type 1 diabetes mellitus with established diabetic nephropathy, 
inadequately controlled with diet or oral agents but adequately 
controlled with insulin DAD/ICD-10 
E10214 
Type 1 diabetes mellitus with established diabetic nephropathy, 
inadequately controlled with insulin DAD/ICD-10 
E10219 
Type 1 diabetes mellitus with established diabetic nephropathy, 
level of control unspecified DAD/ICD-10 
E1022 Type 1 diabetes mellitus with end-stage renal disease [ESRD] DAD/ICD-10 
E10220 
Type 1 diabetes mellitus with end-stage renal disease [ESRD], 
adequately controlled with diet or oral agents DAD/ICD-10 
E10221 
Type 1 diabetes mellitus with end-stage renal disease [ESRD], 
adequately controlled with insulin DAD/ICD-10 
E10222 
Type 1 diabetes mellitus with end stage renal disease [ESRD], 
inadequately controlled with diet or oral agents (and insulin not 
used to stabilize) DAD/ICD-10 
E10223 
Type 1 diabetes mellitus with end stage renal disease [ESRD], 
inadequately controlled with diet or oral agents but adequately 
controlled with insulin DAD/ICD-10 
E10224 
Type 1 diabetes mellitus with end stage renal disease [ESRD], 




Type 1 diabetes mellitus with end stage renal disease [ESRD], 
level of control unspecified DAD/ICD-10 
E1023 
Type 1 diabetes mellitus with established or advanced kidney 
disease DAD/ICD-10 
E1028 
Type 1 diabetes mellitus with other specified kidney 
complication not elsewhere classified DAD/ICD-10 
E10280 
Type 1 diabetes mellitus with other specified renal 
complication, adequately controlled with diet or oral agents DAD/ICD-10 
E10281 
Type 1 diabetes mellitus with other specified renal 
complication, adequately controlled with insulin DAD/ICD-10 
E10282 
Type 1 diabetes mellitus with other specified renal 
complication, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) DAD/ICD-10 
E10283 
Type 1 diabetes mellitus with other specified renal 
complication, inadequately controlled with diet or oral agents 
but adequately controlled with insulin DAD/ICD-10 
E10284 
Type 1 diabetes mellitus with other specified renal 
complication, inadequately controlled with insulin DAD/ICD-10 
E10289 
Type 1 diabetes mellitus with other specified renal 
complication, level of control unspecified DAD/ICD-10 
E10290 
Type 1 diabetes mellitus with renal complication unspecified, 
adequately controlled with diet or oral agents DAD/ICD-10 
E10291 
Type 1 diabetes mellitus with renal complication unspecified, 
adequately controlled with insulin DAD/ICD-10 
E10292 
Type 1 diabetes mellitus with renal complication unspecified, 
inadequately controlled with diet or oral agents (and insulin not 
used to stabilize) DAD/ICD-10 
E10293 
Type 1 diabetes mellitus with renal complication unspecified, 
inadequately controlled with diet or oral agents but adequately 
controlled with insulin DAD/ICD-10 
E10294 
Type 1 diabetes mellitus with renal complication unspecified, 
inadequately controlled with insulin DAD/ICD-10 
E10299 
Type 1 diabetes mellitus with renal complication unspecified, 
level of control unspecified DAD/ICD-10 
E11200 
Type 2 diabetes mellitus with incipient diabetic nephropathy, 
adequately controlled with diet or oral agents DAD/ICD-10 
E11201 
Type 2 diabetes mellitus with incipient diabetic nephropathy, 
adequately controlled with insulin DAD/ICD-10 
E11202 
Type 2 diabetes mellitus with incipient diabetic nephropathy, 
inadequately controlled with diet or oral agents (and insulin not 
used to stabilize) DAD/ICD-10 
E11203 
Type 2 diabetes mellitus with incipient diabetic nephropathy, 
inadequately controlled with diet or oral agents but adequately 
controlled with insulin DAD/ICD-10 
E11204 
Type 2 diabetes mellitus with incipient diabetics nephropathy, 
inadequately controlled with  insulin DAD/ICD-10 
E11209 
Type 2 diabetes mellitus with incipient diabetics nephropathy, 
level of control unspecified DAD/ICD-10 
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E1121 Type 2 diabetes mellitus with established diabetic nephropathy DAD/ICD-10 
E11210 
Type 2 diabetes mellitus with established diabetic nephropathy, 
adequately controlled with diet or oral agents DAD/ICD-10 
E11211 
Type 2 diabetes mellitus with established diabetic nephropathy, 
adequately controlled with insulin DAD/ICD-10 
E11212 
Type 2 diabetes mellitus with established diabetic nephropathy, 
inadequately controlled with  diet or oral agents (and insulin not 
used to stabilize) DAD/ICD-10 
E11213 
Type 2 diabetes mellitus with established diabetic nephropathy, 
inadequately controlled with  diet or oral agents but adequately 
controlled with insulin DAD/ICD-10 
E11214 
Type 2 diabetes mellitus with established diabetic nephropathy, 
inadequately controlled with   insulin DAD/ICD-10 
E11219 
Type 2 diabetes mellitus with established diabetic nephropathy, 
level of control unspecified DAD/ICD-10 
E1122 Type 2 diabetes mellitus with end-stage renal disease [ESRD] DAD/ICD-10 
E11220 
Type 2 diabetes mellitus with end-stage renal disease [ESRD], 
adequately controlled with diet or oral agents DAD/ICD-10 
E11221 
Type 2 diabetes mellitus with end-stage renal disease [ESRD], 
adequately controlled with insulin DAD/ICD-10 
E11222 
Type 2 diabetes mellitus with end-stage renal disease [ESRD], 
inadequately controlled with diet or oral agents ( and insulin not 
used to stabilize) DAD/ICD-10 
E11223 
Type 2 diabetes mellitus with end-stage renal disease [ESRD], 
inadequately controlled with diet or oral agents but adequately 
controlled with insulin DAD/ICD-10 
E11224 
Type 2 diabetes mellitus with end-stage renal disease [ESRD], 
inadequately controlled with insulin DAD/ICD-10 
E11229 
Type 2 diabetes mellitus with end-stage renal disease [ESRD] 
,level of control unspecified DAD/ICD-10 
E1123 
Type 2 diabetes mellitus with established or advanced kidney 
disease DAD/ICD-10 
E1128 
Type 2 diabetes mellitus with other specified kidney 
complication not elsewhere classified DAD/ICD-10 
E11280 
Type 2 diabetes mellitus with other specified renal 
complication, adequately controlled with diet or oral agents DAD/ICD-10 
E11281 
Type 2 diabetes mellitus with other specified renal 
complication, adequately controlled with insulin DAD/ICD-10 
E11282 
Type 2 diabetes mellitus with other specified renal 
complication, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) DAD/ICD-10 
E11283 
Type 2 diabetes mellitus with other specified renal 
complication, inadequately controlled with diet or oral agents 
but adequately controlled with insulin DAD/ICD-10 
E11284 
Type 2 diabetes mellitus with other specified renal 
complication, inadequately controlled with insulin DAD/ICD-10 
E11289 
Type 2 diabetes mellitus with other specified renal 




Type 2 diabetes mellitus with renal complication unspecified, 
adequately controlled with diet or oral agents DAD/ICD-10 
E11291 
Type 2 diabetes mellitus with renal complication unspecified, 
adequately controlled with insulin DAD/ICD-10 
E11292 
Type 2 diabetes mellitus with renal complication unspecified, 
inadequately controlled with diet or oral agents  (and insulin not 
used to stabilize) DAD/ICD-10 
E11293 
Type 2 diabetes mellitus with renal complication unspecified, 
inadequately controlled with diet or oral agents but adequately 
controlled with insulin DAD/ICD-10 
E11294 
Type 2 diabetes mellitus with renal complication unspecified, 
inadequately controlled with insulin DAD/ICD-10 
E11299 
Type 2 diabetes mellitus with renal complication unspecified, 
level of control unspecified DAD/ICD-10 
E1320 
Other specified diabetes mellitus with incipient diabetic 
nephropathy DAD/ICD-10 
E13200 
Other specified diabetes mellitus with incipient diabetic 
nephropathy, adequately controlled with diet or oral agents DAD/ICD-10 
E13201 
Other specified diabetes mellitus with incipient diabetic 
nephropathy, adequately controlled with insulin DAD/ICD-10 
E13202 
Other specified diabetes mellitus with incipient diabetic 
nephropathy, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) DAD/ICD-10 
E13203 
Other specified diabetes mellitus with incipient diabetic 
nephropathy, inadequately controlled with diet or oral agents 
but adequately controlled with insulin DAD/ICD-10 
E13204 
Other specified diabetes mellitus with incipient diabetic 
nephropathy, inadequately controlled with insulin DAD/ICD-10 
E13209 
Other specified diabetes mellitus with incipient diabetic 
nephropathy, level of control unspecified DAD/ICD-10 
E1321 
Other specified diabetes mellitus with established diabetic 
nephropathy DAD/ICD-10 
E13210 
Other specified diabetes mellitus with established diabetic 
nephropathy, adequately controlled with diet or oral agents DAD/ICD-10 
E13211 
Other specified diabetes mellitus with established diabetic 
nephropathy, adequately controlled with insulin DAD/ICD-10 
E13212 
Other specified diabetes mellitus with established diabetic 
nephropathy, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) DAD/ICD-10 
E13213 
Other specified diabetes mellitus with established diabetic 
nephropathy, inadequately controlled with diet or oral agents 
but adequately controlled with insulin DAD/ICD-10 
E13214 
Other specified diabetes mellitus with established diabetic 
nephropathy, inadequately controlled with insulin DAD/ICD-10 
E13219 
Other specified diabetes mellitus with established diabetic 
nephropathy, level of control unspecified DAD/ICD-10 
E1322 





Other specified diabetes mellitus with end-stage renal disease 
[ESRD], adequately controlled with diet or oral agents DAD/ICD-10 
E13221 
Other specified diabetes mellitus with end-stage renal disease 
[ESRD], adequately controlled with insulin DAD/ICD-10 
E13222 
Other specified diabetes mellitus with end-stage renal disease 
[ESRD], inadequately controlled with diet or oral agents (and 
insulin not used to stabilize) DAD/ICD-10 
E13223 
Other specified diabetes mellitus with end-stage renal disease 
[ESRD], inadequately controlled with diet or oral agents but 
adequately controlled with insulin DAD/ICD-10 
E13224 
Other specified diabetes mellitus with end-stage renal disease 
[ESRD], inadequately controlled with insulin DAD/ICD-10 
E13229 
Other specified diabetes mellitus with end-stage renal disease 
[ESRD] ,level of control unspecified DAD/ICD-10 
E1323 
Other specified diabetes mellitus with established or advanced 
kidney disease DAD/ICD-10 
E1328 
Other specified diabetes mellitus with other specified kidney 
complication not elsewhere classified DAD/ICD-10 
E13280 
Other specified diabetes mellitus with other specified renal 
complication, adequately controlled with diet or oral agents DAD/ICD-10 
E13281 
Other specified diabetes mellitus with other specified renal 
complication, adequately controlled with insulin DAD/ICD-10 
E13282 
Other specified diabetes mellitus with other specified renal 
complication, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) DAD/ICD-10 
E13283 
Other specified diabetes mellitus with other specified renal 
complication, inadequately controlled with diet or oral agents 
but adequately controlled with insulin DAD/ICD-10 
E13284 
Other specified diabetes mellitus with other specified renal 
complication, inadequately controlled with insulin DAD/ICD-10 
E13289 
Other specified diabetes mellitus with other specified renal 
complication, level of control unspecified DAD/ICD-10 
E13290 
Other specified diabetes mellitus with renal complication 
unspecified, adequately controlled with diet or oral agents DAD/ICD-10 
E13291 
Other specified diabetes mellitus with renal complication 
unspecified, adequately controlled with insulin DAD/ICD-10 
E13292 
Other specified diabetes mellitus with renal complication 
unspecified, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) DAD/ICD-10 
E13293 
Other specified diabetes mellitus with renal complication 
unspecified, inadequately controlled with diet or oral agents but 
adequately controlled with insulin DAD/ICD-10 
E13294 
Other specified diabetes mellitus with renal complication 
unspecified, inadequately controlled with insulin DAD/ICD-10 
E13299 
Other specified diabetes mellitus with renal complication 
unspecified, level of control unspecified DAD/ICD-10 
E1420 





Unspecified diabetes mellitus with incipient diabetic 
nephropathy, adequately controlled with diet or oral agents DAD/ICD-10 
E14201 
Unspecified diabetes mellitus with incipient diabetic 
nephropathy, adequately controlled with insulin DAD/ICD-10 
E14202 
Unspecified diabetes mellitus with incipient diabetic 
nephropathy, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) DAD/ICD-10 
E14203 
Unspecified diabetes mellitus with incipient diabetic 
nephropathy, inadequately controlled with diet or oral agents 
but adequately controlled with insulin DAD/ICD-10 
E14204 
Unspecified diabetes mellitus with incipient diabetic 
nephropathy, inadequately controlled  with insulin DAD/ICD-10 
E14209 
Unspecified diabetes mellitus with incipient diabetic 
nephropathy, level of control unspecified DAD/ICD-10 
E1421 
Unspecified diabetes mellitus with established diabetic 
nephropathy DAD/ICD-10 
E14210 
Unspecified diabetes mellitus with established diabetic 
nephropathy, adequately controlled with diet or oral agents DAD/ICD-10 
E14211 
Unspecified diabetes mellitus with established diabetic 
nephropathy, adequately controlled with insulin DAD/ICD-10 
E14212 
Unspecified diabetes mellitus with established diabetic 
nephropathy, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) DAD/ICD-10 
E14213 
Unspecified diabetes mellitus with established diabetic 
nephropathy, inadequately controlled with diet or oral agents 
but adequately controlled with insulin DAD/ICD-10 
E14214 
Unspecified diabetes mellitus with established diabetic 
nephropathy, inadequately controlled with insulin DAD/ICD-10 
E14219 
Unspecified diabetes mellitus with established diabetic 
nephropathy, level of control unspecified DAD/ICD-10 
E1422 
Unspecified diabetes mellitus with end-stage renal disease 
[ESRD] DAD/ICD-10 
E14220 
Unspecified diabetes mellitus with end-stage renal disease 
[ESRD], adequately controlled with diet or oral agents DAD/ICD-10 
E14221 
Unspecified diabetes mellitus with end-stage renal disease 
[ESRD], adequately controlled with insulin DAD/ICD-10 
E14222 
Unspecified diabetes mellitus with end-stage renal disease 
[ESRD], inadequately controlled with diet or oral agents (and 
insulin not used to stabilize) DAD/ICD-10 
E14223 
Unspecified diabetes mellitus with end-stage renal disease 
[ESRD], inadequately controlled with diet or oral agents but 
adequately controlled with insulin DAD/ICD-10 
E14224 
Unspecified diabetes mellitus with end-stage renal disease 
[ESRD], inadequately controlled  with insulin DAD/ICD-10 
E14229 
Unspecified diabetes mellitus with end-stage renal disease 
[ESRD], level of control unspecified DAD/ICD-10 
E1423 
Unspecified diabetes mellitus with established or advanced 




Unspecified diabetes mellitus with other specified kidney  
complication not elsewhere classified DAD/ICD-10 
E14280 
Unspecified diabetes mellitus with other specified renal 
complication ,adequately controlled with diet or oral agents DAD/ICD-10 
E14281 
Unspecified diabetes mellitus with other specified renal 
complication ,adequately controlled with insulin DAD/ICD-10 
E14282 
Unspecified diabetes mellitus with other specified renal 
complication, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) DAD/ICD-10 
E14283 
Unspecified diabetes mellitus with other specified renal 
complication, inadequately controlled with diet or oral agents 
but adequately controlled with insulin DAD/ICD-10 
E14284 
Unspecified diabetes mellitus with other specified renal 
complication, inadequately controlled with insulin DAD/ICD-10 
E14289 
Unspecified diabetes mellitus with other specified renal 
complication, level of control unspecified DAD/ICD-10 
E14290 
Unspecified diabetes mellitus with renal complication 
unspecified, adequately controlled with diet or oral agents DAD/ICD-10 
E14291 
Unspecified diabetes mellitus with renal complication 
unspecified, adequately controlled with insulin DAD/ICD-10 
E14292 
Unspecified diabetes mellitus with renal complication 
unspecified, inadequately controlled with diet or oral agents 
(and insulin not used to stabilize) DAD/ICD-10 
E14293 
Unspecified diabetes mellitus with renal complication 
unspecified, inadequately controlled with diet or oral agents but 
adequately controlled with insulin DAD/ICD-10 
E14294 
Unspecified diabetes mellitus with renal complication 
unspecified, inadequately controlled  with insulin DAD/ICD-10 
E14299 
Unspecified diabetes mellitus with renal complication 
unspecified, level of control unspecified DAD/ICD-10 
I12 Hypertensive renal disease DAD/ICD-10 
I13 Hypertensive heart and renal disease DAD/ICD-10 
N080 
Glomerular disorders in infectious and parasitic diseases 
classified elsewhere DAD/ICD-10 
N081 Glomerular disorders in neoplastic diseases DAD/ICD-10 
N082 
Glomerular disorders in blood diseases and disorders involving 
the immune mechanism DAD/ICD-10 
N0831 
Glomerular disorders in diabetes mellitus, chronic kidney 
disease, stage 1 DAD/ICD-10 
N0832 
Glomerular disorders in diabetes mellitus, chronic kidney 
disease, stage 2 DAD/ICD-10 
N0833 
Glomerular disorders in diabetes mellitus, chronic kidney 
disease, stage 3 DAD/ICD-10 
N084 
Glomerular disorders in other endocrine, nutritional and 
metabolic diseases DAD/ICD-10 
N0835 
Glomerular disorders in diabetes mellitus, chronic kidney 
disease, stage 5 DAD/ICD-10 
N0838 Other glomerular disorders in diabetes mellitus DAD/ICD-10 
250 
 
N0839 Unspecified glomerular disorders in diabetes mellitus DAD/ICD-10 
N085 Glomerular disorders in systemic connective tissue disorders DAD/ICD-10 
N088 Glomerular disorders in other diseases classified elsewhere DAD/ICD-10 
N180 End-stage renal disease DAD/ICD-10 
N181 Chronic kidney disease, stage 1 DAD/ICD-10 
N182 Chronic kidney disease, stage 2 DAD/ICD-10 
N183 Chronic kidney disease, stage 3 DAD/ICD-10 
N184 Chronic kidney disease, stage 4 DAD/ICD-10 
N185 Chronic kidney disease, stage 5 DAD/ICD-10 
N188 Other chronic renal failure DAD/ICD-10 
N189 Chronic kidney disease, unspecified DAD/ICD-10 
N19 Unspecified kidney failure DAD/ICD-10 
403 Hypertensive renal disease OHIP dx-code 
585 Chronic renal failure, uremia OHIP dx-code 
G450 Vertebro-basilar artery syndrome DAD/ICD-10 
G451 Carotid artery syndrome (hemispheric) DAD/ICD-10 
G452 Multiple and bilateral precerebral artery syndromes DAD/ICD-10 
G453 Amaurosis fugax DAD/ICD-10 
G458 
Other transient cerebral ischaemic attacks and related 
syndromes DAD/ICD-10 
G459 Transient cerebral ischaemic attack, unspecified DAD/ICD-10 
H340 Transient retinal artery occlusion DAD/ICD-10 
H341 Central retinal artery occlusion DAD/ICD-10 
I600 Subarachnoid haemorrhage from carotid siphon and bifurcation DAD/ICD-10 
I601 Subarachnoid haemorrhage from middle cerebral artery DAD/ICD-10 
I602 Subarachnoid haemorrhage from anterior communicating artery DAD/ICD-10 
I603 
Subarachnoid haemorrhage from posterior communicating 
artery DAD/ICD-10 
I604 Subarachnoid haemorrhage from basilar artery DAD/ICD-10 
I605 Subarachnoid haemorrhage from vertebral artery DAD/ICD-10 
I606 Subarachnoid haemorrhage from other intracranial arteries DAD/ICD-10 
I607 Subarachnoid haemorrhage from intracranial artery, unspecified DAD/ICD-10 
I609 Subarachnoid haemorrhage, unspecified DAD/ICD-10 
I610 Intracerebral haemorrhage in hemisphere, subcortical DAD/ICD-10 
I611 Intracerebral haemorrhage in hemisphere, cortical DAD/ICD-10 
I612 Intracerebral haemorrhage in hemisphere, unspecified DAD/ICD-10 
I613 Intracerebral haemorrhage in brain stem DAD/ICD-10 
I614 Intracerebral haemorrhage in cerebellum DAD/ICD-10 
I615 Intracerebral haemorrhage, intraventricular DAD/ICD-10 
I616 Intracerebral haemorrhage, multiple localized DAD/ICD-10 
I618 Other intracerebral haemorrhage DAD/ICD-10 
I619 Intracerebral haemorrhage, unspecified DAD/ICD-10 
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I631 Cerebral infarction due to embolism of precerebral arteries DAD/ICD-10 
I632 
Cerebral infarction due to unspecified occlusion or stenosis of 
precerebral arteries DAD/ICD-10 
I633 Cerebral infarction due to thrombosis of cerebral arteries DAD/ICD-10 
I634 Cerebral infarction due to embolism of cerebral arteries DAD/ICD-10 
I635 
Cerebral infarction due to unspecified occlusion or stenosis of 
cerebral arteries DAD/ICD-10 
I638 Other cerebral infarction DAD/ICD-10 
I639 Cerebral infarction, unspecified DAD/ICD-10 
I64 Stroke, not specified as haemorrhage or infarction DAD/ICD-10 
G454 Transient global amnesia DAD/SDS 
G460 Middle cerebral artery syndrome DAD/SDS 
G461 Anterior cerebral artery syndrome DAD/SDS 
G462 Posterior cerebral artery syndrome DAD/SDS 
G463 Brain stem stroke syndrome DAD/SDS 
G464 Cerebellar stroke syndrome DAD/SDS 
G465 Pure motor lacunar syndrome DAD/SDS 
G466 Pure sensory lacunar syndrome DAD/SDS 
G467 Other lacunar syndromes DAD/SDS 
G468 Other vascular syndromes of brain in cerebrovascular diseases DAD/SDS 
I608 Other subarachnoid haemorrhage DAD/SDS 
I620 Subdural haemorrhage (acute)(nontraumatic) DAD/SDS 
I621 Nontraumatic extradural haemorrhage DAD/SDS 
I629 Intracranial haemorrhage (nontraumatic), unspecified DAD/SDS 
I630 Cerebral infarction due to thrombosis of precerebral arteries DAD/SDS 
I636 
Cerebral infarction due to cerebral venous thrombosis, 
nonpyrogenic DAD/SDS 
I650 Occlusion and stenosis of vertebral artery DAD/SDS 
I651 Occlusion and stenosis of basilar artery DAD/SDS 
I652 Occlusion and stenosis of carotid artery DAD/SDS 
I653 
Occlusion and stenosis of multiple and bilateral precerebral 
arteries DAD/SDS 
I658 Occlusion and stenosis of other precerebral artery DAD/SDS 
I659 Occlusion and stenosis of unspecified precerebral artery DAD/SDS 
I660 Occlusion and stenosis of middle cerebral artery DAD/SDS 
I661 Occlusion and stenosis of anterior cerebral artery DAD/SDS 
I662 Occlusion and stenosis of posterior cerebral artery DAD/SDS 
I663 Occlusion and stenosis of cerebellar arteries DAD/SDS 
I664 Occlusion and stenosis of multiple and bilateral cerebral arteries DAD/SDS 
I668 Occlusion and stenosis of other cerebral artery DAD/SDS 
I669 Occlusion and stenosis of unspecified cerebral artery DAD/SDS 
I670 Dissection of cerebral arteries, nonruptured DAD/SDS 
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I671 Cerebral aneurysm, nonruptured DAD/SDS 
I672 Cerebral atherosclerosis DAD/SDS 
I673 Progressive vascular leukoencephalopathy DAD/SDS 
I674 Hypertensive encephalopathy DAD/SDS 
I675 Moyamoya disease DAD/SDS 
I676 Nonpyogenic thrombosis of intracranial venous system DAD/SDS 
I677 Cerebral arteritis, not elsewhere classified DAD/SDS 
I678 Other specified cerebrovascular diseases DAD/SDS 
I679 Cerebrovascular disease, unspecified DAD/SDS 
I680 Cerebral amyloid angiopathy DAD/SDS 
I681 
Cerebral arteritis in infectious and parasitic diseases classified 
elsewhere DAD/SDS 
I682 Cerebral arteritis in other diseases classified elsewhere DAD/SDS 
I688 Other cerebrovascular disorders in diseases classified elsewhere DAD/SDS 
I690 Sequelae of subarachnoid haemorrhage DAD/SDS 
I691 Sequelae of intracerebral haemorrhage DAD/SDS 
I692 Sequelae of other nontraumatic intracranial haemorrhage DAD/SDS 
I693 Sequelae of cerebral infarction DAD/SDS 
I694 Sequelae of stroke, not specified as haemorrhage or infarction DAD/SDS 
I698 Sequelae of other and unspecified cerebrovascular diseases DAD/SDS 
I500 Congestive heart failure DAD/ICD-10 
I501 Left ventricular failure DAD/ICD-10 
I509 Heart failure, unspecified DAD/ICD-10 
I510 Cardiac septal defect, acquired DAD/ICD-10 
I511 Rupture of chordae tendineae, not elsewhere classified DAD/ICD-10 
I512 Rupture of papillary muscle, not elsewhere classified DAD/ICD-10 
I513 Intracardiac thrombosis, not elsewhere classified DAD/ICD-10 
I514 Myocarditis, unspecified DAD/ICD-10 
I515 Myocardial degeneration DAD/ICD-10 
I516 Cardiovascular disease, unspecified DAD/ICD-10 
I517 Cardiomegaly DAD/ICD-10 
I518 Other ill-defined heart diseases DAD/ICD-10 
I519 Heart disease, unspecified DAD/ICD-10 
428 Congestive heart failure OHIP dx-code 
INSTFTYP=4 admitted from nursing home DAD 
INSTFTYP=9 admitted from home for aged DAD 
INSTTYP=4 discharged to nursing home DAD 
INSTTYPE=9 discharged to home for aged DAD 
SCU=10 Medical intensive care nursing unit DAD 
SCU=20 Surgical intensive care nursing unit DAD 
SCU=25 Trauma intensive care nursing unit DAD 
253 
 
SCU=30 Combined medical/surgical intensive care nursing unit DAD 
SCU=35 Burn intensive care nursing unit DAD 
SCU=40 Cardiac intensive care nursing unit surgery DAD 
SCU=45 Coronary intensive care nursing unit medical DAD 
SCU=60 Neurosurgery intensive care nursing unit DAD 
SCU=80 Respirology intensive care nursing unit  DAD 
F000 Dementia in Alzheimer's disease with early onset DAD/ICD-10 
F001 Dementia in Alzheimer's disease with late onset DAD/ICD-10 
F002 Dementia in Alzheimer's disease with late onset DAD/ICD-10 
F009 Dementia in Alzheimer's disease, unspecified DAD/ICD-10 
F010 Vascular dementia of acute onset DAD/ICD-10 
F011 Vascular dementia DAD/ICD-10 
F012 Subcortical vascular dementia DAD/ICD-10 
F013 Mixed cortical and subcortical vascular dementia DAD/ICD-10 
F018 Other vascular dementia DAD/ICD-10 
F019 Vascular dementia, unspecified DAD/ICD-10 
F020 Dementia in Pick's disease DAD/ICD-10 
F021 Dementia in Creutzfeldt-Jakob disease DAD/ICD-10 
F022 Dementia in Huntington's disease DAD/ICD-10 
F023 Dementia in Parkinson's disease DAD/ICD-10 
F024 
Dementia in human immunodeficiency virus [HIV] 
disease DAD/ICD-10 
F028 Dementia in other specified diseases classified elsewhere DAD/ICD-10 
F03 Unspecified dementia DAD/ICD-10 
F04 
Organic amnesic syndrome, not induced by alcohol and 
other psychoactive substances DAD/ICD-10 
290 Senile dementia, presenile dementia OHIP dx code 
 
Appendix H-Linear regression model assessment 
i. Assessing goodness of fit 
1) We checked the R^2 value and F value to assess goodness of fit (see table below). The F 
value was statistically significant (p<0.05) which would indicate that that independent 
variable is able to predict the dependent variable. However, the R^2 value  is quite low 
(R^2=0.1365, adjusted R^2=0.1186). This R^2 value indicates that only 13.65% of the 
variation in the dependent variable can be explained by the independent variable.  This could 







The above figure (residual-fit spread plot) indicates that there is residual variance that 
cannot be explained by variability in our x variable (shown by the increase in spread of 
the residuals as compared to the fit-mean). Also, there are some outliers in the residuals 
but not the plotted values, indicating there is an error in the model not an outlier in the 






We would expect the data points in the above figure to fall within the 95% confidence limits if the model 





We would expect the predicted values in the above figure to lie on the 45° line if the model were 
a good fit (i.e. the model correctly predicted the behavior of the dependent variable).  




We used the proc loess to smooth feature to the fit between the dependent and independent 
variables in order to assess for a linear or polynomial relationship. As is evident in the figure 
below we found no evidence of a linear relationship.  
 
 





In the above figure we can check to see if the assumption of constant variance is met. We 
see that the distribution of the residuals is widespread which indicates evidence of non-
constant variance. We can also check if the residuals are normally distributed and the 
residuals and symmetric around zero (as this would indicate the model is a good fit). Here 
we see that the residuals are not  completely symmetric or normally distributed.  
 
 
2) The above is a histogram of residuals density. We see that the data is slightly right skewed, 





The above is a Q-Q plot used to assess for normality. If the data points fell on the diagonal, we 
would say that the assumption of normality had been met, however this is not the case. We also 
see a lack of a linear relationship. Explored modeling the data with an exponential and lognormal 
distribution but this was an even poorer fit for the data.  
Appendix I-CERNER and ICES cohort build 
i. CERNER 
 
Note: Total number of hospitalizations after exclusion is greater than that after step 5 as 
CERNER continuously updates. The total number of hospitalizations was measured a few days 
after step 5.  
 
Step Description #Excluded #Encounters #Patients
1
All Patients discharged from LHSC or St.Joseph's 
Health Care Londonbetween January 1 2011 and 
March 31 2018 14,954,198 896,999
2 Total BEFORE exclusions
3 Length of stay(LOS)<1 14,244,921 709,277 337,285
4 Age <55 at registration 398,528 310,749 128,389
5 Encounter type not equal to 'Inpatient' or 'One Day Stay' (SJHC only)90,844 219,905 110,145
6 Total AFTER exclusions 219,899 110,136







Appendix J-Standardized differences for baseline conditions pre- vs. post-HUGO 
 
 









Demographics         
Age          
  Mean(SD)        75.22 ± 7.13 
       75.43 ± 
7.10        75.12 ± 7.14 0.04 
  Median(IQR)           74 (69-80) 
          74 (69-
80)           74 (69-80) 0.05 
Sex         
  Female(%N) 
         8,202 
(44.6%) 
         2,669 
(44.0%) 
         5,533 
(44.8%)   
  Male(%N) 
        10,203 
(55.4%) 
         3,394 
(56.0%) 
         6,809 
(55.2%)   
Income          
  Q1 (%N) 
         3,404 
(18.5%) 
         1,072 
(17.7%) 
         2,332 
(18.9%) 0.03 
  Q2 (%N) 
         3,712 
(20.2%) 
         1,206 
(19.9%) 
         2,506 
(20.3%) 0.01 
Step Description #Excluded #Encounters #Patients
1
All patients in Cerner dataset where patients that 
were prescribed one of the medications of interest. 
Align Cerner records with DAD based on discharge 
dates (Cener, dischargedate=DAD ddate), IKN's, 
and institutions . 148,808 85,232
2 Total BEFORE exclusions
3
Data cleaning: Invalid IKN,  Age <66 yo or >105 
yo, non-Ontario residents, site names not equal to 
'UH', 'VH', 'St. Joseph's Campus' 45,692 103,116 58,508
4 Death date<= discharge date +5 days 10,073 93,043 53,357
5 Insttype not equal to ’AT’ or ‘AP’ (non-psych patients) 0 93,043 53,357
6 Readmitted within 5 days of discharge 4,116 88,927 52,520
7 Total AFTER exclusions 88,927 52,520
Table 1.2 Cohort inclusion/exclusion-ICES
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  Q3 (%N) 
         3,561 
(19.3%) 
         1,164 
(19.2%) 
         2,397 
(19.4%) 0.01 
  Q4 (%N) 
         3,751 
(20.4%) 
         1,219 
(20.1%) 
         2,532 
(20.5%) 0.01 
Q5(%N) 
         3,878 
(21.1%) 
         1,356 
(22.4%) 
         2,522 
(20.4%) 0.05 
Long Term Care 
resident(%N)            132 (0.7%) 
            41 
(0.7%)             91 (0.7%) 0.01 
Comorbidities         
Charlson 
Comorbidity score          
  Mean(SD)         0.80 ± 1.59 
        0.79 ± 
1.55         0.81 ± 1.60 0.01 
  Median(IQR)            0 (0-1)            0 (0-1)            0 (0-1) 0 
Prior conditions         
  COPD (%N)          1,324 (7.2%) 
           450 
(7.4%)            874 (7.1%) 0.01 
  Diabetes (%N)          1,230 (6.7%) 
           492 
(8.1%)            738 (6.0%) 0.08 
  Hypertension 
(%N) 
         2,001 
(10.9%) 
           774 
(12.8%)          1,227 (9.9%) 0.09 
  Ischemic heart 
disease (%N) 
         3,922 
(21.3%) 
         1,484 
(24.5%) 
         2,438 
(19.8%) 0.11 
  Liver disease 
(%N)            256 (1.4%) 
            65 
(1.1%)            191 (1.5%) 0.04 
  Inflammatory 
bowel disease 
(%N) 
         2,166 
(11.8%) 
           716 
(11.8%) 
         1,450 
(11.7%) 0 
  Renal disease 
(%N)          1,317 (7.2%) 
           401 
(6.6%)            916 (7.4%) 0.03 
  Arthritis (%N)            133 (0.7%) 
            38 
(0.6%)             95 (0.8%) 0.02 
  Stroke (%N)            523 (2.8%) 
           162 
(2.7%)            361 (2.9%) 0.02 
  Cerebrovascular 
disease (%N)            678 (3.7%) 
           216 
(3.6%)            462 (3.7%) 0.01 
Dementia (%N)             85 (0.5%) 
            25 
(0.4%)             60 (0.5%) 0.01 
  Congestive heart 
failure (%N) 
         2,990 
(16.2%) 
           965 
(15.9%) 
         2,025 
(16.4%) 0.01 
Admission 
characteristics         
Hospital los         
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Mean(SD)         9.53 ± 12.57 
       10.51 ± 
14.38         9.04 ± 11.55 0.11 
  Median(IQR)            6 (4-11)            7 (4-12)            6 (3-10) 0.21 
Type of inpatient 
service         
  Medical(%N)   39.67% 41.85%   
   Surgical(%N)   56.08% 53.86%   
   Geriatric(%N)   2.98% 2.53%   
  Other(%N)   1.27% 1.76%   
ED to inpatient 
transfer(%N) 
         7,102 
(38.6%) 
         2,433 
(40.1%) 




         5,016 
(27.3%) 
         1,745 
(28.8%) 





        16,501 
(89.7%) 
         5,329 
(87.9%) 




home(%N)            433 (2.4%) 
           188 
(3.1%)            245 (2.0%) 0.07 
Prior healthcare 
utilization         
Primary care 
visits in previous 
year         
Mean (SD)         0.81 ± 1.45 
        0.99 ± 
1.71         0.72 ± 1.29 0.18 
  Median(IQR)            0 (0-1)            0 (0-1)            0 (0-1) 0.21 
Specialist care 
visits in previous 
year         
Mean(SD)         6.99 ± 12.45 
        7.15 ± 
13.42         6.91 ± 11.94 0.02 
  Median(IQR)            3 (1-8)            3 (1-8)            3 (1-8) 0.01 
Medication 
utilization         
Number of 
medication is 
previous year         
Mean(SD)         8.07 ± 5.17 
        8.06 ± 
5.25         8.07 ± 5.14 0 





         6,324 
(34.4%) 
         2,114 
(34.9%) 





Note: Highlighted significant standardized differences 
 
Appendix K-Assessment of segmented regression model 
ii. Assessing autocorrelation (for independence) 
1)  Durbin-Watson stat 
The Durban-Watson statistic (DW=1.9005) indicated no evidence of positive autocorrelation 
(Pr<DW=0.2112) or negative autocorrelation (Pr>0.7888).  
ii. Assessing for presence of outliers and influential points 
iv) Cook’s D 
 
As shown in the above figure there are two potential influential points- interval 18,21.  
 
iii. Assessing goodness of fit 
1) F statistic  
F value is statistically significant (F=16.03, p<0.0001) which would indicate that that 
independent variable  is able to predict  the independent variable.  
2) R-sq statistic 
The R-sq and adjusted R-sq stat are neither high nor low (R-sq=0.5166, adj R-sq=0.4843). This 
R^2 value indicates that 48.43% of the variation in the dependent variable can be explained by 
the independent variable.  




We would expect the predicted values to lie on the 45° line if the model were a good fit (i.e. the 
model correctly predicted the behavior of the dependent variable). Here we see a much better fit 
as compared to the simple linear regression model (see appendix H).  
4) fit-mean vs. proportion less, residual vs. proportion less 
 
Here we see that the right-hand plot is slightly taller that the left-hand plot showing there is some 
variation not explained by the model, but overall a better fit than the simple linear regression 
model. The residuals roughly follow a diagonal and the distribution does not appear to be 
skewed.  
ii. Assessing the assumption of linearity 
 
iii. Assessing the assumption of constant variance and normality 




The above is a histogram of residual density. The distribution indicated that the assumption of 
normality is met.  
2) residuals by regressors for outcome (interval, intervention, time_after) 
 
 
In the residual vs. intervention-what we observe a bimodal distribution, which is would expect 
given intervention is a binary outcome. In the residual vs. interval we observe a fairly random 
distribution, and in the residual vs. time_after we observe a fairly random distribution and the 
grouping at time zero is what we would expect to observe. Overall, this indicates that the 










Appendix L-Sensitivity analyses 
A) Remove interval 18 and 21 from analysis 
i) Assessing autocorrelation 
1) Durbin-Watson stat 
The Durban-Watson statistic (DW=1.7552) indicated no evidence of positive autocorrelation 
(Pr<DW=0.0953) or negative autocorrelation (Pr>0.9047).  
ii) interpretation of coefficients 
model: Proportion(t)= 0.12687 + 0.00328*interval(t) -0.05572*intervention(t) -
0.00337*time_after(t) 
 
Β0=0.12687; Just before the beginning of the observation period 12.69% of medications of 
interest were filled.  
Β1=0.00328; There was significant interval to interval change in the proportion of medications of 
interest filled before HUGO’s implementation (p=0.0002). 
Β2=-0.05572; The proportion of medication of interest filled dropped abruptly by 5.57% after 
HUGO’s implementation (p<0.0001). 
Note that this is a smaller level change (Β2) than in original analysis, however both are still 
significant 
Β3=-0.00337; There was significant interval to interval change in the proportion of  
hospitalizations with medications of interest filled after HUGO’s implementation as compared to 
the interval to interval change in the proportion of hospitalizations with medications of interest 
filled before HUGO’s implementation (i.e. there is a significant difference the slope of the pre- 
and post-HUGO segments) (p=0.0005).  




iii) assessing outliers and influential points 




The plot on left is from sensitivity analysis and plot on right is from original analysis. Potential 
leverage point at 23, which has a greater Cook’s D than the potential influential points in the 
original model. 
iv) Assessing goodness of fit 
1) F stat 
F value is statistically significant (F=11.75, p<0.0001) which would indicate that that 
independent variable  is able to predict  the independent variable. Similarly, the F value from the 
original analysis (F=16.03, P<0.0001) is statistically significant.  
2) R-sq stat 
The R-sq and adjusted R-sq stat are neither high nor low (R-sq=0.4506, adj R-sq=0.4122). This 
R^2 value indicates that 41.22% of the variation in the dependent variable can be explained by 
the independent variable. This R-sq value is lower than the value from the original analysis (R-
sq=0.5166, adj R-sq=0.4843), indicating the model may be a better fit with datapoints 18 and 21 
included.  
 




The plot on the left is from the sensitivity analysis, the plot of the right is from the original 
analysis. We see that clustering of data still present and the fit is essentially the same minus the 
outlier at 0.25 (outcome for plot on right).  
4) residual vs. predicted 
vs.  
The plot on the left is from the sensitivity analysis, the plot of the right is from the original 
analysis. See that clustering of data still present. Fit essentially the same minus the outlier at 
0.20,0.06 (predicted value, residual for plot on right).  
5)fit-mean vs. proportion less, residual vs. proportion less 
vs.  
The plot on the left is from the sensitivity analysis, the plot of the right is from the original 
analysis. We see that the clustering of data is still present. The fit is essentially the same but the 
right plot extends to values of 0.06 for the fit-mean and residual.  
Overall conclusion: Removing intervals 18 and 21 does not appear to generate a better 
fitting model than the original primary analysis.  
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B) excluding interval 19 
i) Assessing for autocorrelation 
1) Durbin-Watson stat 
The Durban-Watson statistic (DW=1.8465) indicated no evidence of positive autocorrelation 
(Pr<DW=0.1603) or negative autocorrelation (Pr>0.8397).  
 
ii) interpretation of coefficients 
model: Proportion(t)= 0.1206 + 0.004273*interval(t) -0.0705*intervention(t) -
0.004093*time_after(t) 
Β0=0.1206; Just before the beginning of the observation period 12.06% of hospitalizations had a 
medication of interest filled.  
Β1=0.004273; There was significant interval to interval change in the proportion of 
hospitalizations with a medication of interest filled before HUGO’s implementation (p<0.001). 
Β2=-0.0705; The proportion of hospitalizations with a medication of interest filled dropped 
abruptly by 7.05%% after HUGO’s implementation (p<0.0001). 
Note this is a slightly larger level change (Β2) than in original analysis (Β2=-0.0698) and both are 
significant. 
Β3=-0.004093; There was significant interval to interval change in the proportion of 
hospitalizations with a medication of interest filled after HUGO’s implementation as compared 
to the interval to interval change in the proportion of medications of interest filled before 
HUGO’s implementation (i.e. there is a significant difference the slope of the pre- and post-
HUGO segments) (p=0.0003).  
 
iii) Assessing outliers and influential points 








Plot on left is from sensitivity analysis and plot on right is from original analysis. Potential 
influential point at interval 18 and 21, with Cook’s distance being greater at interval 18 in the left 
plot vs. the right plot.  
iv) Assessing goodness of fit 
1) F stat 
F value is statistically significant (F=13.48, p<0.0001) which would indicate that that 
independent variable  is able to predict  the independent variable.  
2)  R-sq stat 
The R-sq and adjusted R-sq stat are neither high nor low (R-sq=0.4789, adj R-sq=0.4434). This 
R^2 value indicates that 44.34% of the variation in the dependent variable can be explained by 
the independent variable. This R-sq value is lower than the value from the original analysis (R-





3)  outcome vs. predicted value 
vs.  
The plot on the left is from sensitivity analysis and plot on right is from original analysis. We see 
that clustering of data still present and the fit is essentially the same. 
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4) residual vs. predicted 
vs.  
The plot on left is from sensitivity analysis and plot on right is from original analysis. See that 
clustering of data still present. We observed no major differences in the plots. 
 
5)fit-mean vs. proportion less, residual vs. proportion less 
vs.  
Plot on left is from sensitivity analysis and plot on right is from original analysis. No observed 
major differences in the plots. 
Overall conclusion: We do not believe this sensitivity analysis conveys a better model fit 










Appendix M- Interpretation of the regression coefficients for the segmented linear 
regression model of our data with washout period 
 
Variable Parameter Estimate P-value Interpretation 
Intercept 0.1206 <.0001 Just before the beginning of 
the observation period 12.1% 
of hospitalizations had 
medications of interest filled. 
Baseline Trend 0.0043 <.0001 Baseline slope; there was 
significant interval to interval 
change in the proportion of 
hospitalizations with 
medications of interest filled 
before HUGO’s 
implementation 
Level Change after 
intervention 
-0.0613 <.0001 The proportion of 
hospitalizations with a 
medication of interest filled 
decreased abruptly by 6.1% 
after HUGO’s implementation 
Trend Change after 
intervention 
-0.0043 <.0001 There was a significant change 
in slope (decreasing) after 
implementation of HUGO 
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